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ABSTRACT 
Glycoproteins are involved in important biological processes. Their role can be understood 
by introducing native structures or mimetics at predetermined positions in proteins, and may 
lead to the discovery of new drugs. A scalable synthesis of core-i disaccharide (galactose(A 
1, 3)a-N-acetylgalactosamine), 0-linked to threonine was accomplished. This building 
block was then incorporated into a peptide using solid phase peptide synthesis. 
Additionally, a novel neo-glycopeptidc linkage was created using the Cu(I)-catalysed 
modification of Huisgen cycloaddition (click chemistry), between glycosyl azides and 
peptides modified with acetylene moieties. This linkage can be formed either on solid 
support or in aqueous solution. Moreover, the synthesis was investigated on solid phase of a 
tripeptide scaffold (Ac-L-Cys-L-Lys-L-Cys-NH 2) that displays N-acetyllactosamine through 
the thiol groups of the two cysteine residues as a potential "oligosaccharide mimic". This 
structure can be linked to a peptide via the glycosyl azide of N-acetylglucosamine appended 
to the --amino group of the central lysine residue. Two such oligosaccharide mimics were 
incorporated into an erythropoietin (EPO) derived peptide fragment in 69 % yield using the 
novel nco-glycopeptide linkage in an aqueous solution. 
To demonstrate the tripeptide scaffold displays carbohydrates and can be recognised in a 
biological environment, the EPO peptide fragment bearing two oligosaccharide mimics was 
joined to a Green Fluorescent Protein C-terminal thioester using native chemical ligation. 
Afterwards, the protein-carbohydrate interaction was observed between this glycoprotein 
mimetic and lectin Ricinnus communis RCA 120 immobilised on agarose beads. 
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1. The biological role of glycoproteins 
I 	The biological role of glycoproteins 
Carbohydrates are often found in nature associated with proteins or lipids, to form 
glycoconjugates such as glycoproteins, proteoglycans, glycolipids and GPI-anchors. These 
structures are very important and perform multiple roles in cells. Consequently, these 
molecules have captivated the attention of the chemical and biochemical community.' 
Glycoproteins are the product of a post- or co-translational modification of a protein, called 
glycosylation, which is not under direct genetic control. The outcome of this process is a 
heterogeneous mixture of glycosylated forms, termed 'glycofornis". 2 Such a procedure 
confers an additional level of complexity upon the recipient protein.' This may explain, for 
example, why such a large combination of human protein phenotypes can derive from 
30,000 genes O-Methylation, O-acetylation, O-sulphation, O-phosphorylation or 
oxidation also amplifies the protein phenotype. 
The biological properties of a protein can be influenced by the degree of glycosylation. This 
modification can change its biological and physicochemical properties, eg. protection from 
proteolysis, correct protein folding, enhancement of solubility, and confer antifreezing 
properties .6  Moreover, these structures mediate cellular adhesion, cell growth regulation, 
affect intracellular transport of enzymes to lysosomes, determine human blood groups (ABO 
antigens),' and regulate leukocyte trafficking to sites of inflammation.' Conversely, aberrant 
glycosylation of protein, due to incomplete synthesis of carbohydrate chains and 
accumulation of their precursors on the cell surface of cancer cells, is associated with 
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oncogenesis and has been implicated in metastasis. 2 Also glycoproteins are involved in 
chronic inflammation, 9 autoimmune diseases,"' xenograft rejection, virus replication; virus, 
bacterial and parasitic infection." 
1.1 Structure and biosynthesis of glycoproteins 
The extent to which proteins are glycosylated in nature can differ enormously from collagen 
(1% wlw) to glycogen (99% w/w).' 2 The modified protein may contain one or several 
oligosaccharide side chains. The saccharide residues are most frequently covalently linked 
to the protein backbone through N- or O-glycosidic linkages .2  The N-glycosidic bond 
always uses the side chain amide nitrogen of the asparagine (Asn) residue in the consensus 
sequence Asn-Xxx-Ser/Thr, whereas most of a-O-glycosidic bonds usually require the 
hydroxyl group of serine (Ser) or threonine (Thr), introduced by a peptidic region rich in 
proline. C-, S- and P- dependent glycosidic linkages are found less frequently in nature. 
GPI-Anchors use an ethanolarnine phosphate linkage type between the protein chain and 
carbohydrate structure. 
1.1.1 N-Linked oligosaccharides 
N-Linked glycosylation is the most common form of glycosylation in eukaryotic cells. This 
modification involves a co-translational transfer of a saccharide from a dolichol-linked 
pyrophosphate donor to an asparagine in the consensus sequence Asn-Xxx-Ser/Thr. 
Although all N-glycoproteins share a peptide-linked pentasaccharide motif, called the core 
region, in the biosynthesis of these structures, the activity of different types of enzymes is 
responsible for the high diversity associated with mature N-linked glycoproteins in 
eukaryotic cells. 13 
2 
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The biosynthesis of N-linked oligosaccharides starts on the cytosolic surface of the 
endoplasmatic reticulum (ER) membrane by adding sugars in a stepwise fashion to 
dolichyiphosphate referred to as the phosphodolichol pathway or dolichol cycle (Scheme 
1.1)1415 Two UDP-G1cNAc residues are transferred to phosphodolichol by a I-
phosphotransferase and G1cNAc-transferase: this is followed by the addition of five mannose 
residues catalysed by different maimosyltransferases. After mannosylation, the glycolipid is 
flipped from the cytoplasmatic face of the ER to the lumen. 16  The growing glycolipid 
receives another four mannose and three glucose units from doli chol -phosphate linked 
glycosyl donors. 16  Then, an oligosaccharyltransferase enzyme complex catalyses the transfer 
of the core tetradecasaccharide (Glc 3 Mafl9G1cNAc 2 ) 1718 to the asparagine acceptor in the 
growing polypeptide with a consensus sequence Asn-X-Thr/Ser, where X can be any amino 
acid except prolne' 9 or aspartic acid .20 However, not every asparagine in a consensus 
sequence is glycosylated: steric factors can prevent glycosylation. 
Afterwards, the tetradecasaccharide structure is "trimmed". Three glucoses and one terminal 
mannose are removed by ER a-1,2-glucosidase I, a-1,3-glucosidasc II, and a-1,2-
mannosidase respectively (Scheme 1.1). This deglycosylation process leads to an 
oligosaccharidc structure (Man 8G1cNAc 2) that signals the nascent glycoprotein to be 
transported to the cis-Golgi compartment for further processing. After being "trimmed" of 
the first two glucose residues, the new glycopeptide is released from the ribosome of the ER 
to the lumen, and then associates with membrane bound calnexin or soluble calreticulin, 
chaperones which recognise the monoglucosylated oligosaccharide, and assist the 
glycoprotein to fold correctly. It is at this stage where disulphide bridges are formed. If, 
after the removal of the third glucose, correct folding fails, the chaperone retains the 
glycoprotein in the ER for further re-glycosylations to readdress the improper folding.2 123 
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The high-mannose type glycoprotein structure is transported to the "cis cisternae" of the 
Golgi apparatus by vesicular transport. Depending on the final destination of the mature 
glycoproteins, two possible biosynthetic pathways are believed to exist (Scheme 1.1):2 
• a pliospho-N-GIcNAc unit is added in the position 6 of a mannose, and then a 
phosphodiesterase removes the N-GIcNAc to form a mannose-6-phosphate. This 
structure is finally transported to lysosomes. 
. three units of mannose are cleaved by mannosidases IA, lB and IC (Man 5GlcNAc 2). 
This glycoprotein is finally matured in the "medial cisternae". 
Diversification of N-glycans occurs in the medial cisternae generating different subtypes of 
N-linked glycoproteins: high mannose, hybrid or complex N-oligosaccharides (Scheme 1.2). 
Two mannose units are removed by mannosidase II, and afterwards, two GlcNAc and a 
fucosc residue are added by GIcNAcT II and fucosyltransferase respectively. Finally, in the 
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glycosyltransferases that add: GlcNAc, galactose, and/or sialic acid residues. This final 
elongation step contributes greatly to the highly diverse and complex nature of N-linked 
glycoproteins. 2° 
Scheme 1.2: different subtypes of N-linked glycoproteins: high mannose, hybrid or complex N-
oligosaccharidcs. 
1.1.2 0-Linked oligosaccharides 
In the biosynthesis of 0-glycan, glycosyltransferases act directly to glycosylate proteins in 
the Golgi. As a result of this direct glycosylation, 0-glycans have fewer carbohydrate 
branches than most N-glycans, and arc commonly found as biantennary structures. 
0-Linked oligosaccharides differ in a manner dependent upon how the first sugar molecule 
is attached to the recipient protein. Linkage can occur through serine or threonine residues 
(Scheme 1.3 ).2  Mucin-type 0-glycoproteins, which are highly glycosylated, are commonly 
found on the surface of epithelial cells. These structures exert a number of biological effects 
including structural and functional properties for the carrier protein and are involved in 
molecular recognition and adhesion events-' -2 Mucin-type 0-linked glycoproteins are 
initiated by the addition of the monosaccharide N-acetylgalactosamine, GalNAc. The 
addition of GaINAc in the protein backbone proceeds through the hydroxyl group of Ser/Thr, 
5 
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and is catalysed by polypeptide GaINAc UDP-transferase, ppGaINAcT using UDP-GaINAc 
in the Golgi membrane. A consensus sequence for ppGaINAeT has not been determined, 
although predictive algorithms have been proposed. Glycosidation normally occurs where 
proline is at the - I and +3 position. 227 Prolines appear to influence protein conformation by 
breaking helix formation and promoting the formation of 8 turns and ,8 sheets. Alanine, 







Scheme 1.3: Common core structures of 0-linked glycoprotcins. 
Following the addition of the first monosaccharide to the polypeptide, most O-glycans are 
observed to contain the core-I subtype structure formed by the addition of galactose in a,8- 1,  
3 linkage to the GaINAc (Scheme 1.3). In mammalian cells, this biotransformation is 
performed by core I 8- 1, 3 galactosyltransferase (core I Gall). 
Core 2-type 0-linked glycoproteins can be generated by the addition of GIcNAc to the core 
GatNAc in a,8-1, 6 linkage. The production of core 2 O-giycans requires the presence of 
core 1 structure as a substrate. This reaction is catalysed by core 2 fl6-N-acetylglucosamine- 
6 
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transferase (core 2 P6-GIcNAcT). 2 The enzyme recognises most of the substituents of core 
1: the 4- and 6-hydroxyls of both Gal and GaINAc, and the 2-N-acetyl group of the glycosyl 
acceptor. 28 
Glycosyl addition on core I and core 2 structures generates other types of core structures 
(Scheme 1.3). The product of these gly cosy ltransferases can be sulphated by 
suiphotransferases. Elongation proceeds by :21 
Repeating Galfl-1, 3/4GalNAc sequences (poly-N-acetyllactosamine chains). 
. Branching GlcNAcfl-1, 6 residues. 
The termination process of the elaboration of carbohydrate structure involves the action of a 
fucosyltransferase and a sialyltransferase. Sialylation imparts a negative charge to the final 
carbohydrate, and may protect the O-glycoprotein from being recognised by lectins or the 
immune system. O-Acetylation of sialic acid, performed by acetyl-CoA, protects the sugar 
from degradation by intestinal bacteria. Moreover, Gal or G1cNAc residues of mucins are 
often sulphated, conferring an additional negative charge to O-glycan chains. Sulphated 0- 
glycans may play a role in cell adhesion through selectin binding, 2930 and bacterial binding. 
Sulphated ester groups also control biosynthetic pathways of O-glycans by blocking specific 
glycosylation steps. 31  
Other types of glycosylation afford: 0-linked N-acetylglucosamine (GIcNAc), found in the 
cytoplasm and nucleus of cells; 0-linked fucose, found in the epidermal growth factor (EGF) 
domains; and 0-linked xylose, abundant on the cell surface of the extracellular matrix 
(ECM)." 
Different types of N- and 0-linked glycoproteins with interesting biological activity exist in 
nature. The most relevant for this thesis are erythropoietin and GIyCAM-1. 
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1.2 Recombinant Human Erythropoietin (rhEPO) and its biological role 
Recombinant Human Erythropoietin (rhEPO) is a 166 amino acid residue glycoprotein that 
regulates the proliferation, differentiation and maturation of red blood cells, and 
consequently the haematocrit. Although in the early stages of foetal life, the liver is 
responsible for the production of this secreted hormone, suprarenal glands are responsible for 
EPO generation in adults. At high altitudes, the production of the glycoprotein is increased 
to counter the effects of hypoxia. Conversely, during hyperoxia, there is a reduction of the 
hormone. 33 
EPO is commonly used as a therapeutic for the treatment of anaemia associated with: 
chronic kidney disease, chemotherapy treatment for cancer; HIV infection, and during 
surgery to reduce allogenic blood transfusion requirements. 34.35 
The secreted glycoprotein contains approximately 40% carbohydrate and has an approximate 
molecular weight of 30 kDa. rhEPO has four cysteines linked by disulphide bonds between 
Cys 7-161 and 29-33. Reduction of disulphide bonds results in loss of biological activity, 
that can be restored by reoxidation. 36 rhEPO is glycosylated at N24, 38, 83 and S126 
(Scheme 1.4) .35  
The carbohydrate attached to asparagine has the typical structure of N-linked glycoproteins 
(Scheme 1.4). The carbohydrate attachments influence protein stability and solubility but 
are not required for in vitro activity. Thus the active site is retained in the protein portion of 
the molecule. 34 Sialylation of the carbohydrate is essential for in vivo activity. Desialylation 
exposes galactose residues to hepatic metabolism. Desialylated molecules are sequestered in 
the liver and metabolised, increasing the clearance and consequently decreasing the half life 
of EPO. 
8 
1. The biological role of glycoproteins 
Scheme 1.4: Carbohydrate found in Recombinant Human Erythropoietin (rhEPO). 
1.3 GIyCAM-1 and its biological role 
The presence of glycoproteins on the cell surface facilitates the lymphocyte recirculation 
from the intravascular compartment to the secondary lymphoid organs and also mediates 
immune responses. This recirculation increases the chances of the lymphocyte encountering 
foreign antigens.' 2 
L-Selectins, glycoprotcins from the family of the lectins, present on the surface of the 
leukocytes have different types of biological ligands: GIyCAM-1, CD34, MAdCAM-1 and 
PCLP. Glycosidation-dependent cell adhesion molecule-I (GIyCAM-1), is a secreted 
mucin-type O-glycoprotein of 132 amino acids, with a MW of 50 kDa, that lacks a 
transmembrane domain and contains numerous serine and threonine residues. GIyCAM- 1 is 
present on the surface of high endothelied venules (HEy) in secondary lymphoid organs in 
mice.' This counter-receptor requires carbohydrate-based posttranslational modification for 
recognition by L-selectins. 37 Sialylation and fucosylation are necessary for L-selectin 
recognition .31  Suiphation of carbohydrates increase binding to L-selectin compared to non 
sulphated molecules (Scheme 1.5). '9  
9 
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During inflammation, in zones of injury, there is a decrease in circulation, allowing the 
interaction between blood cells and the vessel endothelium. It is at this stage where L-
selectin and its ligands make low affinity interactions (glycoprotein-lectin), slowing the 
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Scheme 1.5: Process of leukocytes extravasation from the blood stream. 41)  
Afterwards, this leads to the activation of integrins present on the surface of the leukocytcs, 4 ' 
that facilitate strong protein-protein interactions with intercellular adhesion molecule-] 
(ICAM-l) present on the endothclial surface, leading to the firm adhesion of the leukocytes 
on the surface of the blood vessel. Finally, there is a transmigration of leukocytes through 
the endothelial layer, a process called vascular extravasation (Scheme 1.5). 
1.4 Conclusion 
Carbohydrates represent a new level of complexity and diversity above gene expression. 
These molecules, introduced to proteins by nature, confer new properties to the host protein 
1. The biological role of glycoprotcins 
acceptor. Properties that are hidden by its heterogeneity can only be specifically decoded by 
the synthesis and biosynthesis of pure and homogeneous native or unnatural glycoproteins. 
The understanding of the role of glycans is already providing new therapies and treatments, 
and will enlighten science in the corning years. 
2. Synthesis of natural glycopeptides and glycopeptide mimics 
2 Synthesis of natural glycopeptides and glycopeptide mimics 
Polysaccharides are highly functionalised biopolymers with a large number of stercocentres. 
These molecules have attracted the attention of chemists because of their complexity. The 
main problems of the synthesis of these compounds are: 
• Stercoselective glycoside bond formation between the glycosyl donor and the 
acceptor (generation of a or /3 anomer). 
• Regioselective glycosylation of the acceptor. 
• Selective protection and deprotection of different building blocks before and after 
each glycosylation step. 
To combat these challenging problems, scientists have engineered different methods, either 
by chemical or enzyme-catalysed glycosiclation, to overcome these difficulties (Scheme 2. I). 
The routes are complimentary. 
Enzymes are used to accomplish glycosylation with total regio- and stereo-control, in non-
organic solvents. If the desired enzyme is commercially available or if it can be expressed in 
cells, glycosidation is performed with high efficiency and without any protecting groups. On 
the other hand, in chemical synthesis, natural and non-natural saccharide building blocks can 
be assembled with natural or non-natural linkages to generate any oligosaccharide, analogue 
or glycoconjugate. This last approach involves the use of suitable protecting group strategies 
and glycosyl activators. 
12 
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2.1 Solution Phase Oligosaccharide Synthesis 
2.1.1 Protecting groups in oligosaccharide synthesis 
As has been discussed earlier, carbohydrates are highly hydroxylated branched molecules. 
These hydroxyl groups share similar polarity and nucleophilic properties. Moreover, the 
reactivity of these functional groups can vary depending on their environment, suggesting 
that carbohydrate synthesis relies upon a good protecting group strategy to satisfy the stereo-
and regioselectivity synthetic demand. 
This protecting group strategy has to meet different requirements  :42  a given hydroxyl group 
must be protected selectively; a protecting group has to withstand the conditions of the 
intended reactions; and finally, selective deprotection must be achieved at the end of the 
sequence in high yield. 
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The literature describes a variety of different protecting groups for either hydroxyl or amino 
functional groups. 43 Despite this large number, only a fraction of them have emerged as 
suitable protecting groups for carbohydrate chemistry. 42 With modern protecting group 
strategies, there is potential for creating every possible carbohydrate structure, either by 
modifying the chemical properties of the molecule, by controlling the stereochemistry of the 
glycosylation bond formation, or by changing the intrinsic reactivity of the carbohydrate. In 
fact, applying this final property, Fraser-Reid and co-workers , 45 ' 46 developed a sequential 
synthesis from more reactive n-pentenyl glycosides (armed glycosyl donor), furnished with 
electron-donating hydroxyl protecting groups; to less reactive (disarmed) acceptors, 
protected with acyl electron-withdrawing groups. Wong and co-workers have applied this 
difference in reactivity of glycosyl donors modulated with protecting groups to develop one-
pot oligosaccharidc synthesis. 47 
One of the major drawbacks of carbohydrate chemistry is the long and laborious synthesis to 
furnish the sugar unit with the adequate protecting groups, leaving free the desired hydroxyl 
group. Very recently, Hung and co-workers have performed a highly-regioselective one-pot 
protection of carbohydrates (Scheme2.2). 48  With this methodology, it is possible to install 
different protecting groups on a monosaccharide in a one-pot fashion, removing the need to 
carry out multiple synthetic steps, and repeated isolation and purification of intermediates. 
First, they treated the compound la or lb with an aryl aldehyde in the presence of 
trimethylsilyl triflate (TMSOTf) as a catalyst for the formation of compound 8 (Scheme 2.2). 
Addition of another aryl aldehyde, followed by treatment with triethylsilane (Et 3 SiH), 
allowed the generation of 10. TBAF deprotection removed the TMS group at the C-2 
hydroxyl position to afford 2. In addition. 4 was prepared in a one-pot fashion when 2 was 
treated with an appropriate electrophile under basic conditions, followed by the addition of 
14 
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Scheme 2.2: Diagram for the TMSOTf-catalysed one-pot protection of carbohydrates. 
48 
Once the monosaccharide 3 was obtained, selective deprotection of the hydroxyl at C-4 or C-
6, was achieved either by treating the molecule with HCI (5) and Na(CN)BH3 , or with 
BH 3/THF, to obtain 5 and 6, respectively (Scheme 2.2). 
Applying this methodology, the authors claimed to produce "hundreds" of glycobuilding 
blocks. To exemplify their strategy, they generated a library of the influenza virus-binding 
trisaccharide (NeuAc-a-2, 6-Gal-/3-1, 4-GlcNAc). 
15 
2. Synthesis of natural glycopeptides and glycopeptide mimics 
2.1.2 Glycoside bond formation 
Glycoside bond formation generally refers to a process where a carbohydrate is added to an 
acceptor molecule, either a further carbohydrate or another molecule entity. While in nature, 
enzymes catalyse this reaction by bringing together both donor and acceptor, chemists have 
developed different procedures to reproduce this natural process. 
In chemical glycoside bond fonrLation (Scheme 2.3), there is most commonly an activation 
and elimination of a leaving group at the anomeric position of the carbohydrate, called the 
glycosyl donor, to generate an oxo-carbenium species. Stabilisation of this cationic 
intermediate occurs by donation of the oxygen lone pair of electrons, participation of active 
counter ions, such as Inflate; or in some cases, neighbouring group participation (C-2 
substituent participation). Final nucleophilic attack of a free hydroxyl group of another 
carbohydrate unit, the glycosyl acceptor, generates the desired glycosyl bond. Glycosidation 
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participation by C-2 S auxiliary to afford I ,2-cis-glycosides. 49 
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Since Knoenigs-Knorr reported the first efficient glycosylation with glycosyl bromides 
activated with equimolar amounts of silver salts,' ° a wide variety of procedures and 
reviews51 ' 52 have been described in the literature. 
2.1.3 Stereocontrol in glycosidation 
The stereochemistry of the glycosidic bond can be controlled using different protecting 
groups in adjacent position to the anomeric centre (C-2): neighbouring-group participation. 
Traditionally, the presence of an ester group, such as acetate or benzoate, on the 2-hydroxyl 
group, stabilises the intermediate glycosyl cation by cyclisation. This cyclic oxonium ion 
can then be opened in an SN2 fashion by the external nucleophile, with inversion of 
configuration (participation of C-2 substituent, Scheme 2.3.A). 53 
Boons and co-workers developed a general strategy for stereoselective glycosylations. 49 The 
authors introduced on the C-2 of the glycosyl donor a (IS)-phenyl-2-(phenylsulphanyl)ethyl 
moiety, in the presence of a Lewis acid (BF 3 OEt2 ), before introducing the 
trichloroacetimidate leaving group at the anomeric position. 54 Due to steric and electronic 
factors, the su/phoniuin ion is formed as a trans-decalin ring system. Displacement of the 
suiphoniuni ion by a nucleophilic hydroxyl leads to the stereoselective formation of a-
glycosides. Finally, the moiety was removed by treating the oligosaccharide with a Lewis 
acid (BF 3 OEt2) in the presence of acetic anhydride to achieve the acetylation of the 2-
hydroxyl group. 
While C-2 substituent neighbouring participating group fills the synthetic tool-kit for 
glycosylation, 53  8-mannoside formation frequently requires more sophisticated procedures. 
Since 8-mannosylation is disfavoured under the above glycoside bond formation conditions, 
different conditions have been developed to overcome the difficulties (Scheme 2.4 and 2.5). 
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Garegg55 and Paulsen" developed a methodology to perform fl-mannosylation with 
mannosyl bromides, using insoluble silver salts (Scheme 2.4.A). Unfortunately, the degree 
of stereoselectivity was quite variable, and therefore, more stereoselective methodologies 
have been developed. 
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Scheme 2.4: Different types of strategies to achieve a fl-mannosylation: a) insoluble silver salt; 
5556 
inaimosyl sulfoxides; 5759  c) glycosylati on- inversion protocol, either by oxidation-reduction 
60-61  or by 
SN2 displacement.6365 
Crich and co-workers have developed a successful direct /3-mannosylation using a-glycosyl 
sulphoxides. 5759  High fl-stereoselectivity could be achieved when the sulphoxide was 
preactivated at -78 °C with triflic anhydride and 2, 6-di-tert-butyl-4-methylpyridine 
(DTBMP). The formation of an a-glyeosyl triflate intermediate allowed inversion of 
configuration in an SN2 reaction to finally obtain the desired compound (Scheme 2.4.13). 
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Danishefsky and co-workers reported a more elaborate procedure. In a 3 step synthesis, they 
performed a fl-mannosylation from glucal. 6° After treating the molecule with DMDO in the 
presence of a glycosyl acceptor, they subjected the product of the glycosidation to a 
sequential oxidation (DMSO/Ac 20 (2:1)) and reduction (NaBH 4), to achieve inversion from 
the /3-glucoside to the /3-mannoside (Scheme 2.4.C). On the other hand Lichtenthaler and co-
workers6162  oxidized the C-2 position of 2, 3, 4, 6-tetra-0-acetyl-1-bromo-l-deoxy-,8-D-
glucopyranose to achieve the cyclic ketone derivative in four synthetic steps (Scheme 2.4.C). 
After glycosidation, they reduced the carbonyl using NaBH 4 . 
Applying glycosyl-inversion protocols, Kunz and Unverzagt addressed the introduction of 
mannosides by an SN2-type displacement . 6365 The authors reacted an unprotected 2-
hydroxyl of a ,6-glucose residue with triflic anhydride. The inversion of the C-2 position was 
performed by intramolecular nucleophilic attack of a 3-0-carbamate, affording the desired fi-
mannosc after Zdmplen deproteetion 66 (Scheme 2.4.C). 
2.1.3.1 Mannosylation by intramolecular aglycon delivery (LAD) 
lAD methodology was described first by Baressi and Hindsgaul. 67 The glycosyl acceptor is 
introduced using an aglycon structure at the C-2-axial position, forcing the glycosyl acceptor 
to form exclusively the expected /3-stereolsomer (Scheme 2.5). Different types of aglycon 
structures are described for LAD methodology: isopropenyl ether, 67 silylketal structures 68 and 
p-methoxybenzyl (PMB) (Scheme 2.5).69 
The PMB aglycon has become the most widely used LAD aglycon structure for /3-
mannosylation (Scheme 2.5), because it is easy to introduce and the conditions required for 
the formation of the mixed acetal are mild. Methyltrifluoromethanesulfonate (MeOTf) is 
usually the promoter for the /3-mannosylation, once the glycosyl acceptor is appended. 7° 
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Different examples are found in the literature using the PMB aglycon structure for /-
mannosylation. 71 ' 72 
With the development of these technologies, chemists have the potential to synthesise any 
type of complex carbohydrate structure, overcoming the most challenging difficulties. For 
the production of these oligosaccharides, solution phase, solid phase, and also enzymatic 
glycosidation can be applied. 
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Scheme 2.5: Intramolecular aglycon delivery for /J-mannosylation. Different types of aglycon 
structures: a) isopropenyl ether aglycon; °' 7 b) silylketal aglycon; 68 c) PMB aglycon. 7° 
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For fast synthesis of polysaccharides, two major advances have been developed which 
potentially streamline chemical synthesis of oligosaccharides: one-pot reactions and polymer 
supported synthesis, 7 
In one-pot synthesis (Scheme 14 glycosidation occurs sequentially in a single reaction 
vessel: the most reactive glycosyl donor (armed glycosyl donor), ie. the molecule that 
donates the anomeric centre, is triggered first and the least (disarmed) is coerced to engage in 
the final reaction. The reactivity of the sugar is highly dependent on the protecting groups 
and the anorneric activating group used. By adding substrates in sequence from the most 
reactive to the least reactive, one can assure the predominance of a desired target compound. 
These types of reactions are typically performed in solution, but in order to avoid work-up 
and purification steps, the final acceptor, ie. the molecule that accepts the anomeric centre, 
may be attached to a solid support. 75 Compared with stepwise solid-phase synthesis, the 
one-pot approach requires protecting-group manipulation only at the stage of building block 
synthesis and thus holds greater potential for automation, where a computer selects the 
building blocks for sequential one-pot oligosaccharide synthesis, giving a huge diversity of 
oligosaccharidc structures .76,77 
Automated solid phase oligosaccharide synthesis (SPOS) 78 (Scheme 2.6), the reaction is 
performed on a polymeric support, allowing rapid removal of reactants and easy purification. 
Encoding the product can be done either by position or, in mix and split type library 
construction, by an accessory encoding reaction, in which labels are added to the solid 
support as the chain is extended. It can also be encoded by radio frequency-encoded 
combinatorial chemistry technology, allowing the synthesis of oligosaccharide libraries. 
Although it is possible to access many carbohydrate structures on solid-phase, there are 
sequences that remain difficult to make and not all kinds of oligosaccharides can be 
assembled on a polymer matrix. 79 Moreover, the most time consuming step is the synthesis 
21 
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of sufficient quantities of building blocks. These will become commercially available, 
facilitating the work of carbohydrate chemists. 80 
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Scheme 2.6: Scheme for Solid Phase Oligosaccharide Synthesis and One-Pot Synthesis. 73 
Fast and easy accessibility to diverse and complicated glycosyl structures is likely to impact 
significantly on medicine and glycomics. Within all of the advances in carbohydrate 
chemistry, the synthesis of glycoproteins is far from easy and demands huge effort. On the 
other hand, mimicking these molecules permits fast access to elaborate structures and allows 
the study of saccharide interactions that could provide better understanding of biological 
activities and indentify potential targets for development as therapeutic agents. 
2.2 Carbohydrate mimetics 
The term "carbohydrate mimetic" is frequently used to refer to any carbohydrate derivative 
or other compound that has multiple hydroxyl groups and thus looks like a sugar. 8 ' 
Carbohydrate mimetics have a number of advantages over their parent structures as 
therapeutic agents. They can be designed such that they are more stable toward endogenous 
22 
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degradative enzymes, have improved bioavailability and reduced clearance rates, and have a 
higher affinity and selectivity for their cognate receptors by taking advantage of interactions 
that the natural saccharide does not. By constructing polymers or oligomers with multiple 
copies of the mimetic to allow for polyvalent interactions, the affinity can be increased 
further." In the case of inhibitors of glycosyltransferases, glycosidase and carbohydrate-
modifying enzymes (e.g. sulphotransferase), mimetics can be designed that imitate the 
transition states of these reactions, rather than the ground states, and thus can inhibit the 
enzymes better than simple substrate analogues. 8 ' 
Different examples can be found in the literature for carbohydrate mimetics. Wong and co-
workers developed novel fucopeptides as sLc mimetics. 82 They chose O-a-fucosyl-L-
threonine and O-a-fucosyl-( I R,2R)-2-aminocyclohexanol as a template for the incorporation 
of a hydroxyacid (P,) to emulate galactose residues, and a carboxyl ate or sulphate group (P 2 ) 
to replace the sialic acid residue (Scheme 2.7). 
These authors determined the activity of these fucopeptides derivatives with the IC 50 values 
inhibiting the sLe' glycoconjugate binding to E-selectin (Scheme 2.7). According to the 
results, all the functional groups required for E-selectin binding in sLex  existed in 11, and as 
expected it exhibited the same activity as sLe x (IC 50 = 0.5 mM). Compounds 12 and 13 were 
less active than sLex ,  probably due to the presence of a free carboxyl group in the threonine 
moiety. Compound 14 was surprisingly active as the OH group of Tyr in 14 is not exactly a 
spacial mimic of the essential OH groups of the galactose residue in SLeX.  Whether the 
hydrophobic nature of the aromatic group or the additional amino group contributes to the 
binding was unclear. Compounds 15 and 16 were more active than sLex,  perhaps due to the 
increasing constraint of the hydroxyproline-containing peptide bonds. Replacement of the 
threonine component with (IR,2R)-2-aminocyclohexanol resulted in a significant decrease in 
activity. 82 
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Scheme 2.7: A) structure of sialyl Lewis x (sLex)  and schematic structure of the carbohydrate 
mimetics. B) most active carbohydrate mimetics. 82 
Meldal and co-workers" introduced glycopeptides as mimetics of complex oligosaccharide 
structures (a branched mannose pentasaccharide containing two terminal Man-6-P units). 
The idea was that the carbohydrate would provide the specificity of the binding by directing 
the ligand to the oligosaccharide binding site (mannose 6-phosphate receptors), while the 
peptide (Thr-Lys-Thr) would function as a scaffold to provide optimal orientation of the 
glycan portion (Scheme 2.8). In addition, since peptide ligands generally bind with high 
affinity to peptide receptors, it was also expected that the glycopeptide could furthermore 
interact favourably with the carbohydrate-binding receptor through the peptide scaffold, thus 
leading to increased binding affinity. 
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Scheme 2.8: Models of a phosphorylated high-mannose M7 and a glycopeptide mimic which show 
similar conformations. They are seen from the point of interaction with mannose-6-phosphate 
receptor (P. M. St. Hilarire and M. Meldal: Glycopeptide and oligosaccharide libraries. Angew. 
Chem. mt. Ed. 2000, 39,1162-1179. Copyright Wiley-VCH Verlag GmbH & Co.KGaA. Reproduced 
with permission). 
The source of this enhanced affinity of peptides may lie in their ability to perform an induced 
fit because the relatively limited flexibility around peptide bonds leads to fast on-rates for the 
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binding. In contrast to this glycopeptide, highly flexible neo-glycoconjugates do not show 
high affinity due to the large entropic penalty. 84 
The principle of glycopeptides mimicking oligosaceharides was consolidated through 
binding studies with an array of phosphorylated glycopeptides and the divalent mannose 6-
phosphate receptor. The structural similarity between the oligosaccharide and the most 
active glycopeptide ligand was supported by molecular dynamics. 83 
Also based on glycopeptide scaffolds, Rcymond and co-workers, 85 have recently synthesised 
a 15,625 membered peptide dendrimer combinatorial library, furnished with an a-C-fucosyl 
residue, at its four N-termini on solid support (Scheme 2.10), This was screened for binding 
to fucose-specific lectins: UEA-I from Ulex europaeus and PA-IlL form Pseudornonas 
aeruginosa. 
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Scheme 2.10: Library of neo-glycopeptide dendrimers acetylated with fucose at the N-termini. The 
red highlighted amino acids in predetermined positions, formed part of the most active peptide against 
fucose-specific lectins: UEA-1 from Ulex europaeus (1055= Ii pM) and PA-IlL form Pseudornonas 
aeruginosa (1050= 0.14 pM). 
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Bertozzi and co-workers have synthesised mucin mimetics compromising a long, 
synthetically tractable polymer backbone decorated with a-, /3-linked GaINAc residues and 
LacNAc. 86  They introduced the carbohydrates through an oxime linkage from a ketone-
functionalised polymer with an aminoxy Ga1NAc derivative, and LacNAc. Afterwards, the 
authors created a model cell surface, mimicking the membrane-bound mucin glycoproteins 
found in living cells (Scheme 2.11). 
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Scheme 2.11: Modification of the polymer with arninoxy carbohydrate derivatives. Schematic of 
supported lipid bilayer formation from small liposornes and polymer incorporation in a supported lipid 
bi layers. 86 
With this system they studied the interaction of the membrane-associated mucin mimetics 
with proteins (lectins). The study was performed with Helix pomatia agglutinin (HPA), with 
high specificity for a-linked GalNAc, and Bauhinia purpurea agglutinin (BPA) that binds 
specifically to fl-linked GaLVAc. Both lectins were available in fluorescein isothiocyanate 
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binding activity using FITC-conjugated Erythrina cristagalli agglutinin (ECA). In all cases, 
these structures showed predicted interaction with their counter ligand. Thus, the authors 
created a simple recognition model where they mimic cell-surface interactions, relevant to 
cell differentiation or metastasis, by introducing polymeric chains displaying sugars. 
Recently, Davis and co-workers have introduced carbohydrate structures to a leukocyte 
transmembrane human protein, P-selectin-glycoprotein-ligand-1 (PSGL-l) using "click 
chemistiy" (Scheme 2.12). 
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Scheme 2.12: reconstitution of biological activity of PSGL derivatives by the addition of siaLacNAc-
alkyne or sLe°-alkyne, applying "click chemistry". 87 
Applying the technology developed by David Tirrell for incorporation of unnatural amino 
acids into recombinant proteins for chemoselective modifications, 88 the authors introduced 
azidohomoalanine (Aha) and a cystiene chemical-tag to the positions 43 and 439 
respectively (Aha43-Cys439), of PSGL- 1, using protein expression of methionine-
auxotrophic E. co/i. Afterwards, they incorporated a suiphotyrosine mimic group (Tys), by a 
disulphide ligation, followed by the attachment of a siaLacNAc-alkyne or sLe 5 -alkyne 
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derivative applying Cu(I)-catalysed modification of the Huisgen cycloaddition (Scheme 
2.12). With these unnatural modifications, the authors recovered the biological activity of 
PSGL- I, involved in the initial rolling-adhesion events of inflammation response. 
2.3 Conclusions and aims for the project 
Technology related to the semi-synthesis of pure glycoproteins may allow scientists to 
understand the biological role of such structures and will lead the development of new drugs 
and treatments. Unfortunately, many obstacles still have to be overcome. While this 
technology develops, carbohydrate mimetics, due to their simplicity and easy accessibility, 
should help to answer these challenging questions, and therefore, fill the gaps of knowledge 
in the biological role of glycoproteins. 
The Macmillan group already has experience in the synthesis of natural and unnatural 
glycoproteins. In the semi-synthesis of GIyCAM- 1, an 0-linked glycoprotein (Chapter 1), 13 
units of Ga1NAc were introduced in predetermined positions.9  In addition, applying 
auxiliaries for cysteine-free native glycopeptide ligation, GIyCAM- 1 peptide fragments were 
synthesised containing GaINAc 0-linked to threonine. 9° On the other hand, the research 
group also has experience with N-linked glycoproteins: erythropoietin (EPO) (Chapter 1). 
To this protein a site directed mutagenesis/glycosylation approach has been applied to E. 
co/i-expressed rhEPO protein to introduce GlcNAc selectively through the thiol of a cysteine 
without any observable side reaction with any of the other four cysteine residues involved in 
disulphide bonds. 9 ' Moreover, different sugars have been introduced onto EPO peptide 
fragments on solid phase using iodoacctamide carbohydrate derivatives. This technology 
was compatible with native chemical ligation (NCL). 92 Finally. EPO protein backbone was 
selectively cleaved with cyanogen bromide. Afterwards, and applying expressed protein 
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ligation (EPL), an unnatural glycopeptide was introduced on the N-terminus containing 
GIcNAc. 93  While in all the previous examples a carbohydrate was incorporated either on a 
peptide or a protein through a native or unnatural glycosidic bond, in all cases, the sugar 
incorporated was not the physiologically relevant structure found either in G1yCAM-1 or 
EPO. 
Having available previous knowledge accumulated in the research group, the aim this thesis 
project was to produce either natural or unnatural glycopeptides that can be recognised in a 
biological environment. During the development of this research I hoped to discover novel 
methodology that could allow to obtain complex carbohydrate structures, and technology to 
recognise protein-carbohydrate interactions. 
The aims for this project were: 
Synthesis of core-1 disaccharide 0-linked to threonine building block ready to 
incorporate on a peptide using SPPS (Chapter 3). This structure can be more readily 
elaborated to more relevant structure using enzymes. 
Development of a peptide scaffold displaying carbohydrates (PSDC) based on the 
work of Meldal (Scheme.8), 14  which could potentially mimic the typical core 
pentasaccharide found in N-linked glycoprotcins. This structure should be equipped 
with the proper functional groups to attach to a peptide/protein backbone (Chapter 
4). 
Invention of a new methodology to incorporate carbohydrate structures on peptides 
(Chapter 5). This new neo-glycopeptide linker should facilitate the incorporation of 
complex carbohydrate structures such as the PSDC. 
Development of a technology to visualise protein-carbohydrate interactions using 
GFP (Chapter 6), and apply this technology to observe the interactions between the 
carbohydrate structures developed in the thesis and lectins. 
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3 Core-i 0-linked to threonine, a lycobuildin block for SPPS 
3.1 Introduction of amino acid glycobuilding blocks to SPPS 
As discussed in Chapter 1, glycoproteins are the product of co- and post-translational 
modifications of proteins. This process provides the hosts protein molecule a new level of 
complexity and new properties. Moreover, glycosylation of proteins allows biological 
systems to generate a combinatorial library of different glycoproteins, and therefore, 
amplifies the genetic code, by modifying the same core protein structure. Unfortunately, this 
procedure proceeds without gene control, and therefore, a wide variety of heterogeneous 
mixtures are produced. To understand the role and relevance of these compounds, there is a 
need for the production of homogeneous and specific glycoproteins. For this purpose, the 
most convenient pathway to obtain these molecules is through a chemical or enzymatic 
approach. 94 
Synthesis of glycopcptidcs can be achieved either in solution or on solid phase. In both 
cases, the most common synthetic route is the introduction of glyco-amino acid building 
blocks in the stepwise synthesis of the glycopeptide. 95 '96 Alternatively, in N-linked 
oligosaccharides, the carbohydrate can be conjugated directly to a full-length peptide. 97 
For the synthesis of glyco-amino acid building blocks, a good protecting group strategy must 
be applied. Protecting groups have to be compatible and robust during the synthesis of the 
required molecule, the introduction of the glyco-amino acid building block to the peptide, 
cleavage from the resin in SPPS, and also be easily removed in the final deprotection stage. 96 
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Synthesis of N-linked glycosyl amino acid building blocks for the production of 
glycopeptides on solid phase have been widely described in the literature: bis-glycosylated 
intcrleukin 8 (1L8) receptor fragment" or RNasc B fragments, 99 ' °° On the other hand, 
synthesis of the glycobuilding block as glycosyl amines, followed by direct aspartylation 97 in 
solution with the peptide can be achieved under classical peptide coupling conditions for the 
synthesis of N-linked glycopeptides.10 1 - 1 03 
For the semi-synthesis of 0-linked glycopeptides and glycoproteins, a general synthetic 
approach is the synthesis of glycosyl amino acid building blocks ready for SPPS. 95 In 0-
linked glycopeptides and giycoproteins, as described earlier (Chapter 1), the most common 
monosaccharide found is N-acetylgalactosamine (GaINAc), a-0-linked to the amino acid: 
serine or threonine. 
Lemieux and Ratcliffe' °4  used 2-azidogalactosc donors to ensure a-selectivity in the 
glycosylation with the amino acid (Scheme 3.1). Final reduction and acetylation of the azide 
is performed to obtain GalIVAc. On the other hand, Schmidt and co-workers used the 
presence of a "nitroglycal" 20 to perform a Michael addition of the free hydroxyl of the 
amino acid to the monosaccharide. Subsequent reduction of the 2-nitro group and 
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Scheme 3.1: Synthesis of a-0-linked glycosylated amino acid building blocks ready for SPPS. 106 
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Wong and co-workers developed a method to convert unprotected amino sugars to azides 
with retention of stereochemistry by diazo transfer with triflyl azide in the presence of 
catalytic amounts of copper (II), nickel (II) or zinc (II) (Scheme 3.2).' ° Moreover, this 
procedure is scalable without using anhydrous conditions. The authors proposed a 
mechanism where the amino compound complexes with the metal catalyst under basic 
conditions.' °8  Due to the extreme electrophilicity of triflyl azide, nucleophilic attack by the 
amine to the triflyl azide occurs, followed by deprotonation to form a metal-stabilised 
tetrazene. Decomposition of the intermediate would provide the azide product and the 
metal-triflyl imido complex (Scheme 3.2). 
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Scheme 3.2: Schematic procedure for the synthesis of azido sugars from their amino derivatives. 
Possible mechanism for the transition metal-catalysed diazotransfer reaction. 
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Once the carbohydrate is furnished with the required functionalities, it can react with the 
amino acid to obtain the desired glycobuilding block for SPPS. Although glycosylation of 
the protected threonine or serine can be achieved successfully, and with high a-selectivity 
using trichioroacetimidate and phosphate methods, normally, glycosylation of the amino acid 
is achieved employing the Konigs-Knorr procedure. 96" 09 
Two convergent synthetic routes can be followed to synthesise highly elaborate glyco-amino 
acid building blocks: 
• Threonine or serine is glycosylated with 3, 4, 6-tri-O-acetyl-2-azido-2-deoxy-a-D-
galactopyranosyl bromide, and afterwards, the sugar is deacetylated for further 
glycosidation of the hydroxyls in order of reactivity: 6-OH>3-OH>4-OH. '°" This  
I 
synthetic route is called the "cassette approach". ''--114  This methodology partially 
facilitates difficult glycosylation of amino acids, and does not require protecting 
group manipulation. 
• Threonine or serine is glycosylated with a complex oligosaccharide. This strategy is 
called the "classical approach".' °9 
Because of the biological implications of 0-linked glycoproteins in processes such as 
antifreezing glycoproteins, inflammation ,31 and cancer;' 6 there is huge interest in the area, 
and different glyco-amino acid building blocks have been developed. Interestingly, the core-
1 carbohydrate structure (Scheme 1.3, Chapter 1) forms part of most of 0-linked 
glycoproteins. Therefore, this glycobuilding block is a starting point in many synthetic 
routes. 
Meldal and co-workers used the "cassette approach", for the production of glycopeptides 
IH displaying core-I, core-2, core-3, core-4 and core-6 (Scheme 3.3). I I' - Moreover, the 
authors have applied the "classical approach"' 17,1111  for the development of libraries of 
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cancer vaccines."' One common feature of these "glycosyl cassettes" is the fact that the 
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Scheme 3.3: Reagents: i) TMSOTf; ii) Zn, Ac 20, AcOH; iii) Ac 20, pyridine; iv) AcOH (80 %) at 80 
°C; v)TFA." 7 
Meldal and co-workers managed to synthesise four different core carbohydrate structures 
found in mucin domains (Scheme 3.3), iteratively by: i) glycosyiation using 
trichioroacetimidate donors; 120 , 121 ii) concurrent reduction of the azide and cleavage of the 
Teoc- protecting group, followed by acetylation of the free primary amino group; 
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acetylation of free hydroxyl groups; iv) deprotection of benzylidene acetal in the presence of 
80 % aqueous solution of acetic acid at 80 °C; and finally v) deprotection of iert-butyl ester 
in the presence of TFA. 
Also using the same "cassette approach", Pratt and Bertozzi performed a semi-synthesis of 
two different glyco-amino acid building blocks related to 6-suipho sialyl Lewis X, 
corresponding to the core-1 and core-6 branches of the L-selectin ligand (Scheme 34)•123 
Although they did not apply SPPS to these molecules, they demonstrated the immense power 
of using glycosyl transferases to introduce the remaining monosaccharide units in the later 
stages of the synthesis, and as a source for creating diversity, to achieve the desired 
molecules. 
Scheme 3.4: Structure of suiphoadhesin with core-I and core-2 branches highlighted. Synthetic 
targets corresponding to: i) core-I. and ii) core-6. °3 
36 
3. Core-I 0-linked to threoninc, a glycobuilding block for SPPS 
In a "classical approach", Nishimura and co-workers synthesised an antifreeze glycoprotein 
(AFGPs),' 24  by introducing the core-I structure into a tripeptide using glycosyl fluorides 
(Scheme 3.5). 125.126  Further modification of the glycopeptide, and polymerisation of the 
monomer (H 2N-Ala-Ala-Thr(core- l)-CO 2H), employing diphenylphosphoryl azide (DPPA) 
as an efficient promoter in the presence of triethylaminc allowed the authors to obtain an 
artificial AFGP between 10-12 glycopeptide units (Scheme 3.5). Physical studies of a 
glycopeptide library of different lengths of peptide backbone, and displaying either: N-acetyl 
galactosamine, N-acetyl lactosamine, galactose, lactose or core-i structure 0-linked to 
threoninc or serine demonstrated that analogous glycopeptides displaying the same 
disaccharide as the native AFGP, regardless of the peptide backbone length, have more 
antifreeze activity than those which do not display the core-I structure. 6.127 
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Scheme 3.5: Nishirnura's synthesis of AFGP.' 24 
Danishefsky and co-workers, in a "classical approach", developed a convergent synthesis of 
a tumour-associated mucin motif (Scheme 3.6).' ° They joined 2,6-sialyl TN antigen to 
37 
3. Core-i 0-linked to threonine, a glycobuilding block for SPPS 
threonine and serine using a wide variety of glycosyl activators, such as: 
trichloroacetimidates, phosphates and bromides. Interestingly, the glycosyl bromide was 
elected as the best donor to glycosylate the protected amino acid with the free hydroxyl 
group. Afterwards, this glyco amino acid building block was incorporated into a peptide for 
the construction of a tumour associated glycopeptide. 
c 	 45.RH 
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Scheme 3.6: convergent coupling between 2,6-sialyl TN antigen and thrconine or serine. °9 
3.2 Objective: synthesis of core-1 0-linked to threonine for SPPS 
Macmillan research group achieved the semi-synthesis of G1yCAM- 1, by combining SPPS 
and EPL. In this work, 13 units of GalNAc were introduced at predetermined positions to 
the mucin domains using native glycosidic bonds. Finally the glycoprotein was assembled 
by EPL.8925  Despite developing new technology to produce native glycoproteins, the 
carbohydrates attached to the protein backbone, Ga1NAc, were not the physiologically 
relevant structures found in the native GIyCAM-l. In fact, sialyi Lewis X (SLex)  is the 
oligosaccharide found in this L-selectin counter-receptor (Scheme 3.7). 
Based on previous work, the preparative synthesis of core-i structure molecule (Gal-(A 1,3)- 
GaINAc) was decided, which could be the starting point for enzymatic elaboration to 
different carbohydrate structures. To achieve these goals, the synthetic route must be 
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scalable and high-yielding. Application of this structure to SPPS, and modification of the 
glycopeptide by either glycosyl transferases, NCL or EPL should lead to a new level of 
complexity. Having available homogeneous and predefined glycoproteins should allow 
better understanding of the biological role of the glycoproteins and their derivatives. 
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Scheme 3.7: Sulphated 0-linked chains of GIyCAM-1 
3.3 Design and retro-synthetic analysis of core-I glycobuilding block 0-linked 
to threonine for SPPS 
The synthetic strategy taken here was to introduce core-I disaccharide structure into a 
peptide as a glycoamino acid using SPPS. For this goal, the target molecule needed a  fi-
glycosidic bond between the two monosaccharide units; subsequently, this disaccharide was 
attached to the amino acid, threonine, through an a-linkage. 
In order to perform the synthesis of the glycopeptide on solid phase using Fmoc-
chemistry, 129  it was required to choose the appropriate protecting groups that were stable 
under the basic conditions of Fmoc deprotection (20 %-25 % piperidine or SO % morpholine 
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in DMF or NMP), compatible with the peptide coupling reactions, robust to the harshly acid 
conditions of the peptide cleavage, and removable under mild conditions. 43 
For the protection of the 4- and 6- hydroxyl groups of proximal GaINAc subunit, a level of 
flexibility and versatility was introduced as this could allow, in the future, the introduction of 
N-acetyl glucosamine (GIcNAc) to enable the synthesis of the core-2 carbohydrate structure 
or even more ambitious structures. Bearing these precepts in mind, the benzylidene acetal 
protecting group for 4- and 6- hydroxyls of GalNAc, emerged as one of the potential 
possibilities: the benzylidene acetal can be selectively deprotected with Na(Bi-1 3 )CN in TFA 
to afford the free 4-hydroxyl group. Conversely, selective deprotection to afford 6-hydroxyl 
occurs in the presence of LiAIFI 4 and Aid 3 in ether. 42 On the other hand, acetylation of the 
hydroxyl groups could fulfil the requirements needed for the synthesis of the target 
molecule. The acetyl protecting group is robust under a broad set of conditions, including 
Fmoc- chemistry and it is easy to deprotect by Zémplen deprotection. 6 Moreover, due to 
the nature of the /-linkage between the two monosaccharides of core-i structure, 
neighbouring group participation of the acetyl group in the 2-hydroxyl group of galactose 
(Gal) subunit would be necessary to control the stereoselectivity of the glycosyl linkage. 42" 30 
The natural requirement of having an N-acetyl group of GalNAc in the position 2' of core-I 
structure a-0-linked to an amino acid (serine or threonine), required the use of the anomeric 
effect rather than the neighbouring group effect to perform the glycosylation of the amino 
acid. The presence of an azide in the position 2' of the disaccharide could fulfil these natural 
requirements (donor 2, Scheme 3.9). Moreover, mild reduction conditions followed by 
acetylation of the resulting primary amine should lead to the desired final functionality. 
A wide variety of protecting groups are available for the protection of the carboxylic group 
of the amino acid. There arc precedents in the literature for the use of ester groups, such as: 
benzyl or tert-butyl ester; or even pentafluorophenyl esters (Pfp). 95 ' 96 Unfortunately, the 
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requirement to perform giycosylation of the protected amino acid under mild acid conditions, 
discarded the use of tert-butyl ester, due to its acid-lability. 
In the retro-synthetic analysis (Scheme 3.8), the glyco-amino acid building block is 
assembled by reacting the fully protected disaccharide equipped with a good leaving group 
such as fluoride, bromide or trichloroacetitnidate; and Fmoc threonine, in which the 
carboxylic acid could be masked either with a benzyl or Pfp-ester. Obviously, the protected 
threonine would come from the natural unprotected amino acid 70. Formation of an a-
linkage between the carbohydrate and the free hydroxyl group of the amino acid, would be 
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Scheme 3.8: retro-synthetic analysis for the amino acid glycobuilding block f or SPPS. 
The disaccharide would come from a glycosyl acceptor with a free C-3-hydroxyl group, 56, 
and a peracetylated donor with trichloroacetimidate as a good leaving group, 23, that would 
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provide a /3-linkage (Scheme 3.8). Both donor and acceptor units would come from 
commercially available D-galactose, 48. 
3.4 Synthesis of core-1 glycobuilding block 0-linked to threonine for SPPS 
3.4.1 Synthesis of glycosyl acceptor 
The synthesis of the glycosyl acceptor 56 was successfully accomplished on a multigram 
scale (Scheme 3.9), starting with commercially available D-galactose 48. 
Galactose 48 was peracetylated with acetic anhydride, in the presence of a catalytic amount 
of perchioric acid, affording a quantitative reaction within 3 hours (Scheme 3.9). Five 
singlets between 2.18 and 1.97 ppm integrating for 15 protons revealed the peracetylation of 
all hydroxyl groups by 'H-NMR. Moreover, a small coupling constant for Hi denoted the 
generation of the thermodynamic a-product (J12= 1.7 Hz). 
Halides are commonly used as leaving groups in nucleophilic substitution. Bromides, 
chlorides and fluorides are the most commonly used as anomeric halides. They are 
particularly useful as glycosyl leaving groups. Moreover, glycosyl bromides could be used 
for the generation of glycals. Synthesis of the glycosyl bromide 50 was initially attempted 
using titanium tetrabromide, TiBr 4 ' 3 ' Unfortunately, a poor yield of only 37 % was 
achieved. On the other hand, a-bromination was obtained quantitatively when the 
peracetylated galactose was treated with HBr in acetic acid (Scheme 3.9). The presence of 
two isotopic species was observed in FAB-MS (found 409.0 and 411.0), confirming the 
presence of bromine in the molecule. 
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Scheme 3.9: Synthesis of glycosyl acceptor. 
For the production of the galactal 51 through reductive elimination, there are several 
precedents in the literature. 111,133 The reaction was accomplished in high yield by treating 
with zinc in acetic acid. In this reaction there was a simultaneous elimination of the bromide 
and 2-acetyl group, producing a cyclic carbohydrate enol ether, termed a glycal. 
As discussed earlier in this chapter (Section 3.4), it is essential to have and N-acetyl group at 
the C-2 position of the galactopyranose in core- i. Moreover, this monosaccharide has to be 
a-0-linked to the peptide/protein. Therefore, to achieve this target molecule, the most 
common procedure is the introduction of a non-participating azido group at C-2 by 
azidonitration. Later on, it can be easily converted to an N-acetyl group by consecutive 
reduction and acetylation. 
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The azidonitration of protected glycals disclosed by Lemieux and Ratcliffe in 1979,  04  is one 
of the most common routes for the generation of 2-azido sugars, although other successful 
procedures have been described. 107 , 101 , 114-116 In this reaction (Scheme 3.9), the crude glycal 51 
was dissolved in anhydrous acetonitrile, and then, cerium ammonium nitrate (CAN) and 
sodium azide were added. The oxidation of the anomeric position of the glycal with CAN 
facilitated the regioselective incorporation of the azide group at C-2 and the nitrate group, to 
produce the desired molecule (Scheme 3.10). The regiospecificity of this procedure could be 
due to the stability of the radical formed at the anomeric carbon, which was oxidised again 
with CAN to obtain a carbocation that was consequently attacked by the nitrate. The 
formation of the N-acetyl group at the anomeric position of one of the side products 57 could 
be related to a competitive nucleophilic attack of the solvent, acetonitrile, to the carbocation 
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Scheme 3.10: plausible mechanism for the introduction of a non-participating azido group at C-2 by 
azidonitration. 
Anomeric dcnitration is often achieved with sodium nitrite in aqueous dioxane at 80 °C for 3 
days, achieving the resulting hemiacetal in a good yield. On the other hand, and according to 
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a shorter procedure developed by Sina 37 ' 38 and co-workers, the reaction was carried out 
with thiophenol in the presence of DEPEA in dry acetonitrile. The hemiacetal 53 was formed 
in 100% yield and was isolated as an anomeric mixture (a/fl; 1:4)(Scheme 3.9). 
Silyl ethers are commonly used for the protection of alcohols due to their facile introduction, 
relatively good stability and easy deprotection. This type of protecting group is selectively 
removed by treatment with a source of organic soluble fluoride, such as tetrabutylammonium 
fluoride (TBAF) or mixtures of HF/pyridine. 43 Therefore, for the masking of the anomeric 
hydroxyl of the hemiacetal 53, the reaction was carried out with tert-butyldimethylsilyl 
chloride in the presence of imidazole, which also participates by activating the silyl chloride, 
achieving a 88 % yield for the protected molecule 54 (Scheme 3.9). Due to the bulkiness of 
the silyl group, the only product obtained was the JJ-anomer, and its structure was confirmed 
by 'H-NMR: J12= 7.6 Hz. This result suggested that during the course of the reaction 
anomerisation occurred. 
Deacetylation of the monosaccharide was accomplished by dissolving the acetylated sugar 
54 in methanol, and treating the mixture with a base, sodium methoxide, for 20 hours (pH 
below 9).' When the reaction was completed, the crude mixture was neutralised with 
Amberlyst-l5 acid ion exchange resin (Scheme 3.9). Special care must be taken when 
adding the base in the reaction (pH below 8.5), to avoid intermolecular migration of the silyl 
group from the anomeric position to the deacetylated 6-hydroxyl group. 43 
Protection of 55 with benzaldehyde dimethylacetal was performed with a catalytic amount of 
p-tosic acid at 50 °C to obtain the desired product 56 in 89 % yield (Scheme 3.9). 
The acceptor molecule 56 possessed all the requirements defined for the glycosidation with 
the donor 23. While all the hydroxyl groups of the molecule were strategically protected, the 
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C-3-hydroxyl group was free. Therefore, the next aim was the synthesis of the glycosyl 
donor 23. 
3.4.2 Synthesis of glycosyl donor 
Synthesis of the glyeosyl donor was accomplished in three steps (Scheme 3.11). The 
synthetic route also started with the commercially available D-galactose, which was 
peracctylated with acetic anhydride and catalytic perchioric acid. 
Anomeric deacetylation was pursued for the introduction of a trichioroacetimidate as a 
leaving group for glycosidation of the glycosyl acceptor 56. Different approaches were 





Ac,0. '-1C104 	 BnNH,, TI-IF
am 	 0 
48 HO011 	
100 %. 	AcO 	
49 AcO 	OAc 
AcO 	OAc 
- 	







Scheme 3.11: Synthesis of glycosyl donor. 
Previous work carried out in the Macmillan research group achieved the generation of the 
hemiacetal 58 in a preparative two steps synthesis (Scheme 3.11). 49 was converted to a 
thioglycoside 59, and this was followed by the conversion of the molecule into the desired 
herniacetal 58 with NBS, acetone and water in half an hour. 
Although the overall yield over two steps was 68 %, direct hemiacetal formation was studied 
to reduce the number of the synthetic and chromatographic steps, avoid the use of large 
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amounts of toxic and odorous thiophenol, and to increase the yield for the anomeric 
deprotection. 
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Scheme 3.12: synthesis of the hemiacetal through a thiophenol intermediate. 
There are different procedures for selective anomeric deprotection in the literature. In the 
first attempt, the protected monosaccharide 49 was treated with ammonium carbonate in 
methanol to achieve just 16 % yield of the hemiacetal 58, and other by-products as a result of 
non-selective deacetylation of the peracetylated molecule (Scheme 3.13). When the 
molecule was subjected to hydrazine and acetic acid, 139  58 was isolated in 53 % yield, and 47 
% yield of the starting material 49. Finally, 95 % yield of the hemi-acctal 58 was efficiently 
obtained when the peracetylated galactose 49 was treated with benzylamine' 4° in THF at 50 
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Scheme 3.13: different approaches for anomeric deprotection. 
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As described earlier (Chapter 2, section 2.1.2.), there is a wide variety of leaving groups for 
glycosidation. Between all these groups, trichloroacetimidates, introduced by Schmidt and 
co-workers 120  using as an activator the Lewis acid BF 3 'OEt2, allows the formation of the oxo-
carbenium ion, and consequently, this can be trapped by a nucleophile such as a free 
hydroxyl (Scheme 3.14).121 Introduction of trichloroacetimidates to a glycosyl donor is 
achieved by reacting the hemiacetal with trichloroacetonitrile under basic conditions (NaH, 
DBU or K2CO3)  in dry DCM.' 4  The generation of an amide is the driving force for the 
glycosidation reaction. Addition of activated molecular sieves avoids the formation of the 
hydrolysed adduct. In this reaction, different types of Lewis acids can be used as a catalyst 
to generate mild acid conditions to activate the glycosyl donor: BF 3 OEt2 , 120 TMSOTf' 2 ' or 
AgOTf. Glycosyl trichioroacetimidates can be isolated and stored. This elegant 
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Scheme 3.14: Introduction of the trichloroaceti mi date in the giycosyl donor 58 under basic 
conditions, and glycosidation of a glycosyl acceptor 60 in the presence of a Lewis acid catalyst to 
produce a more complex carbohydrate structure 61. 
The introduction of trichioroacetimidate into the hemiacetal 58 was initially conducted with 
K2CO3 in dry DCM, resulting in a 71 % yield of the anomeric mixture of a and /3(2:3), 
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separately isolated by silica flash chromatography. A considerable increase in the yield was 
achieved by treating the hemiacetal with tri chi oroacetonitrile in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), producing exclusively, the a-anomer product, a-23, 
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Scheme 3.15: Introduction of trichloroacetirnidate to the hemiacetal 23. 
3.4.3 Synthesis of P-(fluorene-9-nylmethoxycarbonyl)-O-[2, 3, 4, 6-tetra-0-
acetyl-D-galactopyranosyl-(13- I, 3)-4, 6-diacetyl-2-acetamido-2-deoxy-a-D-
galactopyranosyll-L-thrconine, 
Upon formation of the synthesis of the glycosyl donor 23 with the trichloroacetimidate as an 
activator, and the glycosyl acceptor 56 with the free 3-hydroxyl group, the glycosidation 
reaction between these two monosaccharides was performed (Scheme 3.16). 
The a and 16epimeric mixture of the glycosyl donors 23 was activated with TMSOTf under 
strictly anhydrous conditions; and reacted with the free 3-hydroxyl group of the glycosyl 
acceptor (Scheme 3.16). Despite the lability of the benzylidene acetal group in the acceptor 
monosaccharide under the acidic conditions of the glycosidation, the reaction afforded the 
product in 80 % yield. The /3-stereochemistry of the glycosidated product at the anomeric 
centre was confirmed by 'H-NMR (J12  8.0 Hz). 
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Scheme 3.16: glycosidation between the glycosyl donor and acceptor. 
After the glycosidation between the glycosyl donor 23 and the acceptor 56, the potential 
routes for coupling the core-i disaccharide to threonine to obtain the desired product were 
investigated. To achieve this goal, it was planned to introduce a fluoride, bromide or 
trichioroacetimidate as a leaving group for glycosylation (Scheme 3.17). Moreover, it was 
investigated which protecting groups within the disaccharide and the amino acid were the 
most appropriate for the glycosyiation between the two molecules. 
Silyl deprotection of disaccharide 63 was performed using Takano's procedure, 141 with 
tetrabutyl ammonium fluoride (TBAF), buffered with acetic acid in THF at room 
temperature overnight (Scheme 3.17), obtaining a 76 % yield for the reaction. 
The first reasonable approach to obtain the desired disaccharide equipped with the leaving 
group on the anomeric position to glycosylate the amino acid, based on previous experience, 
was the direct introduction of the trichioroacetimidate. This was performed following the 
procedure of Meldal and trichloroacetonitrile, DBU in dry DCM at 0 °C for 2 
hours, achieved a 100 % yield of the disaccharide as anomeric mixture, with the desired 
activator 64 (Scheme 3.17). 
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Scheme 3.17: synthesis of disaccharide donor equipped with different leaving groups 
(trichioroacetimidate, bromide or fluoride), and protecting groups. 
Synthesis of glycosyl fluorides can be achieved by reacting the hemiacetal with DAST in 
THF, 142 or by reacting a thioglycoside with DAST and NBS. 143 The reactivity of the 
glycosyl fluorides is quite similar to the bromides and chlorides, although several advantages 
make them more attractive: easy synthesis under mild conditions, relatively high stability 
towards manipulation and storage, and wide range of methods for glycosylation. 52 One of 
the disadvantages observed was that during activation, the generation of fluoride ion could 
be inconvenient if the donor or acceptor is protected with silyl groups, leading to the 
undesired deprotection and possible undesired glycosylation (Chapter 4). Nevertheless, 
having available the hemiacetal 63, the fluoride was introduced at the anomeric position 
using DAST in THF to achieve a poor yield (23 %) of the product 65 .  142, The presence of 
the fluoride was detected by ' 9F-NMR spectroscopy, -146 ppm, while a-fluorination of the 
structure was confirmed by H-NMR spectroscopy, which showed a small constant between 
H-i' and H-2' (J 2 2.5 Hz). 
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On the other hand, the possibility of changing the benzylidene acetal for acetyl groups was 
envisaged, as this could decrease steric hindrance and rigidity of the ring structure during the 
formation of the oxo-carbenium intermediate in the glycosylation process, and therefore, 
increase the final yield of the process. To change the protecting groups, an extensive study 
to find suitable conditions for this purpose was performed. Firstly, the hemiacetal 63 was 
treated with catalytic amounts of perchioric acid in acetic anhydride to achieve a 52 % yield 
of the purified product 66. Afterwards, adapting a procedure from Meldal and co-workers,' 3 
the disaccharide 63 was treated with acetic anhydride and sulphuric acid for 15 hours at 0 °C 
to achieve 88 % of 66 on a 0.32 mmol scale (200 mg). Unfortunately, this reaction was 
temperamental when the reaction was scaled up, promoting the decomposition of the 
components under such harshly acidic conditions. By changing sulphuric acid for 
trifluoroacetic acid, acetylation of the hemiacetal was achieved without damaging the 
benzylidene acetal group. Finally, in order to achieve the peracetylation of the molecule, the 
disaccharide 63 was treated first with an aqueous solution of acetic acid 80 % for 2 hours at 
80 °C, and then with acetic anhydride/pyridine (1:2) to achieve a 100 % yield of the 
peracetylated molecule 66. Moreover, this procedure proved to be more robust when scaled 
up to preparative quantities (1.54 g, 2.47 mrnol scale). 
Based on previous experience, the anomeric deacetylation was pursued for the formation of 
the hemiacetal with benzylamine in THF, to achieve a 68 % of the desired product 67. 
Introduction of the trichloroacetimidate was conducted using the same conditions previously 
described to achieve 68 in 58 % yield. On the other hand, introduction of the bromide at the 
anomeric position of the disaccharide proved to be simpler, by treating the peracetylated 
molecule 66 with titanium tetrabromide to produce the a-bromide 69 in 91 % yield (Scheme 
3.17). The a-stereochemistry of the brominated product was confirmed by 'H-NMR (J, 2 = 
3.8 Hz). No column chromatography purification was required to isolate the pure product. 
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Having a small panel of disaccharides with different glycosyl activators (Scheme 3.17), the 
requirements for the amino acid component were addressed. As mentioned before (Section 
3.4), the acceptor molecule must have an Fmoc- group to protect the primary amine; and an 
ester resistant to potentially acidic conditions of glycosylation, but quantitatively removable 
when required, to protect the carboxylic acid. Benzyl and pentafluorophenyl esters emerged 
as potential protecting groups. Obviously, the hydroxyl group of the threonine must be 
accessible for glycosylation. 
Fmoclhr(OBn) 46 was already available in the Macmillan research group. Generation of 
FmocThr(OPf) 72 was achieved following literature procedures. 141,14'  The primary amine 
of the threonine 70 was protected with the fluorenyl protecting group through a reaction with 
FmocOSu in water and acetonitrile, achieving 100 % yield. Afterwards, the formation of the 
Pfp ester was achieved by treatment with pentafluorophenol and DCC in ethyl acetate to 
achieve 75 % yield (Scheme 3.18). 
HO 	CF!3 	 110 
	
CH, 	 110 	CH, 
H1N H 	
F)wcOSuc, ia3 	 Pfp-01-1, DCt, EIOAc
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Scheme 3.18: Synthesis of FmocThr(OPfp) 72. 
Having access to both glycosyl donor and the amino acid acceptor, in suitably protected 
forms, trial glycosylation conditions were studied. 
In preliminary studies, suitable conditions for the glycosylation of threonine were explored. 
Model experiments were carried out between peracetylated galactose trichloroacetimidate, 
and Fmoc- threonine, either with benzyl 46 or Pfp ester 72 protecting the carboxylic acid 
(Scheme 3.19). Similar conditions were applied for the formation of the disaccharide 62. In 
the presence of TMSOTf in dry DCM at -50 °C, the benzyl ester amino acid 46 tended to be 
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hydrolysed faster than the Pfp derivative 72 consequently having a dramatic effect on the 
final yield of the product: 30 % and 70 % respectively. These results were in accordance 
with Mcldal's research work on glycosylation of Pfp ester amino acids, 
112118147-150  and 
pivotal, because it drew the project towards the decision to choose the activated ester as a 
protecting group for the amino acid, when glycosylation with the core-i structure was going 





46; R: -Bn 
o 72; R: -OP1 
TMS-OTf, DCM 
 
74; R: -OPf (70%) 
Scheme 3.19: Model experiments for glycosylation on different protected threonine acceptors. 
Applying this knowledge, it was decided to glycosylate the Pfp ester derivative of threonine 
72 with the disaccharide 64. Using the same conditions previously described, an epimeric 
mixture of the a- and fl-anomer 75 in 32 % and 12 % yield respectively was obtained. 
Unrcacted amino acid 72 was also recovered (Scheme 3.20). 
1-10 	CH 3 
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Scheme 3.20: Glycosylation between glycosyl donor and threonine Pfp ester acceptor. 
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The crude mixture was difficult to purify by flash chromatography due to the large amount 
of undetermined side products. Moreover, TLC demonstrated that some decomposition of 
the Pfp ester occurred on silica gel. Similar results with 64 and 72 were obtained when 
AgOTf was used as activator. As predicted (Section 33),47  better conversion was obtained 
under these same conditions when the peracetylated disaccharide 68 was employed to afford 
76: a-anomcr: 36 %; fl-anomer: 18 % (Scheme 3.20). Purification of the crude mixture and 
stability of the products under the chromatography conditions, seemed to be challenging. 
In an attempt to increase the yield of the glycosylation, reactivity of the glycosyl fluoride 65 
(Scheme 3.17) with threonine was studied. Glycosyl fluorides were introduced by 
Mukaiyama.' 5 ' Glycosylation was achieved using AgCl0 4 and SnC12 as promoters. This 
methodology has been expanded to a repertoire of other promoters: BF 3 Et20,' 52 TMS0Tf, 153 
Cp2Hftl2, 154 Cp2ZrCh-AgBF4 and Cp 2Hft 1 2-AgTfO/AgClO4 126 and Cp2ZrCl2-AgCI04. 125 
Having all these precedents in the literature, and based on Nakahara's work 15 glycosylation 
of threonine derivative 46 was pursued using the modified core-1 structure 65 in the 
presence of Cp 2ZrC12 and AgC104  was carried out. Surprisingly, the benzylidenc acetal 
protecting group did not withstand the acidic conditions of the reaction, and was cleaved to 
provide the partially deprotected adduct as an epimeric mixture in 35 % yield. 
To increase the yield for the glycosylation of threonine, use of bromide as a leaving group 
for glycosylation of threonine was investigated. 
Glycosyl bromides were the first type of glycosyl donors to be used for disaccharide 
formation more than a century ago by Knoenigs-Knorr. ° This reaction involves the 
coupling of a glycosyl bromide (or chloride) with a hydroxyl component in the presence of a 
halophilic promoter, typically a heavy metal ion (silver or mercury). The original activators 
used were insoluble silver oxide or carbonate (A9 20 or A92CO3) but these have been 
superseded by the use of soluble silver triflate or perchlorate (Ag0Tf 56 or AgC104), or by 
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other types of soluble mercury salts (e.g. HgBr 2 or Hg(CN) 2). 157 The general mechanism of 
this reaction (Scheme 3.21) involves the in situ generation of the more reactive fl-halide, 
followed by glycosylation with inversion to achieve the a-glycoside. Construction of the fi-
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Scheme 3.21: Proposed mechanism of the Koenigs-Knorr glycosylation reaction. 
158 
Glycosyl bromides are not particularly stable and normally they are synthesised immediately 
prior to being used for glycosylation. Moreover they need at least a stoichiometric amount, 
or even more, of a heavy metal promoter making the disposal of the metal a problem with 
the methodology. 
Using the reaction conditions for glycosylation of amino acids with glycosyl bromides 
developed by Danishefsky and co-workers,' 09 the disaccharide 69 reacted with the bcnzyl 
ester threonine derivative 46 in the presence of AgC 10 4 in dry DCM at room temperature to 
obtain 34 % of the a-anomcr 77 and 18 % of the fl-anomer. Interestingly, apart from the 
unreacted threonine derivative 46, the presence of the hydrolysed disaccharide 78 was also 
observed (44 % yield). This result could give the potential to recycle the disaccharide by: i) 
acetylation the hemiacetal, and ii) re-bromination of the donor. On the other hand, by simply 
adding 2,4,6-collidine in the reaction (2.5 equiv), a 45 % of the desired a-anonier 77 was 
achieved without any trace of the fl-derivative. A 22 % yield of the hydrolysed disaccharide 
78 was recovered, and this was acetylated successfully with acetic anhydride and pyridine 
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(1:2) in 90 % yield to afford the peracetilated molecule 66, which was recycled to increase 
the overall yield of the process (Scheme 3.22). 
AcO O )4 
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Scheme 3.22: Glycosylation of the thrconine derivative 46 with a-bromide, 69. 
In this glycosylation process it was observed that the yields were lower than predicted. This 
result could be due to an intramolecular hydrogen bonding interaction between the hydrogen 
of the amino group and the pair of electrons of the oxygen of the hydroxyl of the acceptor 
46, decreasing dramatically the nucicophilicity of the amino acid. Polt and co-workers' 59" 6° 
by-passed this drawback by transforming the primary amine into an imine. Therefore, 
benzyl-N-(diphenylmethylene)-L-threonine 79 was synthesised by treating the benzyl ester 
amino acid with diphenylmethylenc imine in DCM for 24 h to achieve a 89 % yield. 161 
Following the Polt 69 reacted with 79 in the presence of silver perchlorate and 
collidine in dry DCM, to achieve the desired product 80 in 44 % yield (Scheme 3.23). This 
low yield is partially in accordance with the results that Polt and co-workers obtained for 
3 ,4,6-tri-0-acetyl-2-dcoxy-2-azido- 1 -bromogalactose.' 6° 
Having the previous results, and therefore, consequent deprotection of the amino group of 
the glyco-amino acid, and re-protection with Fmoc- group, made this final approach 
nonviable for the preparative intentions of the present work. 
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Scheme 3.23: Glycosylation of the threonine derivative 79, by the brominated core-1 structure 69. 
In conclusion, the overall study for glycosylation of threonine led to two different 
approaches: i) glycosylation of the Pfp ester threonine derivative 72 with the 
trichioroacetimidate derivative, either 64 or 68, lead to a epimeric mixture of 75 and 76 
respectively (Scheme 3.20); but conversely, ii) glycosylation of threonine benzyl ester 
derivative 46 with brominated disaccharide 69 in the presence of 2,4,6-coilidine provides 
only, the a-anomer product 77 (Scheme 3.22). 
Once the core-i structure 77 was formed (Scheme 3.24), the reduction of the azide at the C-2 
position, followed by subsequent acetylation of the amino group, was achieved successfully 
in a one-pot fashion, affording the N-acctylated product 81 in 95 % yield. 
Scheme 3.24: Synthesis of core-i structure a-O-Iinked to threoninc 82 for SPPS. 
Finally, the removal of the benzyl ester protecting group was performed by catalytic 
hydrogenation using 10 % palladium on charcoal in methanol, in 3 hours. The 
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hydrogenolysis afforded the generation of the desired glyco-amino acid building block 82 in 
95 % yield (Scheme 3.24). 
Having available the different glyco-amino acid building blocks ready for SPPS: a-75, a-76 
and 82, it was intended to assess the insertion of these structures into a peptide, using 
standard procedures of SPPS (Scheme 3.25). The testing glycopeptide sequence for these 
molecules was: Cys Ser SerG1wLeuGlc-Thr(core- 1)• Ser, molecule 83. The synthesis of the 
R. 
glycopeptide was carried out on a pre-loaded Fmoc-Ser(tBu)-NovaSyn TGT resin (loading = 
0.22 mmol/g). The scale of the synthesis was 0.10 mmol. For each peptide coupling it was 
used 10 equivalents of each amino acid with HBTU/HOBt and DIPEA, for 3 hours. On the 
other hand, 1.5 equivalents of the glyco-amino acid building block reacted with the peptide 
on the solid support, in the presence of 1.5 equivalents of DCC/HOBt, for 24 hours in DMF 
(see Experimental section). 
Ph 
Scheme 3.25: glyco-amino acid building blocks a-75 and 82 ready for SPPS for the synthesis of the 
glycopeptide sequence: Cys Ser SerGlu LeuGlcThr(core- I) Ser. 
Purification of a-75 and a-76 tended to be very difficult for small amounts of the crude 
reaction. But when the production of these compounds was scaled up, the purification 
proved impossible. In addition, the purification of a-75 from the Pfp ester linked to 
threonine 72 was unsuccessful. This contamination of the compound a-75 was a limitation 
of this synthesis of the desired glycopeptide. When it was applied on SPPS, a mixture of two 
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products was obtained: the desired glycopeptide and the unglycosylated peptide. An obvious 
explanation could justify this result: traces of the contaminant, Pfp ester threonine 72 reacts 
faster with the growing peptide than the desired glycosylated reagent a-75. This could be 
due to the fact that the impurity has lower molecular weight than the fully elaborated glyco-
amino acid building block. Moreover, the presence of a disaccharide on the activated Pfp-
amino acid could reduce the accessibility of the primary amine of the growing peptide, due 
to steric hindrance. This produced an inevitable loss of yield. This drawback obligated to 
obtain highly purified glyco-amino acid building blocks to react on SPPS. 
The molecule 82 seemed to meet all the previous requirements of purity and scalable 
synthesis. When this component was applied to SPPS, applying the same reaction conditions 
(see Experimental section), the desired glycopeptide was obtained after cleavage from the 
resin. Finally, the disaccharide of the glycopeptide was deacetylated in phosphate buffer 0.1 
M, pH 8 solution, with 5 % hydrazine hydrate and 10 % DTT; obtaining the desired 
glycopeptide 83 in 29 % yield (Scheme 3.26). 
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Scheme 3.26: LC-MS of the purified desired glycopeptide 83: MW 0i : 1347.52, MW0b5 : 1348. 
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This last successful approach for the synthesis of the molecule 83, established the glyco-
amino acid building block 82 as the chosen structure for SPPS, for the synthesis of 
glycopeptides. 
3.5 Conclusions and future work 
The successful synthesis of the glyco-arnino acid building block 82 opened a wide variety of 
different research opportunities, using the molecule as starting material for SPPS. 
As part of Macmillan research program, development of technology for the production of 
pure glycopeptides and glycoprotcins is a priority. Consequently, bacterial expression of 
active human core-2 fl-GlcNAc transferase is part of the interest of the Macmillan research 
group. This enzyme is a mammalian glycosyl transferase that transfers a single unit of 
GlcNAc to core 1, by a fl-1,6 linkage, employing a-UDP-GlcNAc. The glycopeptidc 83 
could help to evaluate the activity of this new active human core-2 fl-GlcNAc transferase. In 
the presence of this bacterial expressed enzyme, and a-UDP-GlcNAc; and in the appropriate 
medium, an increase in the molecular weight of the glycopeptide substrate should be 
observed by LC-MS, related to the transfer of a unit of GlcNAc to 83. However, it has not 
been possible to overexpress soluble and active core-2 fl-GlcNAc transferase from E. coil 
and consequently this approach has had to be abandoned. 
Regardless of the successful synthesis of core-I structure 0-linked to threonine ready for 
SPPS 82; the synthetic route is notoriously laborious and time consuming. Moreover, 
although the synthesis of this structure is convergent, through a "classical approach", the 
glycosylation of threoninc requires very strict conditions of dryness, and still, the yield is 
low for such a valuable disaccharide. 
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Owing to the complexity of the synthesis of the core-1 glyco-building block, and lack of 
available enzymes, it was decided to explore more productive methodologies to elaborate 
complex carbohydrate structures based on Meldal's 84 research work (Chapter 4). In addition, 
preliminary investigations using triazole formation to make modified glycoproteins were 
proving more successfull and this avenue was also explored (Chapter 5). 
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4 Synthesis of a novel unnatural peptide scaffold to display carbohydrates 
(PSOC) 
4.1 Introduction 
Production of native glycoproteins is a challenging task. While the total synthesis of these 
structures has been achieved by the Macmillan research group and by others. 9162164  the 
methodology remains far from simple. The difficulties stem from long and laborious 
synthesis of complex carbohydrates; high demand for stereo- and rcgiocontrol of each 
glycosidation and low efficiency of protein glycosidation. 
As previously discussed, a number of attempts have been made to address these issues. 
Promising strategies include improved methods of glycosidationl glycosylation. 5 ' solid phase 
oligosaccharide synthesis, 165  or enzymatic carbohydrate synthesis. 166 Moreover, NCL and 
EPL' 67  have provided the opportunity to assemble building blocks for the production of 
glycoproteins. However, with all these advances, production of glycoprotein and 
glycopeptides is still difficult. 
One option to tackle these difficulties is the synthesis of glycoprotein/glycopeptide mimics. 
These compounds have been created to study saccharide function, modification of the 
targeting properties, improvement of the biological activity, and ease of synthesis. Different 
strategies used for preparation of glycoproteins mimics exist (Scheme 4.1). In the first 
approach, the protein backbone remains, but the saccharide is substituted. In another 
approach, the protein is unchanged, the saccharide may or not may be replaced, but the 
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linkages between the carbohydrate and protein and the location of glycosylation are altered. 












Scheme 4.1: Different approaches for designing glycoprotein mirnetics.' 
Introduction of neo-glycopeptide linkages, through chemoselective ligation,' <' 5 using eg. 
acctamides,' 69 disulphide bond or "click chemistry" glycosydic bonds,' 7 ' has 
facilitated the glycosylation of peptides or proteins (Chapter 5). In contrast, the construction 
of complex carbohydrate structures remains challenging. 
Kent and co-workers"'- 17' accomplished the total synthesis of an homogeneous polymer-
modified erythropoiesis protein (SEP). An unnatural tetra-branched polymer was introduced 
into predetermined positions (Lys24 and Lys 126) using a chemical ligation 161  (Scheme 4.2, 
A). One of the aims of this work was to avoid the synthesis of the complex polysaccharide 
found in EPO (Scheme 1.4). Introduction and display of negative charges at physiological 
pH was achieved through appending carboxylic acids to the polymeric chain (Scheme 4.2, B, 
carboxylic acids highlighted in red). This structure was intended to mimic the native 
tetraentanery polysaccharide that displays negative charges through the presence of sialic 
acid residues at the ends of the sugar (Scheme 1.4). 
The polymeric chain to the peptide fragments (SEP 1-32 and SEP 11 7-166) was introduced 
by oxime-forming ligation at predetermined positions. Ordered sequential ligations were 
64 
4. Synthesis of a novel unnatural peptide scaffold to display carbohydrates 
carried out to connect the different building blocks. Final folding of the molecule provided 
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Scheme 4.2: Synthesis of Synthetic Erythropoiesis Protein (SEP). A) Diagram of SEP indicating the 
amino acid sequence, disulphide bonds and the modified lysines (Lys24 and Lys 126), and cysteines 
(Cys89 and CysI 17). B) Structure of branched, negatively charged, polymer moiety. C) Scheme for 
the synthesis of SEP by chemical ligation. 172 
This unnatural glycoprotein exhibited specific activity in vitro and extended half life in vivo, 
relative to human erythropoietin (EPO). This was attributed to a decrease of metabolism due 
to the protective effect of the negative charges of the carboxylic acids of the polymeric 
chain. Unfortunately, this molecule showed an inmunological response in humans during 
clinical studies (information provided by Prof. Stephen B. H. Kent, December 2005). 
Nishimura and co-workers 174  attempted to increase the solubility and decrease hepatic 
decomposition of Insulin (a non-glycosylated pancreatic peptide hormone that controls the 
glucose levels in blood, and is therapeutically used for the treatment of diabetes). The 
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terminal glutamine residue of a mutagenic insulin: lns(B-F1Q). 	Sia-2,6-Lac was 
subsequently obtained through the use of a recombinant a-2,6-sialyltransferase (Scheme 
4.3). 
This insulin-mimic demonstrated a longer half life in vivo than either the wild type or the 
lactose modified peptide (Lac-lns(B-F1Q)). Extending this principle with mono-, di- or 
trisialyloligosaccharide dendrimers, it was demonstrated that the in vivo half life of the 
modified peptide increases with the number of sialic acids displayed."' 
il-N 	 C) 
Scheme 4.3: Synthesis of glycosylated insulin (Sia2,6-Lac-Ins(BF I Q). 
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4.2 Objective: synthesis of a Peptide Scaffold Displaying Carbohydrates 
(PSOC) 
Based upon literature precedents concerning the introduction of unnatural substrates that 
mimic sugars to peptides or proteins, possibility to synthesise a PSDC through the residues 
of the amino acids was envisioned. The resulting structure could then be incorporated in a 
final polypeptide fragment or protein. 
The architecture of the PSDC was based on Meldal and co-worker's research. 83 As 
described earlier (Chapter 2, Section 2.2), the authors introduced glycopeptides as mimetics 
of complex oligosaccharide structures (a branched mannose pentasaccharide containing two 
terminal Man-6-P units). The idea was that the carbohydrate introduced as a building block 
could provide the specificity of the binding by directing the ligand to the oligosaccharide 
binding site (mannose 6-phosphate receptors), while the peptide (L-Thr-L-Lys-L-Thr) would 
function as a scaffold for optimal orientation of the glycan portion. The principle of 
glycopeptides mimicking oligosaccharides was consolidated through binding studies with an 
array of phosphorylated glycopeptides and the divalent mannose 6-phosphate receptor 
With the PSDC it is possible to produce complex unnatural carbohydrate structures, avoiding 
long and difficult synthesis, bypassing the need of regio- and stereoselective control of each 
glycosylation (Chapter 2 and 3). In the case of N-linked glycoproteins, the requirement of 
performing 6.mannosylation greatly increased the complexity of the oligosaccharide 
synthesis (Chapter 2, Section 2.1.3). 
Therefore, the aim was to generate a PSDC, as a mimic of the N-linked diantennary 
nonasaccharide found in EPO (Chapter 1, Scheme 1.4). This structure could further be 
introduced into an EPO peptide fragment, applying the technology that was developed for 
producing neoglycopeptides (Chapter 5)•171 The synthesis of the scaffold should be 
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straightforward employing available building blocks. Finally, incorporation of the final 
structure on the EPO peptide fragment should also be readily available. 
4.3 Design and retro-synthetic analysis of the PSDC 
As discussed earlier, the PSDC is inspired on Meldal research work (Scheme 2.8). Based on 
the Macmillan research group experience, it was decided to develop the peptide structure and 
the introduction of the carbohydrates on solid phase. The solid-phase synthesis of the 
modified peptide could provide easier access to new levels of complexity. This approach 
avoids purification of intermediates and allows libraries to be constructed from varied amino 
acids and oligosaccharide building blocks. Finally, this structure could be attached to a 





















Scheme 4.4: Structure of diantennary nonasaccharide structure found in EPO and PSDC, 104. 
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Based on Macmillan research 12  for the introduction of carbohydrates on a solid support to a 
peptide, cysteine was chosen as the amino acid to form part of the peptide scaffold backbone. 
Moreover, based on Meldal's work, lysine was the chosen to be the central amino acid for 
the peptide scaffold (Scheme 4.4). The primary amine of the lysine can be protected with a 
wide range of protecting groups. Interestingly, allyoxycarbonyl (A/bc-) has been used in the 
past on solid support without damaging the integrity of either the peptide or the linker. This 
is accomplished with palladium tctrakistriphenyl phosphine (Pd(PPh 3 )4) and a 
nucleophile.' 7 ' 79  Using this protecting group, it may also be possible to generate a library 
of peptide scaffolds on the solid support, by changing the number of carbons of the amino 
acid, and consequently control the distance between the carbohydrates presented through the 
peptide scaffold and the peptide/protein backbone (Scheme 4.4). 
At the final it appeared desirable to "seal" the tripeptidc core scaffold with an amide bond at 
the C-terminus, and an acetyl group on the N-termini (Scheme 4.4), to make the molecule 
less reactive and resistant to carboxypeptidases, increasing the in vivo half life.' 80 
To demonstrate that the pre-designed PSDC could mimic the diantennary polysaccharide of 
EPO, N-acetyl lactosamine attached through cysteines, and N-acetyl glucosamine (GIcNAc) 
attached through lysine were the chosen carbohydrate structures for the study. Therefore, a 
carboxymethyl chain should be inserted in the 4-hydroxyl group of G1cNAc (Scheme 4.4). 
Finally, this PSDC would be attached to the peptide/protein backbone. The fact that either 
aspatilation, 97  acetamide glycosylation' 69 or "click chemistry" glycosylation' 7 ' require at 
some stage in the synthesis the presence of an azide group at the anomeric position, 
suggested the need to insert the mentioned functional group into GIcNAc. 
Therefore, having determined the final architecture of the PSDC, the retro-synthetic analysis 
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0-acetyl-4-0-carboxymethyl-/3-D-glucopyranosyl azide 100 coud coulple with the lysine of 
the peptide on the solid support. The intermediate comes from glycosylation between 
LacNAc bromoacetamides 90, and the thiols of two cysteines of the tripeptide. Altering the 
order of the reactions could lead to formation of an epimeric mixture due to the 





Scheme 43: retrosynthetic analysis of 103 and 104. 
4.4 Synthesis of the glycobuilding blocks 
4.4.1 Synthesis of 2, 3, 4, 6-tetra-0-acetyl-D-galactopvranosyl-( 18-1, 4)-2-
acetamido-2-deoxy-3, 6-di-O-acetyl- 1-N-Fl -(2-bromo)acetyl] -18- D-
glucopyranose building block, 90 
For the synthesis of LacNAc bromoacetamide 90, the procedure developed by Bertozzi and 
co-workers was adopted.' 81  With some modifications, the synthesis was accomplished 
successfully in 6 steps (Scheme 4.6). 
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The synthesis of the bromoacetamide glycobuilding block began with the commercially 
available glucosamine hydrochloride 84. This was pre-treated with a stoichiometric solution 
of NaOMe in dry methanol, filtered and treated with phthalic anhydride. Next and finally, 
the molecule was peracetylated with acetic anhydride in pyridine, to obtain the fully 
protected intermediate 85 in 30 % yield. 112 The generation of the beta product was 
demonstrated by 'H-NMR. 
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Scheme 4.6: Synthesis of 90 and 91. 
The introduction of an azide group at the anomeric position was performed following the 
procedure of Szilagyi and co-workers. 183 The protected monosaccharide 85 was treated with 
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TMS-N3 in the presence of SnCI 4  as a Lewis acid, to obtain, exclusively, the beta product 86 
in a yield of 73 % 
In the subsequent sequence of reactions, the protected azido monosaccharide 86 was treated 
first with catalytic amounts of sodium methoxide in dry methanol, to perform a Zemplén 
deprotection (Scheme 4.6).66 This was followed by a regiospecific protection of the 6-
hydroxyl group of the sugar with tert-butyl diphenylsilyl chloride, to obtain the desired 
product 87 with the 3 and 4 hydroxyl groups free, in 93 % yield. 
Following the procedure of Bertozzi and co-workers,"' the protected glycosyl acceptor 87 
reacted with 2,3,4,6-tetra-0-acetyl-a-D-galactopyranOsyl fluoride 92,' 14  silver triflate, tin (11) 
dichloride and collidine in a mixture of DCM/toluene (5:1). Unfortunately, a yield of only 
40 % was obtained rather than the claimed 84 %. Moreover, when the reaction was scaled 
up (3.00 g, 5.24 mmol), a 33 % yield of the desired product was obtained, and 29 % of a 
disaccharide lacking the silyl protecting group. The regioselectivity of the glycosylation was 
not determined. 
Having available 2,3 ,4,6-tetra-O-acctyl-a-D-O-galactopyranosyl trichloroacetimidate 23, the 
same reaction conditions were applied for the synthesis of core-I disaccharide 62. One 
equivalent of the protected glycosyl acceptor 87 reacted with two equivalents of 
peracetylated galactose 23 with catalytic amounts of TMSOTf, in DCM, to obtain a 92 % 
yield of the required disaccharide 88 (Scheme 4.6). The regioselectivity of the glycosidation 
was determined to be as desired by comparison with the spectroscopic data provided by 
Bertozzi and co-workers.' 8 ' The regioselectivity of the glycosylation could be due to steric 
factors, namely the bulk of the silyl and phthalic protecting groups directing the donor 
towards the 4-hydroxyl group of the acceptor molecule. 
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Having generated the disaccharide 88, a sequence of reactions was performed to obtain the 
peracetylated N-acetyl lactosamine 89. Silyl deprotection in the presence of TBAF and 
acetic acid in THY was followed by phthalamide deprotection. Per-O-acetylation of the 
disaccharide was achieved by treatment with a mixture of acetic anhydride and pyridine 
(1:2). 
Finally, the azide group of the peracetylated disaccharide was reduced by catalytic 
hydrogenation. The desired glycobuilding block 90 was isolated in a yield of 95 %, 
following treatment with bromoacetic anhydride (Scheme 4.6). In parallel, the 
iodoacetamidc derivative 91 was also produced in 32 % yield, by treating the reduced 
intermediate with 2-iodoacetyl chloride. 
Efforts were then directed towards the glycobuilding block 100, designed to couple with the 
lysine residue (Scheme 4.7). 
4.4.2 Synthesis of 2-acetamido-2-deoxv-3,6-di-O-acetyl-4-O-CarbOXvmethYl-fl-D-
glucopyranosyl azide, 100 
The synthesis of glycobuilding block 100 was started from commercially available N-acetyl-
D-glucosamine, 93 (Scheme 4.7). In a domino reaction, the molecule was peracetylated and 
a chloride was introduced at the anomeric position, to obtain the desired thermodynamic 
molecule 94, in 34 % yield. 
As discussed earlier in this chapter, the insertion of an azide group at the anomeric position 
was considered critical to access the desired peptide scaffold, 103 or 104 (Scheme 4.5), 
either by acetamide linkage' 69 or "click chemistry" glycosylation.' 7 ' Therefore, this 
functional group was introduced by displacement of the chloride with sodium azide in the 
presence of tetrabutylammonium hydrogensuiphate (TBAI-IS), to obtain the adduct 95, in 82 
% yield. Afterwards, in a sequence of reactions, Zemplén deprotection was performed, 6 ' 
73 
4. Synthesis of a novel unnatural peptide scaffold to display carbohydrates 
followed by protection of the hydroxyls in the position 4 and 6 with p-anisaldehyde 
dirnethylacetal, and final acetylation of the free 3-hydroxyl group, furnished the intermediate 
96 in 71 % yield. Finally, regioselective acetal ring opening with Na(CN)BH 3 and TFA in 
DMF, generated the desired monosaccharide 97 in 66 % yield, with the 4-hydroxyl group 
free (Scheme 4.7). 
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Scheme 	4.7: 	Synthesis 	of 	2-acetamido-2-deoxy-3,6-di-O-acetyl-4-O-carboxymethyl-fl-D- 
glucopyranosyl azide 100. 
The preparation of the tert-butyl acetate ether of the 4-hydroxyl group of the monosaccharide 
97 was not a straightforward procedure (Scheme 4.7). Model experiments were carried out 
with derivatives of 87 (Scheme 4.6), where the 3-hydroxyl was acetylated: 101 (Scheme 
4.8). Treatment of the monosaccharide 101 with tert-butylbromo acetate in the presence of 
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sodium hydride failed to generate the desired product. Instead, a complex mixture of 
undefined degradation products was obtained (Table 4.1). Addition of the catalyst TBAI did 
not improve results. It was suspected that deacetylation reactions were occurring under such 
harsh basic conditions. Consequently, milder conditions were required for the success of the 
reaction. 
A920, pyridine. DMF 
% 	 4,OTBDPS 	 46 	 OTF3DF'S 
HO 	
0 	 Br j Bll'O2CO ° co:&~  
101 	NPhth 	 h. 	 102 	NPhth 
Ag 2O, NEt 3 , DMF 
59 % 
Scheme 4.8: Model experiments for the introduction to the 4-hydroxyl position of teri-butylbrorno 
acetate. 
Applying the protocol of Giese and co-workers,  114  the monosaccharide 101 was treated with 
5 equivalents of tert-butylbromo acetate and silver (I) oxide in DMF. Unfortunately, no 
reaction was observed after 24 hours and heating to 50 °C had no effect. Surprisingly, after 
the addition of pyridine 28 % of the desired product 102 was obtained. Similar results were 
obtained when the order of addition of reagents was switched: no reaction was observed 
when the monosaccharide 101 was treated with 5 equivalents of tert-butylbromo acetate, and 
10 equivalents of pyridine; only when 2.5 equivalents of silver oxide were added a 46 % 
yield of the desired product 102 was achieved (Scheme 4.8). Optimisation of the reaction 
conditions afforded a 59 % yield when pyridine was replaced with triethylamine in the 
presence of silver oxide. 
Application of the latter conditions to the intermediate 97 generated modest results. Further 
optimisation led to 57% yield, when the monosaccharide 97 reacted in the presence of 3.6 
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equivalents of tert-butylbromo acetate, 1.8 equivalents of silver (1) oxide, and 2 equivalents 
of triethyl amine, in dry DMF with exclusion of light for 16 hours (Scheme 4.7). 
Monosaccharide 	
zert-butylbromo 
A920 	 Base 	 Yield acetate 
101 	 2 equiv. - 	 2 equiv. Nail 	Decomposition 
101 	 2 equiv. 
2 equiv. NaH and 2 equiv. 	Decomposition 
- TBAI 
101 	 2 equiv. 
- 	 2 equiv. NaI-I and 0.1 Decomposition 
equiv. TBAI 
101 	 5 equiv. 
1.5
. 	 - 	 No reaction equ iv. 
101 	 5 equiv. 
1.5
. 	3 equiv. pyridine 	28% equiv. 
101 	 5 equiv. - 	 10 equiv. pyridine 	No reaction 
101 	 5 equiv. 
2.5 10 cquiv. pyridine 	46% 
equiv. 
101 	 5 equiv. 
5 2. . 	1.2 equiv. DI PEA 	24% 
equlv. 
101 	 2equiv. 
2 1. 1.5equiv.NEt 3 	18% 
equiv. 
101 	 5 equiv. 
2.5 1.2 equiv. NEt 3 	49% 
equiv. 
101 	 5 equiv. 
2.5. 	1.5 equiv. NEt 3 	59% 
equ iv. 
97 	 5 equiv. 
2.5
1.5 equiv. NEt3 	42% equiv. 
97 	 5 equiv. 
2.5. 	2 equiv. NEt3 	 49% equ iv. 
97 	 3.6 equiv. 
1.8 
. 	 2 equiv. NEt3 	 57% equiv. 
Table 4.1: Different sets of conditions for the formation of tert-butyl acetate ether with the 4- 
hydroxyl group of the monosaccharide. 
During the development of this reaction, it became clear that the reaction did not proceed 
without the presence of silver oxide and a low pKa base (pyridine or triethylamine). 	The 
coupling of a hard, hindered nucleophile, such as a secondary hydroxyl group, with a soft 
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electrophile, might be expected to be challenging, however, the requirement for silver (I) 
oxide was unexpected. 
Having successfully obtained 98, PMB deprotcction was carried out under standard 
oxidative conditions. This was followed immediately by peracctylation with acetic 
anhydride to produce the intermediate 99 in quantitate yield. Tert-butyl ester hydrolysis 
yielded the glycobuilding block 100, ready for SPPS (Scheme 4.7). 
Once the different glycobuilding blocks: 90 and 100 were available, it was decided to 
introduce them to the solid support, by simple coupling with unprotected cysteine or lysine, 
respectively. 
4.5 Synthesis of a peptide scaffold to display carbohydrates on solid phase 
As stated previously (Section 4.3), the assembly of the peptide core scaffold was to be 
carried out on a solid support, using SPPS. The introduction of the glycobuilding blocks 90 
and 100 was planned after orthogonal deprotection of the relevant cysteinc and lysine 
protecting groups. 
Rink amide MBHA resin was selected as a solid support for the synthesis. 5 When the 
peptide is cleaved from the resin under acid conditions it produces the desired amide bond at 
the C-termini. The synthesis of the peptide core scaffold was straightforward, using 20 % 
piperidine in DMF for Fmoc- deprotection, and standard peptide coupling conditions 
(HBTtJ/HOBt and DIPEA for three hours) to couple the next amino acid. The sequence of 
amino acids introduced to the synthesis of the peptide scaffold core was: L-Cys-L-Lys-L-
Cys. The thiols of the cysteines were protected with tert-butyldithiol groups , 92 and the 
primary amine of the lysine was masked with an Alloc- protecting group (Scheme 4.9). 
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Finally, after the coupling of the last amino acid, cysteine, Fmoc- deprotection was carried 
out, followed by acetylation of the amino group with acetic anhydride and pyridine (1:2). 
After each step, small aliquots of cleaved resin were qualitative monitored by MS and Kaiser 
test (Scheme 4. 10). 
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Scheme 4.9: Synthesis of the peptide core structure on solid support: i) /erz-butyldithiol deprotection 
with DTT and ii) introduction of LacNAc bromoacetamide, 90, into the peptide scaffold. 
From previous work, 92  it was known that orthogonal deprotection of the disulphides of a 
peptide on solid support could be achieved by treatment of the resin with dithiothreitol 
(DTT). Therefore, treatment of the core peptide structure with DTT in dry DMF, and 2.5 % 
v/v DIPEA, for 16 hours, generated the desired intermediate, as verified by MS (Scheme 
4.10.i). Exhaustive washings of the resin with DMF, mixtures of DMF/H 20 (1:1), DMF and 
DCM were performed to remove any residual DTT that could interfere in the following 
steps. 
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H. HS 	 S 
Fl 	
) 	 Nil- 0 
0 (H2C) NHAII0C 
	 477,17 
C74 U 	7N9O4S2 
1825,61 
Scheme 4.10: Mass spectra of cleaved samples during the synthesis of the peptide scaffold after: i) 
tert-butyldisulphide deprotection, ii) coupling with 90, and iii) A/loc-deprotection. 
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Treatment of the resulting resin, twice, with 3 equivalents of LacNAc iodoacetamide 91 per 
thiol (section 4.4.1), 2.5 % v/v pyridine in DMF,92 failed to achieve complete coupling 
between the peptide on the resin and the disaccharide. However, when the resin was treated 
with 2 equivalents of LacNAc bromoacetamide 90 per thiol, and an excess of triethylamine, 
in dry DMF for 24 hours (Scheme 4.9), MS analysis of the cleaved PSDC demonstrated the 
acetylation of the peptide cysteines and no presence of the starting material (Scheme 4.1 O.ii). 
Once LacNAc bromoacetamide 90 was mounted on to the peptide scaffold, the next step was 
A/bc- deprotection. A number of examples of this reaction on solid support had been 
reported in the literature. 116-179 Common to each was the need for palladium (0), and an allyl 
scavenger, such as PhSiH 3 177178 or N-methylmorpholine.' 76 ' 79 The procedure of Albericio 
and co-workers 177.179 was applied wherein palladium tetrakisphenyiphosphine (Pd(PPh 3 )4) 
was the source of palladium (0), and phenylsilane, the allyl scavenger. A ninhydrin test and 
MS analysis confirmed the deprotection of the primary amine of lysine (Scheme 4.10.iii). 
The glycobuilding block 100 reacted specifically with the free lysine of the peptide scaffold, 
under standard coupling conditions, in the presence of 5 equivalents of DCC and HOBt in 
DMF for 24 hours. Although this procedure was performed twice, the ninhydrin test and MS 
analysis revealed the presence of uncoupled peptide scaffold. 
Finally, the resin was treated with a cleavage cocktail (95 % TFA, 2.5 % ethane dithiol, 2.5 
% water) to liberate the peptide from the solid support. After precipitating the peptide with 
cold ether, lyophilising the precipitate, and purifying it by semi-preparative 1-IPLC in reverse 
phase, a 5 % of yield of 103 was obtained over 10 steps, in the best of the cases. Due to this 
adverse result obtained, it was studied where the peptide scaffold has gone. The resin was 
treated a further two times with the cleavage cocktail to isolate additional material, 
unfortunately not enough material was obtained to address this question. 
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Based upon previous experience of both the SPPS and bromoacetamide methodologies, it 
appeared unlikely that either of these steps had been particularly problematic. It was decided 
to review the A/bc- deprotection protocols. Re-synthesis of the PSDC on a 0.25 mmol scale 
revealed that the resin began to shrink unexpectedly upon lysine deprotection, and seemed 
likely that by changing this conditions this effect might be avoided. 
Applying Griffin and co-workers conditions, 116  the resin was subjected to 3 equivalents of 
Pd(PPh 3)4 , in chloroform, N-methylmorpholine and acetic acid (37.5:2:1), for 4 and then 12 
hours. Despite repeated washings of the resin with DCM and DMF after the reaction, the 
solid support was still stained black, due to the persistent presence of palladium. After 
coupling the glycobuilding block 100 and the peptide cleavage, 103 was obtained in a yield 
of 8 %, over 10 steps. At this stage it was clear that the limiting step was the A/bc-
deprotection. It was noted that the use of N-methylmorpholine in place of phcnylsilane 
prevented loss of material from the resin. Finally, applying the procedure of Tabor and co-
workers, 179  the resin was treated with 2 equivalents of Pd(PPh 3 )4 in a specific solvent system: 
DMF/CHCI 3/AcOH/NMM (18.5:18.5:2:1). It was shaken for 2 hours with exclusion of air 
and light. Finally, the resin was washed sequentially with: i) 0.5 % DIPEA in DMF (v/v); ii) 
DMF; iii) 0.5 % sodium diethyldithiocarbamate trihydrate in DMF (w/v), and iv) DMF 
(Scheme 4.11). Applying this sequential washing procedure, most of the residual palladium 
was eliminated from the resin. The natural colour and the state of the resin were re-
established. Moreover, MS analysis of the cleaved peptide (Scheme 4.10) and a ninhydrin 
test indicated deprotection of the lysine and no presence of unreacted glycopeptide. Finally, 
after coupling 5 equivalents of the glycobuilding block 100 with the resin and peptide 
cleavage, 103 was generated in a 17 % yield over 10 steps. 
During development of these sets of reactions, a number of additional peaks were noted in 
the HPLC trace. These peaks exhibited retention times similar to that of the peracetylated 
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PSDC 103 (tR=  30.3 minutes). Closer inspection of the relevant fractions by MS revealed a 
difference in molecular mass of "42 x n" less than 103. This range of compounds could be 
related to deacetylations of the carbohydrate produced during the course of the synthesis 
(molecular weight of the fragment CH 3CO-= 42). Therefore, it was decided to treat the resin 
bound mixture with a solution of pyridine and acetic anhydride (2: I) for 16 hours to re-
acetylate the deacetylated hydroxyl groups. After exhaustive washing of the polymer with 
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Scheme 4.11: (Continued from scheme 4.9) Synthesis of the peptide core structure on solid support: i) 
Al/ac- deprotection, ii) coupling of 100 with the peptide scaffold and iii) peracetylation of the 
molecule, and iv) final cleavage of the PSDC, 103, from the resin. 
Peracetylation of the whole molecule with pyridine and acetic anhydride (2:1) allowed 
identification of further by-products of the synthesis of the peptide scaffold: the Al/ac-
protected lysine adduct ([M]: 1826.6. [M] 2 : 913.8); and the peracetylated lysine adduct 
([M]: 1784.60, [M] 2 : 892.8), that corresponded to the uncoupled peptide scaffold with the 
glycobuilding block 100 (Scheme 4.12). 
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Scheme 4.12: HPLC trace of the crude of the peptide scaffold displaying carbohydrates. Mass spectra 
of 103, MW: 2113,40 (MW 0010 : 2113.05); and related by-products: MW: 1785.00 and 1825.20 
(MW 0010 : 1783.60 and 1825.61). 
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These results are in accordance with previous highlighted observations. Therefore double 
Alloc- deprotection and more reactive coupling conditions between the peptide scaffold and 
the glycobuilding block 100 should increase the overall yield of the total synthesis on solid 
phase. In the process, a better HPLC chromatogram would be obtained, and consequently, 
the yield of the desired product would be improved. 
Therefore, the Alloc- deprotection was performed twice, followed by coupling of the peptide 
scaffold with 2.5 equivalents of the glycobuilding block 100, 2.5 equivalents PyBOP, 2.5 
equivalents HOBt, and 5 equivalents DIPEA in DMF for 16 hours, twice, to ensure total 
conversion of in the reaction. Final dcacctylation of the product cleaved from the resin with 
a water/methanol solution (10:1) of 5 % hydrazine (6 mL), yielded the desired product in 47 
%, over 10 steps (Scheme 4.13). 
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Scheme 4.13: (Continued from scheme 4.9) Synthesis of the peptide core structure on solid support: 1) 
A/bc- deprotection, ii) coupling of 100 with the peptide scaffold, iii) cleavage of the PSDC from the 
resin and iv) final deacetylation of the molecule. 
84 
4. Synthesis of a novel unnatural peptide scaffold to display carbohydrates 
Elution of the deacetylated product 104 was more rapid than the peracetylated PSDC (tR = 





Scheme 4.14: HPLC trace of the crude of the pcptidc scaffold displaying carbohydrates. Mass spectra 
of 104, MW: 1525.00 (MW: 1524.54). 
With both peptide scaffolds available, 103 and 104, they could be inserted in a peptide, 
either by Lansbury aspartilation 97  or bromoacetamides after reduction of the azide. 
Unfortunately, in both cases, the reduction of the azide could produce epimerisation in the 
anomeric centre. On the other hand, Cu(I)-catalysed modification of the Huisgen 
cycloaddition could be applied to directly introduce 103 or 104 to a modified peptide 
fragment without any extra synthetic step. 
171 The development of this novel neo- 
glycopeptide linkage is explained in the following chapter. 
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4.6 Conclusions and future work 
During this work, a peptide scaffold bearing carbohydrates on solid phase that could 
potentially mimic the diantennary carbohydrate structure found in N-linked glycoproteins 
has been synthesised. The PSDC allows the construction of highly complex unnatural 
carbohydrate structures from pre-defined glycobuilding blocks, avoiding control of the regio-
and stereochemistry, and therefore simplifies the total synthesis of the desired molecule 
(Chapter 3). This concept has been exemplified by avoiding the complication of the /3-
mannosylation. 
In addition, having available this new methodology to obtain PSDC on solid phase, a library 
of these molecules could be prepared by increasing the number of cysteines, and therefore 
changing the number of carbohydrate side chains displayed. Moreover, the lysine residue 
could be altered by changing the number of carbons of the alkylic side chain. This could 
provide the opportunity to identify peptide scaffolds showing better biological activity. 
One of the main problems found during the construction of core- 1 0-linked to threonine 
glycobuilding block for SPPS, lay in the glycosylation of 46 with the glycosyl bromide 69 
(Scheme 3.23). This process proved to be low yielding, and encouraged investigation of new 
pathways to introduce, in a convergent synthesis, carbohydrates on peptides. Cu(t)-catalysed 
modification of Huisgen cycloaddition seemed to fill the requirements of orthogonal 
reactivity with control of regioselectivity and the development of the synthesis of a novel 
neo-glycopeptide linkage using "click chemistry", described in the next chapter.' 71 
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5 Novel neo-glycopeptide linkage using Cu(I) catalysed 1, 2, 3-triazole 
formation 
5.1 Introduction 
As discussed earlier, protein glycosylation can be incredibly challenging and difficult. 
Parallel to the research and development of advanced methodologies to overcome these 
technical difficulties of glycosylation,' 05 there is increasing interest in the development of 
novel unnatural glycosidic bonds. The primary goals of these type of linkages are to perform 
chemoselective and site-specific glycosylations for the synthesis of glycoprotein 
analogues. 186 
Various examples of non-native glycosidic bonds are described in the literature (Scheme 
5.l),186 with chemoselective ligation, 168,187-189 acetamides' 69 and disulphide bond linkages' 
90 
being the most relevant examples to this thesis. These linkages aim to meet the need for 
regio- and glycan-specific glycosylation on proteins. Chemoselective ligation is based on 
the introduction of two mutually and uniquely reactive functional groups onto unprotected 
fragments (ketone or aldehyde, and aminooxysugars), and the convergent coupling of the 
fragments for the construction of glycopeptide mimetics. The acetamide linkage approach 
and disulphide bond linkage methodologies are based on the selective linkage of the 
carbohydrate to the peptide/protein backbone, through a free cysteine group, either through a 
bromo/iodo acetamide or a thiosugar, respectively (Scheme 5.1). 
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Scheme 5.1: Chemoseleetive and site-specific glycosyl linkages. 
The Macmillan research group has applied the "site directed mutagenesis glycosylation 
approach" to E. Co/i-expressed rhEPO protein, 91 and on SPPS for the synthesis of unnatural 
glycopeptides. 92  The native glycosylated asparagine residues were changed for cysteines in 
three mutant rhEPO proteins (His 10-Asn24Cys, His 1 0-Asn38Cys, His 10-Asn83Cys,). A single 
unit of GIcNAc iodoacetamide was introduced selectively through the thiol of a cysteine 
without any observable side reaction with any of the other four cysteine residues involved in 
disulphide bonds (C29-C33 and C7-C 161). In a later example, iodoacetamide carbohydrate 
derivatives (GIcNAc, LaeNAc, Gic, Lac, and chitobiose) were selectively introduced into a 
peptide on solid phase, through a selectively deprotected thiol of a eysteinc (Scheme 5.2). 
Moreover, it was also demonstrated that this technology was compatible with the generation 
of thioesters using the "safety-catch" linkers, Native Chemical Ligation (NCL) and 
Expressed Protein Ligation (EPL). 
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Scheme 5.2: Synthesis of a novel glycopeptide produced by: i) orthogonal deprotection of tert-butyl 
dithiol, followed by ii) introduction of carbohydrate derivatives on cysteines, iii) activation of "safety 
catch" resin and production of a thioester, and finally iv) trityl deprotection of the N-terminal cysteine. 
Although this type of technology facilitates the chemoselective and site-specific ligation of 
carbohydrates on a peptide or protein, it is not exempt from extra modifications of the 
reactive functional groups and it employs unstable glycosamines, which are prone to 
hydrolysis and anomcrisation. 
"Click chemistry" has emerged as a potent chemoselective and regioselective reaction that 
facilitates the chemistry of carbon-heteroatom bond formation, allowing easier and faster 
access to a generation of new compounds. Consequently, it could have huge potential for the 
synthesis of glycopeptides and glycoproteins 
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5.2 "Click chemistry" 
The term "click chemistry" was introduced by Barry K. Sharpless and co-workers to refer to 
a group of reactions that must be modular, of wide scope, produce high yields, generate only 
inoffensive by-products that may be removed by non-chromatographic, and be stereospecific 
(but not necessarily enantioselective). Required process characteristics include simple 
reaction conditions (the process should be insensitive to oxygen and water), readily available 
starting materials and reagents, the use of no solvent or solvent that is benign (such as water) 
or easily removed, and simple product isolation. Purification, if required, must be by non-
chromatographic methods, such as crystallization or distillation, and the product must be 
stable under physiological conditions.' 9 
Nevertheless, in chemistry jargon, "click chemistiy" normally refers to the modification of 
the Huisgen 	 a 1,3-dipolar cycloaddition between an alkyne and azide, in the 
presence of copper (I) (Cu(I)) as a metal catalyst. 	This reaction was modified 
simultaneously and independently by the research groups of Meldal' and 5rpl5594 to 
ligate two types of modular molecules: peptides and alkyl building blocks. In a postulated 
mechanism (Scheme 5•3),194 the catalytic cycle begins with the metal insertion of Cu (I) into 
the alkyne. This slow process can occur at pH values ranging from 4 to 12.' They 
subsequently obtained the thermally and hydrolytically stable 1, 4-disubstituted 1, 2, 3-
triazole with a complete regioselectivity,' 94 in an irreversible fast stepwise sequence via a 
six-membered copper-containing ring intermediate. 
One of the major drawbacks of using Cu(I) as a catalyst is its low thermodynamic stability 
which results in its oxidation to Cu(II) and/or disproportionation to Cu(0) and Cu(ll), 
compromising the scope of conditions for this type of reaction. 196  A breakthrough in 
overcoming this problem came with the introduction of the ligand iris-
(benzyltriazolylmethyl)amine (TBTA). This molecule has the ability to envelope the Cu(l) 
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centre tightly, providing additional electron density through the tertiary amine, so that the 
ligand protects the metal from water and oxygen, and accelerates Cu(I)-catalysed 
transformations. 196 
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Scheme 5.3: Proposed catalytic cycle for the Cu(l) catalysed ligation. 194 
The orthogonal reaction between an azide and an alkync has found a wide range of uses in 
bioconjugation,' 9720 ' organic synthesis, 	combinatorial t rial chemistiy, 204 and carbohydrate 
chemistry .  205-20 
Although most of the applications of "click chenistry" in the field of carbohydrate research 
have been to study the reactivity and synthesis of large building block; some authors have 
envisioned the potential to bypass some of the biggest problems this area of research 
presents: the stereoselectivity of glycosidation of unprotected sugars,
2I  and direct 
glycosylation of amino acids." 
1,212 
5.3 Objective: Development of a novel neo-glycopeptide linkage compatible 
with native chemical ligation 
Based on the potential of Cu(l) catalysed I ,2,3-triazole formation, and previous literature 
precedent of this type of reaction with carbohydrates, the possibility to introduce azido 
al 
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carbohydrates directly on n acetylene modified peptide, either on solid phase or in solution 
can be envisaged. To achieve this goal, preliminary studies in solution between simple 
structures should be carried out to understand the outcome of these reactions. Afterwards, 
the knowledge generated could be used directly to modify a peptide. This new technology 
should facilitate and accelerate the production of glycopeptide mimetics. 
For example, having available this novel neo-glycopeptide linkage, it could be applied to 
introduce two PSDC (Chapter 4) on an EPO peptide fragment, avoiding extra synthetic steps, 
and consequently, increasing the overall yield of the total synthesis of a glycopcptide 
mimetic. 
5.3.1 Preliminary studies in solution: model experiments. 
171 
In preliminary work, the type of linker to use for the introduction of carbohydrates on 
peptides and the best conditions suitable for the "click chemistry" reaction were investigated. 
The reaction was performed between an azido sugar 86, and an alkyne, N-(propargyl) 
acetamide 111 with catalytic amounts of copper sulphate pentahydrate as a source of Cu(II), 
with the same catalytic amounts of sodium ascorbate, to reduce Cu(II) to Cu(l); in a biphasic 
system: CHC1 3/EtOH/H 20 (9:1:1) (Scheme 
5•4),209 Interestingly, this reaction was so slow 
that after 48 hours at 37 °C that the starting materials was recovered. A similar result was 
obtained under the same reaction conditions for 95. Wang and co-workers 209 reported a one-
pot synthesis of triazole-linked glycoconjugates to develop neo-glycoconjugates derived 
from unprotected and peracetylated azido oligosaccharides. Interestingly, the authors had 
reacted peracetylatcd D-mannose with N-(propargyl) bromoacetamide 112, a compound that 
was generated in 76 % yield, from the reaction between propargyl amine 115 and 
bromoacetic anhydride 116 in a saturate aqueous solution of NaHCO 3 (experimental 
section). Using N-(propargyl) bromoacetamide 112, and applying identical reaction 
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conditions, satisfactory results were obtained in preparing 114 and 113 in 66 % and 100 % 
yield, respectively (Scheme 5.4). 
The previous unsuccessful attempts for the formation of the triazole ring appeared to be in 
accordance with observations that Thorson 213  and Bertozzi' 98 reported, where they noted that 
the presence of an electro-withdrawing group proximal to the alkyne accelerates the rate of 
the cycloaddition. In the present case, the presence of a halogen, namely bromide, S to the 
alkyne 112, seems to have a decisive effect on the kinetics of the reaction. This acceleration 
of the process could be due to an electronic effect of the electronegative atom on the alkyne 
facilitating the limiting step of the "click chemistry", the metal insertion of the copper into 
the triple bond. 
	
III 	0 	 112 
NP 	
rhii 
hih 86 	 1 	 Ui) 
1 1 	 H 
NIIA 	 95 
on 
Scheme 5.4: "Click chemistry" between azido sugars and propargyl amide derivatives: CuS0 4 5H20, 
sodium ascorbate, CHCI 3/EtOH/H 20 (9:1:1). 
To understand the chemistry that was going to be developed later for solid phase, model 
experiments in solution phase were necessary. 2-Acetamido-2-deoxy-3, 4, 6-tri-O-acetyl-/3-
D-glucopyranosyl azide 95 was used as the source of the azido sugar, N-(propargyl)-
bromoacetamide 112 was the source of the alkyne, and benzylmercaptan 117 was used as the 
model thiol (in place of cysteine). Since the alkyne motif 112 could be used as an acceptor 
for "click chemistry" and SN2 reactions, it was interesting to investigate the versatility of this 
methodology and, in particular, whether the order of the reactions alter the outcome (Scheme 
5.5). 
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Given previous work on "click chemistry" with azido sugars and N-(propargyl)-
bromoacetamide 112, the conditions described earlier were applied to reproduce the 
synthesis of the compound 114 (Scheme 5.5). Based on the experience with 
bromoacetamides, 92 114 was reacted with benzylmercaptan 117 and triethylamine in DMF at 
room temperature for 16 hours, to obtain the thioether product 118 in 75 % yield. Given 
these encouraging results, the versatility of this method was investigated, where an SN2 
reaction between 112 and benzylmercaptan 117 was performed first, and then the product 
reacted with 95 to obtain 118. This could potentially be of great benefit for the synthesis of 
glycopeptides and glycoproteins because the whole synthetic process would be convergent, 
that it is by first introducing the acetylenes on a peptide/protein and subsequently performing 
the "click chemistry" reaction with the azido sugars; it would increase the overall yield of 
these structures and reduce amounts of starting materials required. When 112 reacted with 
benzylmercaptan 117 with triethylamine in DMF at room temperature for 16 hours in an SN2 
fashion, 119 was obtained in 84 % yield. Subsequent application of triazole formation 
between 119 and 95, under identical conditions as described previously, allowed the 
formation of 118 in a 91 % yield. 
To establish whether the products might be stable to the usual peptide cleavage conditions, 
118 was treated with 95 % TFA, 2.5 % 1l2O and 2.5 % 1,2-ethariedithiol for 3 hours. 'H-
NMR analysis of the crude material after evaporation revealed no decomposition of the 
starting material. This result confirmed the triazole structure is stable under the peptide 
cleavage conditions. 
Finally, the acetyl esters of 118 were cleanly removed upon exposure to 2 % v/v hydrazine 
hydrate in ethanol for 72 hours, and the fully deprotected compound 120 was obtained in 66 
% yield (Scheme 5.5). The low yield and the long reaction time for the reaction was related 
to the insolubility of the starting material under the reaction conditions. Alternative 
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conditions could be used to accelerate and increase the reaction yield, but the aim of these 
experiments was to demonstrate the compatibility of these reactions that were subsequently 
going to be applied to the synthesis of glycopeptides. Encouraged by the ability to 
demonstrate the facility and the flexibility of these sets of reactions, it was decided to apply 
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Scheme 5.5: Model reactions between 95, 112 and benzylmercaptan 117, to demonstrate that the 
order in which the reactions took place had no effect upon the resulting product. 
Parallel to these studies, it was decided to investigate if unprotected azido carbohydrates 
could react with acetylenes in these systems. This could have a huge effect in present 
research because they could open up the possibility of performing a final direct orthogonal 
coupling between peptides or proteins furnished with acetylenes and azido polysaccharides, 
in water, or even in buffer solutions. 
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Preliminary studies were performed using 121 and 112. When these compounds reacted in 
the presence of catalytic amounts of copper sulphate pentahydrate and sodium ascorbate in 
water/tert-butanol (l:l),2b0 the desired product 122 was obtained in 35 % yield (Scheme 5.6). 
Due to the insolubility of 112 in water, it was necessary to use a binary solvent system to 
solubilise all the components of the reaction. Significant progress was made when the ligand 
tris-(benzyltriazolylmethyl)amifle (TBTA) was introduced into the reaction.' 96 Under the 
same set of conditions, the desired product 122 was obtained in 71 % yield (Scheme 5.6). 
However, by changing the source of copper to (Cu(CNCH 3 )PF6) and carrying out the 
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Scheme 5.6: Model reactions of "click chemistry", between an azido sugar and acetylene. 
These encouraging results could allow the possibility to perform couplings between different 
building blocks, either in water or in buffer solutions. 
5.3.2 Studies on solid phase: novel neo-glycopeptide linkage using "click 
chemistry" 7 ' 
The technology was applied to solid phase (experiments carried out by Dr. D. Macmillan). 
The peptide fragment 123, similar in sequence to human EPO (residues 21-32) was 
assembled with an N-terminal cysteine residue, and furnished with two disulphide bond 
protected cysteine residues at pre-determined positions. The peptide was assembled using 
96 
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standard protocols for Fmoc- solid phase peptide synthesis and in an automated fashion. The 
cysteine residues were deprotected on solid phase by exposure to 10 % w/v dithiothreitol 
(DTT) containing 2.5 % v/v DIPEA to expose the thiol functional groups (Scheme 
5•7)92 
N-Acetylglucosamine and the disaccharide chitobiose were then incorporated by exposure of 
the resin to bromoacetamides 114 or 124, employing three equivalents of the modified 
sugars per thiol in each reaction. After 16 hours reaction at room temperature, cleavage of a 
small resin sample indicated that the reaction was complete as it was unable to detect any 
starting material by MS. After cleavage from the solid support by treatment of the resin with 
peptide cleavage cocktail for 4 hours, the crude products were purified by semi-preparative 
HPLC, lyophilised, and treated with 2 % v/v aqueous hydrazine hydrate containing 5 % w/v 
DTT to obtain the fully deprotected products 125 and 126 in quantitative yield as, 
determined by HPLC (Scheme 5.7). 
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10% w/v DTT. 2.5% DIPEA, DMF, 16 Ii. 
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2% v/v aqueous hydrazine monohydrate. I h. 
OFt 	 S 	 OH 
0 )1 0 j JH H 
R -H. 125 
0 	OH 	5 	Ott 	 0 	Ott 	fl-c,lcVAc-, 126 
Scheme 5.7: Reaction and conditions for the synthesis of glycopeptides 125 and 126 (Results 
provided by Dr. D. Macmillan). 
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Applying the same methodology developed previously in solution, it was attempted to 
perform the "click chemistry' reaction on solid phase (Scheme 5.8). First, tert-butyl dithiol 
deprotection was accomplished with 10 % w/v DTT containing 2.5 % v/v DIPEA, to expose 
the thiol functional groups. Next, the free cysteines of the peptide were subjected to 
alkylation with 112 and triethylamine in DMF for 16 hours. Finally, the modified peptide on 
the resin 127 was resuspended in CHCI 3/EtOH/5OmM sodium phosphate buffer (9:1:1), with 
the azido sugar 95 in the presence of catalytic amounts of sodium ascorbate and copper 
sulphate pentahydrate, and incubated at 37 °C at 500 rpm, for 24 hours, to obtain the desired 
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Scheme 5.8: Application of "click chemist,-V" on solid phase to obtain a novel neo-glycopcptidc 128 
(Results provided by Dr. D. Macmillan). 
Once the reliability of formation of this neo-glycopeptide linkage on solid phase was 
established, it was decided to study the compatibility of this technology with native chemical 
ligation (NCL). 
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5.3.3 Native Chemical Ligation (NCL). 	Compatibility of the novel neo- 
glycopeptide linkage with NCL 
NCL involves the coupling of two unprotected synthetic peptide fragments, where the first 
step is a reversible chemoselective reaction at physiological pH of an unprotected synthetic 
peptide-a-thioester in the C-terminal, while the other segment contains an N-terminal 
cysteine residue to give a thioester-linked intermediate as the initial covalent product. This 
initial transthioesterification reaction is then followed by a rapid intramolecular S-N acyl 
shift via a 5 membered ring transition state to generate an amide bond at the ligation junction 
(Scheme 59)214.215 
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Scheme 5.9: Scheme of Native Chemical Ligation. 
This reaction has been widely used for ligating two synthetic peptide fragments together, 
where the necessary functionalities can be incorporated into the fragments during SPPS. 
Incorporation in the ligation reaction of guanidinium chloride or urea can avoid peptide 
aggregation. Addition of exogenous thiols can modulate the reaction and avoid oxidation of 
cysteines. 
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It was aimed to demonstrate the compatibility of the novel neo-glycopeptide linkage using 
Cu(I) catalysed I ,2,3-triazole formation with NCL (experiments carried out by Dr. D. 
Macmillan). It was decided to couple the fragment 126 with a peptide thioester (EPO 
residues 1-19) (Scheme 5.1 0).214 
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Scheme 5.10: The nco-glycopeptide is compatible with NCL (Results provided by Dr. D. Macmillan). 
The construction of the peptide thioester, corresponding to human EPO residues 1-19, and its 
release from the solid support were monitored using the dual-linker approach described by 
Unverzagt and co-workers.' °°  In the ligation reaction equimolar quantities of each peptide 
were combined in 0.25 mL of 6 M guanidine hydrochloride containing 300 mM sodium 
phosphate buffer; pH 8, 0.1 % w/v mercaptocthanesulfonic acid (MESNA) and 10 mM tris-
carboxycthylphosphinc (TCEP) for 36 hours with shaking at room temperature. After this 
time the reaction mixture was purified by directly loading it onto a semi-preparative I-IPLC 
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column. The ligated product 129 was the only species observed by HPLC and certified by 
MS, demonstrating the robustness and versatility of this methodology. 
Having demonstrated that the novel neo-glycopeptide linkage using Cu(1) catalysed 1,2,3-
triazole formation is compatible with NCL, the possibility to use this methodology to 
introduce a PSDC on an EPO peptide fragment was investigated. 
5.4 Introduction of two PSOC on an EPO peptide fragment applying the novel 
neo-glycopeptide linkage using Cu(I) catalysed 1, 2, 3 triazole formation. 
The capacity of this methodology to introduce two PSDC units in an EPO peptide fragment 
was investigated. The peracetylated PSDC 103 reacted with 112, under the same conditions 
employed to couple azido carbohydrates with acelylenes (Scheme 55)•209  The reaction 
proceeded without any complication and after 16 hours, the presence of 130 was detected by 
MS (Chapter 7, Experimental). Unfortunately, the work-up proved to be difficult and was 
complicated by the formation of an orange solid. As a result, the isolated yield of the desired 
product varied significantly. A possible explanation could derive from the insolubilities of 
either the reactant 103 or the product 130. Due to the limited solubility and the limited 
availability of the PSDC, replacement of 103 with the deacetylated derivative 104 might 
provide a more efficient alternative synthesis, based in previous results obtained with 121, in 
a mixture of water and teri-butanol (Scheme 5.6). 
Exposure of the compound 104 to N-propargylbromoacetamide 112, in the presence of 
catalytic amounts of sodium ascorbate, tris-bcnzyltriazolylmethylarnine (TBTA), and 
CuS04 5H2O, in water/tert-butanol (1:1) generated the desired molecule 131 (MW: 
1700.55), in 64 %. Moreover, work-up was simple, and during the purification by HPLC, 
the product was readily isolated from the excess of acetylene 112 (Scheme 5.11). 
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Scheme 5.11: l-IPLC trace of the crude reaction between 104 and 112. Mass spectra data for 131, 
MW: 1701.40 (MW ca i c : 1700.55). 
Having obtained the PSDC with the bromoacetamide moiety 131, it was decided to introduce 
this structure to a peptide fragment of EPO applying the technology described above. 92" 71 
The modified PSDC 131 and an EPO peptide fragment (21-32) 132 with the two free thiols 
were reacted in a buffered solution of sodium phosphate, pH 7.4, to afford the desired 
unnatural glycopeptide 133 in 29 % yield 
.92,171 Quantitative deprotection of the Acm- group 
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was subsequently achieved after dissolving the modified peptide in acetic acid in the 
presence of mercury (II) acetate. To this was added dithiothreitol. MS analysis of the HPLC 
fractions determined the presence of the desired product 134 (Scheme 5.12). 
134 
Scheme 5.12: HPLC trace of the crude reaction after removing Acm-protecting groups from the EPO 
peptide fragment (21-32), 133, that displays two peptide scaffolds furnished with carbohydrates. 
Mass spectra data for 134, MW: 4401.20 (MW a i c: 4399,65). 
Encouraged by the results obtained for attaching the peptide scaffold displaying 
carbohydrates to an EPO peptide fragment, it was decided to further investigate the 
technology developed in-house (Chapter 5)." The possibility to modify peptides with N-
(propargyl)-bromoacetamide 112 would allow the incorporation of complex carbohydrate 
structures to the core peptide, avoiding elaborated synthetic routes. The resulting increase in 
the efficiency of the procedure would minimise loss of precious material. 
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An initial proposal was to introduce the peptide scaffold to an EPO peptidc on solid support 
through the thiols of two cysteines. Previous experience demonstrated that ter/-butyl 
disulphide deprotection is useful for the modification of small peptides on solid support .92 
However, parallel research demonstrated that when this technology was applied to larger 
peptides (greater than 10 amino acids), or depending on some amino acid sequence, 
complications could arise. Total deprotection, on solid support, of two cysteine residues of 
EPO fragment (1-32) had proved difficult (Dr. S. Mezzato personal communication). The 
major product observed was the unreduced substrate, followed by the monodeprotected 
material. The desired double deprotected peptide was identified only in small amounts 
(Scheme 5.1 3). Moreover, studies of Cu(I)-catalysed modification of Huisgen cycloaddition 
performed on solid support for the synthesis of cyclic peptides' 95 suggested that the rate of 
the reaction is slower when the acetylene, rather than the azide, is on the solid support. As 
discussed earlier (Chapter 5, Section 5.2), the copper (I) insertion in the acetylene is the 
limiting step in the cycloaddition reaction. When the acetylene is in solution, the kinetics of 
the process should be fast enough to avoid generation of side products. In such a case the 
performance of the reaction would be improved. Consequently, having all these precedents, 
incorporation of different units of the PSDC to an EPO peptide fragment would be preferred 
to be performed in solution. 
To demonstrate this hypothesis and to evaluate the potential of the work,"' 112 was 
introduced to an EPO peptide fragment (22-32) 135, on solid support, through the thiols of 
two cysteine residues (Cys24 and Cys 30). Cleavage of the molecule from the resin, was 
followed by purification by semi-preparative HPLC and freeze drying. At this point it was 
decided to perform the "click chemistiy" reaction between the peptide fragment 136, and the 
un-natural carbohydrate scaffold 104. 
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Scheme 5.13: E-IPLC trace of EPO (1-32) fragment, after tert-butyl dithiol deprotection: 5 % DTT and 
2.5 % DI PEA in DMF for 24 hours (picture donated by Dr. S. Mezzato). 
Lin and co-workers had modified the expressed proteins, maltose binding protein (MBP) and 
enhanced green fluorescent protein (EGFP). In both cases an unnatural amino acid with an 
alkyne chain was introduced at the C-terminus. These compounds were then conjugated 
with azido molecules, either containing G1cNAc, biotin or fluorescein isothiocyanate (FITC). 
Finally, the modified alkyne MBP was mounted on an azido-modified glass slide efficiently 
using "click chemistry". Site-specific ligations were performed with biotinylated maltose to 
corroborate optimal modifications .216  Applying the protocols of Lin and co-workers, the 
alkyne modified EPO peptide fragment (22-32) 136 was treated with 7 equivalents of the 
104 (3.5 equivalents of peptide scaffold displaying carbohydrates per acetylene), 36 
equivalents of tris-(2-carboxyethyl)phosphinc hydrochloride (TCEP), tris-
benzyltriazolylmcthylamine (TBTA) and 11 equivalents of buffered copper (II) sulphate. 
However, after 24 hours, all PSDC 104 equipped with an azido group appeared to have been 
fully reduced to the amine. MS-analysis of the HPLC fractions confirmed the reduction of 
the azide at the anomeric position, 137, and the HPLC trace showed the presence of an 
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epimeric mixture (Scheme 5.14). At this stage it was necessary to consider a possible 




Scheme 5.14: HPLC trace of the crude from direct glycosylation of the EPO peptide fragment (22-32) 
by "click chemistry" in the presence of TCEP Mass spectra data from the reduced PSDC, 137: MW: 
1500.00 (MWcaic : 1498,54). 
Conceivably, the alkyl chains were shielded from reaction by the steric bulk of the 
surrounding peptide scaffold. This could diminish the rate of the reaction significantly. 
Alternatively, the combination of excess of TCEP and reducing phosphine additive could 
favour a competitive process such as the Staudinger reaction. This, in turn, would generate 
the mixture of epimers observed, 137. 
It was still considered valuable to perform the Cu(t)-catalysed modification of the Huisgen 
cycloaddition on the modified peptide scaffold in buffered solution. As a result, efforts were 
directed towards optimising this transformation. In model studies, the modified EPO peptide 
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fragment (22-32) would remain the source of alkynes, while N-acetylglucosamine azide 121 
would be used to replace the key PSDC, 104 (Table 5.1). 
Cu 
Reducing TBTA Solvent Time Temperature 
Yield 
agent ligand (%) 
0.2 equiv 0.4 equiv. 02 equiv.  . 	 .
PBS buffer , 16 1i 40°C 18% 
CuSO4 TCEP 0.1 M, pH 8 
0.2 equiv 
0.4 cquiv. 
sodium 0.2 equiv. 
PBS buffer , l6h 40°C 15% 
CuSO4 ascorbate 
0.1 M, pH 8 
0.2 equiv 
0.4 equiv. 





H20/'BuOH 16h 40°C NO 
CuSO45H2O ascorbate 
(1:1) 
0.2 equiv 1.8 cquiv. 04 euiv.  .q 	.
PBS buffer , 48h 40°C 23% 
CuSO4-5H20 TCEP 0.1 M, pFl 8 
0.2 cquiv 
1.8 equiv. 
sodium 0.4 equiv. 




0.1 M, pH 8 
1.8 equiv. 




sodium 10.. 0 
PBS buffer, 48 h 20°C 61% 
CuS045H2O ascorbate 
equiv. 0.1 M, p!-1 8 
Table 5.1: Different sets of conditions applied during the development of the "click chemistry 
reaction in solution, between a modified peptide 136, and an azido sugar 121. 
The Cu(I)-catalysed modification of l-luisgen cycloaddition between 136 and 121 was 
attempted under a range of conditions (Table 5.1). In each case the reaction was performed 
on a micromolar scale (1.04x 10-3  mmol), with respect to the peptide, and the reaction was 
monitored by MS-analysis of the HPLC fractions. 
From these experiments, a number of conclusions could be drawn: i) increased amounts of 
reducing agent avoided the formation of peptide dimers through the N-terminal cysteine 
residues; ii) the presence of buffer also minimised dimer formation; and iii) increased 
amounts of the TBTA additive generally led to cleaner reactions with higher yields of the 
desired products. 
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Having reviewed the literature 216 and analysed the outcome of the model experiments, it was 
possible to devise an optimal protocol for this transformation. The reaction conditions used 
were: PBS buffered (0.1 M, pH 8), 1 equivalent of CuS0 4 5H20, and 25 equivalents of 
sodium ascorbate and TBTA ligand. No TCEP was employed and the reaction time would 
be reduced, because it did not affect to the final yield after 24 hours (Scheme 5.15). 
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Scheme 5.15: i) reaction conditions between an azido sugar 121, and an acetylene modified EPO 
peptide fragment (22-32) 136, to obtain an unnatural peptide, 138. ii) HPLC trace of the crude of 
previous reaction. iii) Mass spectra of the fraction containing the unnatural peptide 138, MW: 
1844.20 (MW5315 : 1842.66). 
The next step was to apply this protocol to introduce the PSDC 104 to the alkyne modified 
EPO peptide fragment (22-32) 136. Therefore, 104 and 136 were dissolved together in a 0. 1 
M PBS buffer solution pH 8.0, in the presence of 25 equivalents of sodium ascorbate and 
TBTA, and I equivalent of CuS0 4 5H 2O; and the mixture was stirred for 24 hours at 20 °C 
and 1200 rpm. After HPLC purification, the desired modified EPO peptide fragment (22-32) 
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with 2 PSDC attached 139 was obtained in 69 % yield, and 18 % of recovery of unreacted 
104 (Scheme 5.16). 
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Scheme 5.16: HPLC trace of the reaction between the PSDC 104, and the EPO peptide fragment (22-
32) 136, to produce an unnatural glycopeptide 139, MW: 4402.80 (MW caic : 4400.60). 
This final result demonstrated the potential of the Cu(I)-catalysed modification of Huisgen 
cycloaddition for introducing carbohydrates to peptides, regardless of the size of the sugar, 
either on solid phase or in buffer solution. Moreover, the complex reactions involved in fi-
mannosylation and glycosyl elaboration, were avoided (Chapter 4). 
5.5 NMR observations 
During the development of the nco-glycopeptide linkage compatible with NCL,' 7 ' interesting 
effects were observed by 1 H-NMR spectroscopy during the formation of the triazole ring. 
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This phenomenon was also observed in the case of the PSDC, either linked with the 
acetylene motif or with the EPO peptide fragment. 
When the peracetylated azido GIcNAc 95 reacted with N-(propargyl)-bromoacetamide 112 
in the presence of copper (I), a triazole ring was generated. Formation of the aromatic ring 
was indicated in the 'H-NMR spectrum, by the appearance of an apparent singlet signal at 
7.72 ppm. This singlet couples with another apparent singlet at 4.19 ppm that corresponds to 
the two protons a to the triazole (coupling determined by COSY experiments). Furthermore, 
the methyl component of the N-acetyl moiety is shifted to lower frequency, from 1.96 to 1.52 
ppm on the formation of the aromatic ring (see experimental part, Chapter 7). A similar 
observation was made in the case of deacetylated azido GIcNAc molecule: from 2.16 (121) 
to 1.71 ppm (122) (Scheme 5.17). A possible explanation for this process could be related to 
the fact that the protons of the N-acetyl group were located perpendicular to the aromatic 
ring. In this position, they would be aligned oposit to the orientation of the magnetic field of 
the triazole. Consequently, the singlet that corresponds to 3 protons, was shifted to lower 
frequency. Theoretical model structures analysed by ChemDraw 3D®,  confirmed the 
proposed stereoconformation previously described for 122. 
Scheme 5.17: two different conformational angles for 122, visualised by ChemDraw 3D® . 
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These effects were also observed once the PSDC, 104 (Scheme 5.18), was attached to the 
EPO peptide fragment (22-32), 136 (Scheme 5.19). In this case, the shift of the methyl 
group in 104 was 2.05 ppm, while in 136 it was 1.82 ppm. 
To verify the previous hypothesis of stereocon formation of the methyl of the N-acetyl group, 
it would be interesting to obtain a crystal structure of derivatives from 122. 
eL 	S 	S 	
f) 	
S 	SO 	4.5 
Scheme 5.18: U-NMR spectrum of 104, with amplifications of the aromatic and the aliphatic 
regions. 
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Scheme 5.19: 'I-l-NMR spectrum of 136, with amplifications of the aromatic and the aliphatic 
regions. 
5.6 Conclusions and future work 
A new methodology to facilitate the incorporation of carbohydrates (azido sugars) on 
modified peptides with acetylenes has been developed. This new technology can be applied 
without any restriction in the presence of previous orthogonal functional groups, avoiding 
harsh and complicated sets of conditions for glycosylation (Chapter 3). In addition, this 
methodology is also versatile and flexible because: i) it can be applied either on solution or 
solid phase; ii) the order of the reactions do not alter the outcome of the reaction; iii) the 
chemistry is compatible with all the peptide components and functional groups; and iv) the 
product is also compatible with harsh acid conditions and ligations, such as NCL. 17 ' 
112 
5. Novel neo-glycopeptidc linkage using Cu(I) catalysed 1, 2, 3-triazole formation 
Applying this orthogonal reaction it should be possible to incorporate more elaborated and 
ambitious carbohydrate structures on a peptide. 
In addition, two PSDC units (Chapter 4) have been attached to an EPO peptide fragment in 
aqueous solution, both by an SN2 reaction between PSDC bromoacetamide and cysteine thiol 
group, or by Cu(I)-catalysed modification of Huisgen cycloaddition. Finally, diamagnetic 
effects on the protons of the methyl group of the N-acetyl close to the anomeric centre, after 
the formation of the triazole ring have been observed. Crystal structure determination should 
confirm the hypothetical conformation of the methyl group. 
Contemporary to this work, Danishcfsky and co-workers also reported a similar 
methodology to prepare neo-glycopcptides using "click chemistty" for the production of 
anticancer vaccines 143 (Scheme 5.20)217 In this work, they attached to a peptide backbone 
through modified lysines with acetylenes 141; either an amino acid 142, or a tripeptide 
scaffold furnished with Tn and Sin antigens; and equipped with a 3-aminopropyl azide 
residue. Applying "click chemistry", they manage to ligate these two building blocks in the 
presence of copper. This neo-glycopeptidc linkage facilitates the insertion of elaborated 
structures to a peptide increasing the yields and avoiding extra-modifications compared with 
aspartilation carried out in their research group. 
At this stage, it remained to demonstrate that, although these structures are unnatural and 
have a neo-glycopeptide linkage, they behave and can be recognised as the native 
oligosaccharide found in N-linked glycoproteins. Therefore, a qualitative method to 
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Scheme 5.20: Carbohydrate-based anticancer vaccines 143 through "click chemisl#y". 217 
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6 Protein-carbohydrate interactions between PSDC and lectins visualised 
using modified GFP 
6.1 Introduction 
Supramolecular interactions occur between the three classes of natural biopolymers: nucleic 
acids, proteins and carbohydrates. These forces are responsible for significant biological 
effects. Although the study of nucleic acid and protein interactions are well known through 
genornics and proteomics respectively (Scheme 6.1), glycornics, the study of carbohydrate 
interactions with the two other biopolymers and the biological consequences, is an emerging 
scientific discipline in its early stages. 
	
GENOMICS 	 PROTEOMICS 











Scheme 6.1: Interactions of the three main 	 218  
Since carbohydrate interactions are involved in cell recognition and adhesion, glycomics 
promises to be a fertile ground for glycobiology. 219 It can be anticipated that modulating, 
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amplifying or suppressing these supramolecular interactions will allow the understanding of 
their biological roles and may lead to the discovery and availability of new therapeutic drugs 
and treatments 
Chemists have developed many methodologies to generate pure saccharides (described in 
Chapter 2). Now, with the development of high-throughput screening, such as microarray-
based methods, glycochips, surface plasmon resonance spectroscopy (SPR), mass 
spectrometric methods, NMR or ELISA-type methods, it is possible to quantify the 
interactions of a large number of carbohydrates with their biological counter ligand. 21922 ' 
Microarray-based methods or glycochips, is a technique analogous to those developed for 
DNA and proteins. Carbohydrates are covalently or non-covalently immobilized on a 
surface (polystyrene, thiol-derivatised glass slides, or gold slides) . 2 ' This immobilization 
has emerged as a new tool to facilitate the study of carbohydrate-protein interactions and for 
the identification of optimal sugar ligands and inhibitors. 208 Covalent immobilization can be 
achieved through a Diels-Alder, hetero-Michael addition or 1,3-dipolar cycloaddition 
reaction between an azide and alkyne group, in the presence of catalytic amounts of copper 
(I) . 220 
Shin and co-workers 222 developed carbohydrate chips for studying high-throughput 
carbohydrate-protein interactions. They prepared carbohydrate microarrays by immobilizing 
maleimide-linked carbohydrate on thiol-derivatised glass slides (Scheme 6.2.A). In addition, 
sLe x was prepared from GlcNAc attached to the glass slide, by three consecutive glycosyl 
trans ferase-catalysed reactions to obtain the desired final oligosaccharide structure (Scheme 
6.2.C). These glycochips allowed the authors to quantify the binding affinities between the 
carbohydrates and lectins. Moreover, binding affinities of lectins to carbohydrates were also 
quantitatively analysed by determining IC 50 values of soluble carbohydrates with the 
carbohydrate array. 
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Scheme 6.2: A) Fabrication of the carbohydrate microarrays by immobilizing maleimide-linked 
carbohydrates on thiol coated glass slides via chemoselective ligation. B) Fluorescence images of 
microspots containing mono- and disaccharide probes with FITC-labelled lectins (Con A: 
Concanavalin A, NPA: N. pseudonarcissus. EC: E. cristagalli, TV: T. vulgaris, AA: A. aurantia). C) 
Enzymatic synthesis of sLe from GIcNAc by three glycosyl trans ferases, and fluorescence images of 
microspots containing oligosaccharides with FITC-labelled lectins (Reprinted with permission from I. 
Am. Chem. Soc. 2004, 126, 4912-4819. 10.1021/ja0391661 CCC: $27.50 © 2004 American Chemical 
Society). 
Globo H tumour antigen hexasaccharide is an epitope found on the cell surface in breast, 
prostate and ovarian cancers cells. Wong and co-workers 223 developed a carbohydrate 
microarray for profiling antibody interaction with this hexasaccharide tumour antigen 
(Scheme 6.3). The authors arrayed covalently, on glass slides, a library of different length 
Globo I-I polysaccharides obtained by one-pot oligosaccharide synthesis. 
4' Thereafter, they 
used two monoclonal antibodies (MRrI and VK-9) against the hexasaccharide and serum 
from breast cancer patients using fluorescence-based binding analysis. Analysis with the 
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monoclonal antibodies showed that the terminal tetrasaccharide and the native 
hexasaccharide bind equally well (Scheme 6.3.A., 144a, 144b, 145a and 145b). In addition, 
the fucose residue was found to be required for effective binding. On the other hand, serum 
bound both defucosylated pentasaccharide and fucosylated hexasaccharide without a 
significant difference (Scheme 6.3.13., 145a, 145b and 146). This final result could be 
caused either due to a possible polyclonal nature of the antibodies from the patients against 
Globo H, or the antibodies were generated at different stages to recognise the defucosylated 
pentasaccharide and fucosylated hexasaccharide. 
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Scheme 6.3: A) Binding of monoclonal antibodies to Globo Fl and truncated sequences. Slide image 
obtained from fluorescence scan after antibody incubation assay with VK-9. B) Detection of 
antibodies in breast cancer patient serum. Slide image obtained from fluorescence scan after cancer 
patient serum assay with 1gM detection (Reprinted with permission from Proc. Nat!. Acad. Sd. USA 
2006, 103, 15-20. doi: 10.1073Ipnas:0509693 102). 
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Seeberger and co-workers used protein-carbohydrate interactions to develop a carbohydrate-
functionalised soluble poly(p-phenylene ethylene) (PPE) that can be used as a fast method 
(10 and 15 minutes) for the detection of Escherichia coli (Scheme 6.4). 
 224  They 
functionalised the polymer after polymerisation with mannose and galactose. The molecule 
derivatised with mannose showed strong affinity to E. coli. This interaction and cell 
aggregation is due to multivalent interactions between the mannosylated polymer and 






'! 	 D) 
/ l) 
 





'1 	 FIS 	 IF 
- 0 
147 R-011:x:y=O:1 
148a R OH or 5FI(CH,)0H: x y I I 
sugar - rna000sc 
149b R= Oil or NH(CH),OHz x. y 	S I 
sugar = galactose 
Scheme 6.4: Laser scanning confocal microscopy image of A) mutant E. coil that does not bind to 
174a (mannose derivative polymer). B) fluorescent bacterial aggregate due to multivalent interactions 
between the mannose-binding bacteria phi and 174a. C) fluorescence microscopy image of a large 
fluorescent bacterial cluster. D) Structure of the polymers used in the study (Reprinted with 
permission fromf. Am. Chem. Soc. 2004, 126, 13343-13346. 10.1021/ja047936i CCC: $27.50 © 2004 
American Chemical Society). 
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6.2 Objective: development of a methodology to visualise protein-
carbohydrate interactions 
Based upon literature precedent for detection of protein-carbohydrate interactions, a new 
simple methodology to visualise these interactions using fluorescence was set out by 
attaching three carbohydrate tags linked through cysteines of a peptide to Green Fluorescent 
Protein (GFP). The rationale behind using GFP is because it is easy to produce by bacteria 
expression. Moreover, the product would be an unnatural glycoprotein, a molecule that is 
more relevant to the biological studies than attaching the unnatural glycopeptide to a dansyl 
or fluorescein tag. 
The introduction of the sugar molecules was carried out applying the technology described 
previously. 92  The introduction of the modified peptide with carbohydrates to GFP would be 
achieved by expressed protein ligation (EPL). 89" 28 
To visualise protein-carbohydrate interactions, it was envisaged that the modified GFP 
would be dissolved in an aqueous solution. In the presence of agarose beads coated with 
lectins, the carbohydrates present on the modified GFP should interact specifically with their 
counter ligand-lectin, staining the agarose beads green. After several washes, this type of 
interaction should remain intact, with the green colour staining the agarose beads. 
Once the viability of the methodology to visualise protein-carbohydrate interaction was 
demonstrated, it could be used to demonstrate that the PSDC which was developed (Chapter 
4) can be recognised by a lectin once it is on a protein, and therefore corroborate the 
hypothesis that these structures, although unnatural, behave similarly to typical native 
polysaccharide structures found in N-linked glycoproteins. 
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6.3 Green Fluorescent Protein (GFP) 
GFP is a protein produced by the Pacific North West jellyfish Aequoria Victoria. 221 Wild-
type GFP is a stable proteolysis-resistant single chain of 238 residues. The protein has a 
fluorescent activity at 394 nm, with an emission maximum of 508 nm. This fluorophore 
results from the autocatalytic cyclization of the polypeptide backbone between residues Ser 65 
66 
and G1y 67 and oxidation of the a—flbond of Tyr. 
Expression of the protein in E. coli22 and crystal structure determination, 227 has been crucial 
for the widespread use of GFP as a reporter for gene expression and protein localization. 227 
The Macmillan research group has developed the technology to express on E. coli GFP 
thioester, allowing the modification of the protein by expressed protein ligation (EPL). 
6.4 Expressed Protein Ligation (EPL) 
EPL is a procedure to synthesise recombinant proteins based on the natural posttranslational 
phenomenon of protein splicing. This is a process in which a single protein sequence 
undergoes an intramolecular rearrangement resulting in the extrusion of an internal 
sequence, intein, and the joining of lateral sequences, exteins (Scheme 6.5 
).228-231  In EPL, 
the expressed protein can be bound to an affinity resin, where the incipient thioester can be 
trapped by thiolysis or with an N-terminal cysteine peptide fragment, thus eluting the target 
protein as a C-terminal thioester or the desired modified protein; and leaving the remainder 
of the fusion protein bound to the affinity resin. 
EPL is a very powerful technique for the modification of proteins. Molecular biology and 
chemistry come together, providing the opportunity to generate large proteins or introduce 
unnatural substrates to the protein, providing to the acceptor molecule new physical and 
chemical properties. 
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Scheme 6.5: Scheme of Expressed Protein Ligation and Protein Splicing. 
It has been possible to perform intein-mediate protein splicing in living cells, with the 
horizon of new biological applications. Different strategies are described in the literature: 
• Non-covalent association of 2 intein fragments to generate an active molecule that 
performs the splicing event to produce a functional protein. 232-234 
• Binding of a small molecule to activate an intein that can then activate a target 
molecule. 235 
Muir and co-workers 229  synthesised a pair of biologically active proteins, C-terminal Src 
kinase, Csk, molecule of 50 kDa. Wong, 236 et. al., combined EPL with cysteine derivatives, 
like H-Cys-Asn(G1cNAc)-OH, and later modified this by galactosyl transfcrase. As 
mentioned earlier, Macmillan and Bertozzi, 9912  were also able to synthesise a physiological 
glycoprotein using this technique. A larger number of other proteins have been engineered 
using EPL, 237 
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Applying EPL it would be possible to modify GFP thioester available in the Macmillan 
research group, to introduce unnatural glycopeptides, such as 134 and 139. 
6.5 Development of methodology to visualise carbohydrate-protein interaction 
6.5.1 Synthesis of N-(iodoacetyl)-p-aminophenyl mannopyranoside 
For the successful synthesis of N-(2-iodoacetyl)-p-aminophenyl mannopyranoside 155, four 
synthetic steps were necessary (Scheme 6.6). This molecule was synthesised as an 
iodoacetamide derivative with a view to being incorporated into peptides through cystcinc 
residues, and then to be attached to a protein by EPL. Therefore, the synthesis of the desired 
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Scheme 6.6: synthesis of N-(2-iodoacetyl)p-aminophenyl mannopyranoside 155. 
p-Nitrophenyl mannopyranose 150 was quantitatively peracetylated with a solution of acetic 
anhydride and pyridine (1:2) to obtain the desired product 151 (Scheme 6.6). Afterwards, 
the nitro group was reduced by catalytic transfer hydrogenation (10 % PdIC, 
NH4HCO 3 ),238 ' 239  to obtain p-aminophenyl-2,3 ,4,6-tetra-O-acetyl- a-D-mannopyranoside in 
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100 % yield. The primary amino group was then acetylated with 2-iodoacetyl chloride 
153169 with stoichiometric amounts of pyridine, in dry DCM, at -30 °C, to achieve the 
product 154 in 69 % yield. Finally, the compound was deacetylated, by subjecting the 
molecule to Zempldn dcprotection, 66 to afford N-(2-iodoacetyl)-p-aminophcnyl 
mannopyranoside 155 in 92 % yield. 
6.5.2 Semi-synthesis of GFP modified with an unnatural glycopeptide displaying 
three mannoses, for protein immobilisation 
Once the desired mannose derivative was obtained, this structure was introduced to a 
peptide, on solid phase. First a peptide fragment was synthesised using Fmoc-SPPS. The 
predefined sequence was: L-Cys-L-Ser-L-Cys-L-Cys-L-Cys-L-Ser. The N-terminus was 
protected with a Boc- group, the hydroxyls of the serines were protected with the tert-butyl 
protecting group, the thiol of the terminal cysteine was protected with trityl group, and the 
other thiols of the remaining cysteines, were protected with tert-butyl disulphide protecting 
group (Scheme 6.7). The disulphide bond protected cysteine derivatives were reduced in the 
presence of 10 % DTT and 2.5 % DIPEA in DMF. 92 Afterwards, 155 was incorporated into 
the peptidc with a mixture of 2.5 % pyridinc in DMF. After TFA cleavage, and purification, 
the desired hexamer was obtained with three mannose derivatives incorporated. Finally, the 
modified glycopeptides were incorporated on Green Fluorescent Protein (GFP), using (EPL). 
GFP Chitin Binding Domain (CBD) Fusion Protein was overexpressed in Escherichia coli 
strain BL21-DE3 transformed with pTYBI-GFP. The protein was loaded on chitin beads 
New England Biolabs (NEB) and equilibrated with column buffer (20 mM Tris-HCI pH 8.0. 
500 mM NaCl, 1 mM EDTA, 1 mM PMSF). The cell-free extract loaded was provided as a 
gift by Dr. D. Macmillan. 
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Scheme 6.7: semi-synthesis of modified Green Fluorencent Protein (GFP) in the C-terminus 161, with 
a peptide displaying mannose derivatives through the thiols of 3 cysteines. 
Afterwards, the chitin beads (NEB) were washed with 200 mM sodium phosphate buffered 
solution, pH 8.0, 100 mM sodium chloride, 2 % w/v mercaptoethancsulfonic acid (MESNA), 
5 mM tris-(2-carboxycthyl)phosphine hydrochloride (TCEP-HCI) solution (5.0 mL), and the 
column was allowed to drain by gravity flow. 
The modified peptide was dissolved in aqueous solution, and the contents were mixed gently 
for 48 hours. After eluting and washing the chitin beads (NEB) with buffer, the samples 
were concentrated in a Vivaspin 5 2 mL concentrator, 10,000 pm MWCO PES, to remove the 
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Scheme 6.8: a) structure of the mannose derivative incorporated into the peptide through cysteines to 
synthesise peptide tags; b) ESI-MS of the peptide tag: MW: 1539.00 (MW ca ic : 1537.41); c) ESI-MS of 
the peptide tag incorporated into GFP; d) photograph of the fluorescence of GFP coated on 
concanavalin A beads. 
6.53 Protein-carbohydrate interaction test on agarose beads, visualised with 
modified GFP 
Once the modified GFP with an unnatural glycopeptide displaying 3 mannose derivatives 
was obtained, it was decided to perform interaction protein-carbohydrate studies between the 
unnatural glycoprotein and lectin-coated agarose beads. 
In these interaction studies, native GFP served as s control test, while modified GFP protein 
with a peptidc displaying 3 units of mannose was the test experiment. It was decided to use 
agarose beads coated with Concanava/in A, as a solid support to visualise protein-
carbohydrate interactions between these two molecules. Concanavalin A is a legume lectin 
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form Cancivalia ensformis that specifically recognises mannose residues of many complex 
glycans. 240 
Consequently, both molecules were in PBS solution and dispatched in separate 1.5 mL 
eppendorfs tubes. Afterwards, small amounts of agarose beads coated with a lectin, 
Concanavalin A, were added to each eppendorf, and the mixture was shacken gently. After 
30 minutes, any protein-carbohydrate interaction was observed in the test experiment 
eppendorf (Scheme 6.9: + ConA-agarose beads). Finally, after washing the agarose beads 
coated with the lectin with PBS solution, the agarose beads were still stained with GFP 
visually indicating the predicted protein-carbohydrate interaction between the lectin and the 
mannose tags (Scheme 6.9). 
Control 
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Scheme 6.9: Interaction studies between GFP labelled peptide displaying mannose, and lectin (Con 
A)-coated agarose beads. 
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6.6 Recognition of the PSDC in a biologically relevant environment 
Once a method to visualise specific protein-carbohydrate interaction was developed, this 
technology was applied to verify if the PSDC, once attached to the EPO peptide fragments 
134 and 139 displayed carbohydrates in such a way that can be recognised by a lectin, and 
therefore, certify that the structure mimics the natural nonasaccharide structure found in N-
linked glycoproteins (Scheme 4.4). 
6.6.1 Semi-synthesis of GFP modified with an EPO peptide fragment containing 
two PSDC, for protein immobilisation 
GFP was overexpressed as a fusion intein-CBD in E. co/i. Subsequently, the protein was 
loaded on chitin beads. The suspension of chitin beads coated with GFP was provided, as a 
gift, by Dr. J. P. Richardson (Macmillan research group). Afterwards, the beads were 
washed with 200 mM sodium phosphate buffer solution, pH 8.0, 100 mM NaCl, 2 % w/v 
MESNA, 5 mM TCEP solution (5.0 mL). The column was allowed to drain by gravity flow. 
Finally, the modified EPO fragments with the peptide scaffold displaying carbohydrates 134 
and 139 were dissolved in the column buffer, and the contents were mixed gently, for 48 
hours. SDS-PAGE analysis of samples from the reaction indicated partial success in the 
reaction (Scheme 6. 10). 
Afterwards, the reaction mixture was eluted with PBS buffer, and the eluted samples were 
concentrated and dialyzed with Dulbecco's PBS solution, 241  in a Vivaspin®  2 mL 
concentrator, 10,000 pm MWCO PES, a membrane that dialyses all particles with molecular 
weight bellow 10 kDa. Finally, the green dialysed protein was resuspended again with 
Dulbecco's PBS solution. 
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Scheme 6.10: Introduction of EPO peptide fragment 139 with to PSDC, to GFP, using EPL. SDS-
PAGE analysis: of the starting material (centre) and the product of the EPL reaction (right). 
6.6.2 Protein-carbohydrate interaction test on agarose beads, visualised with 
modified GFP 
Having the methodology to qualify and visualise protein-carbohydrate interactions (Scheme 
6.9), it was decided to apply it to the new GFP protein that was modified with an EPO 
peptide fragment containing two PSDC. In this case, the test to visualise the protein-
carbohydrate interaction was carried out with agarose beads coated with Ricinnus Communis 
RCA 120 , 242  a lectin that has specific avidity for galactose (the terminal monosaccharide of the 
PSDC is galactose, see Chapter 4). 
Consequently, the modified proteins with the peptide 134 and 139 were dissolved in 
Dulbecco's PBS solution and dispatched separately in eppendorfs. Native OFF was used as 
a control test in a separated eppendorf tube (Scheme 6.11). Afterwards, agarose beads 
coated with Ricinnus Communis RCA 120, were added to each eppendorf, and the mixture was 
shaken gently for 30 minutes. Finally, after washing the agarose beads coated with the lectin 
with Dulbecco's PBS solution, no green colouration of the agarose beads was observed. 
This unfortunate result appeared to reveal that no interaction occurred between the lectin and 
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the GFP modified with the EPO peptide fragment furnished with two PSDC molecules. 
Studying carefully this result, it was realised that during the ligation between GFP-intein 
chitin binding and the unnatural glycopeptides, 134 and 139 (Scheme 6.10), an undetermined 
excess of the unnatural glycopeptides were dissolved in the reaction mixture, and therefore, 
the remaining excess would be in the crude product. Therefore, the presence of excess 134 
and 139 in the test could compete and interfere with the interaction between the lectin 
(RCA 120) and the GFP modified with the EPO fragment containing two PSDC. As a 
consequence, excess of 134 and 139 could inhibit the protein-carbohydrate interaction. 
A possible reason for the presence of excess of 134 and 139 could have been due to the 
obstruction of the pores of the dialysis membrane when the crude of ligation reaction was 
dialyzed in the Vivaspin 2 mL concentrator, 10,000 1uni MWCO PES. Consequently, the 
dialysis was repeated using a porous filter diameter of 30,000 sum, assuming that better 
dialysis efficiency could be achieved (dialyzed all compounds below MW: 30 kDa), and 
eliminating the excess of unreacted unnatural glycopeptide (134, MW: 4401.20 (MWca j c : 
4399.65); 139, MW: 4402.80 (MWcaic : 4400.60)). 
Once again, the interaction test was repeated between unnatural glycoprotein and agarose 
beads coated with Ricinnus Communis RCA 120. When the agarose beads were washed with 
Dulbecco's PBS solution, a green coloration of the agarose beads was observed, 
demonstrating interaction between the galactose present in the PSDC and the lectin Ricinnus 
Communis RCA 120  (Scheme 6.11). This coloration of the solid support was not as intense as 
the previous experiments when GFP labelled peptide displaying mannose was studied 
(Scheme 6.9). This could be due to a remaining presence of excess of non-ligated EPO 
peptide fragment displaying two PSDC (134 and 139) and consequently, partially inhibiting 
the interaction of the modified GFP with the lectin. 
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can be recognised in a biological environment. Having previous positive results, it is 
possible to extend this technology for the semi-synthesis of non-natural erythropoietin, 
where the terminal galactose could be enzymatically modified by the addition of sialic acid. 
For the semi-synthesis of non-natural EPO, protein fragment should be expressed on E. coil. 
Afterwards, and applying the technology that the Macmillan research group developed, the 
expressed protein could be selectively cleaved with cyanogen brornide, 93 introducing an 
internal cysteine to the N-terminus (Scheme 6.12). 
On the other hand, an EPO peptide fragment (1-32) has been synthesised using Fmoc- SPPS, 
using a "safety-catch" linker to generate, afterwards, a thioester. In this peptide sequence, in 
positions 24 and 30, a cysteine modified with an alkyne chain through the thiol has been 
introduced.' 71 Finally, the unnatural EPO peptide fragment has been cleaved by activating 
the "safety-catch" linker and generate a thioester in the presence of a thiol (Scheme 6.12). 
SH 
-N 	CO 2 11 
	
SN'S 	 CNBr. 80 % HCO2F1 
() 	V 	 0 
J__COSR + 
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Scheme 6.12: Possible semi-synthesis of an alkyne-modified mutant EPO (Asn24Cys and Asn30Cys). 
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Having available the two different EPO polypeptide fragments, and applying expressed 
protein ligation, the full length EPO protein (1-166) could be generated, 89 where, as 
mentioned before, in the positions 24 and 30, the protein would have an alkyne substituent 
(Scheme 6.12). 
Afterwards, and applying the technology described in Chapter 5, the "click chemistry" 
reaction could be performed, in buffered solution at pH 8, between the modified EPO 
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Scheme 6.13: Introduction of two PSDC through the alkynes of the modified mutant EPO by click 
chemistry, addition of sialic acid with a-2,3-sialyltransferasc, and final folding to achieve a 
therapeutic unnatural EPO. 
Finally, and using a commercially available sialyltransferase, a sialic acid could be inserted 
on the 3-hydroxyl group of the galactose to obtain the desired structure. Final protein 
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folding should provide an unnatural therapeutic glycoprotein with 4 to 8 sialic acid residues, 
responsible for protecting hrEPO from hepatic metabolism, and therefore increasing the 




Carbohydrates are very important and perform multiple roles in biology. They can influence 
and modify the biological and physicochemical properties of proteins. Consequently, these 
molecules have captivated the attention of the chemist and biochemist community.' 
Unfortunately, glycosylation is not under genetic control, and a heterogeneous mixture of 
glycosylated forms is generated. Therefore, semi-synthesis of homogeneous glycoproteins 
should allow the understanding of the biological role of the structures. 
Synthesis of natural glycoproteins can potentially help to comprehend the different functions 
of these molecules in biology. Unfortunately, the semi-synthesis of glycoproteins is far from 
easy and demands a large number of steps. On the other hand, mimicking these molecules 
may permit more rapid access to complex structures and allow the study of saccharide 
interactions that could provide better understanding of the biological activity and potential 
target for therapeutic agents provided that the unnatural elements of the structure are 
tolerated. 
Based on the knowledge accumulated in the Macmillan research group, 899328 the semi 
synthesis of a natural 0-linked glycopeptide was accomplished, and unnatural N-linked 
glycoprotein. These molecules can be recognised in a biological environment. 
A successful preparative synthesis of the glyco-amino acid building block 82 has been 
accomplished. The molecule could allow different research opportunities, using the 
molecule as starting material for SPPS. Moreover, most of the reactions developed for the 
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synthesis of core-1 building block, could be used for the synthesis of the core-2 structure. 
On the other hand, this synthetic route was laborious and time consuming, and the final 
glycosylation step to attach the disaccharide to threonine appeared to be unproductive for 
such a valuable molecule. In the end, the glyco-amino acid building block 82 was prepared 
in 6.83 % yield after 15 synthetic steps. 
Consequently, a PSDC on solid phase has been developed. Based on the work of Meldal 
(Scheme 2. 8),14  103 and 104 were designed to mimic the diantennary carbohydrate structure 
found in N-linked glycoproteins. The PSDC allows the construction of highly complex 
unnatural carbohydrate structures from only two predefined glycobuilding blocks, avoiding 
the need to control of the regio and stereochemistry in many instances, and therefore 
simplifying the total synthesis of the desired molecule. This concept is exemplified by 
avoiding the difficult /3-mannosylation step. The deacetylated PSDC 104 was ultimately 
prepared in 10 steps in 47 % yield. 
In addition, having available the methodology to obtain PSDC on solid phase, a library of 
these molecules could be prepared by increasing the number of cysteines, and therefore 
changing the number of carbohydrates displayed. Moreover, the lysine residue could be 
altered by, for example, changing the number of carbons of the alkyl chain. This should 
provide the opportunity to identify which peptide scaffold shows better biological activity. 
The PSDC synthesis does however still need optimization and detailed conformational 
studies before it can be truly described as an oligosaccharide mimic. 
A novel neo-glycopeptide linkage using Cu(I) catalysed 1 ,2,3-triazole formation has been 
developed. With this new technology it is possible to introduce carbohydrates to peptides. 
Moreover, it can be applied in the presence of various orthogonal functional groups, 
avoiding harsh and problematic set of conditions for glycosyiation. In addition, the novel 
neo-glycopeptide linkage is also versatile and flexible because: i) it can be applied either in 
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solution or on solid phase; ii) the order in which the reactions are performed does not appear 
to alter the outcome of the reaction; iii) the chemistry is compatible with all the peptide 
components and functional groups; and iv) and the product is also compatible with harsh 
acid conditions and ligations, such as NCL.' 71 Applying this new linkage, two PSDC have 
been attached to a EPO peptide fragment in aqueous solution, either by an SN2 reaction 
between PSDC bromoacetamidc and cysteine thiol group (19 % yield in 2 steps), or by 
Cu(I)-catalysed modification of Huisgen cycloaddition (69 % yield in 1 step). 
Finally, a method to visualise protein-carbohydrate interactions has been developed, where 
GFP modified with a peptide containing carbohydrates (mannose), interacts with agarose 
beads coated with lectins (Concanavalin A). This interaction is visualised by the green 
colour of the modified GFP that stains the agarose beads, and the colouration remains after 
several buffer washes. Applying this methogology to visualise protein-carbohydrate 
interactions demonstrated that the PSDC attached to an EPO peptide fragment presents 
correctly galactose, and so, they can be recognised in a biological environment by a lectin (in 
this case RCA 120). Therefore, this technology can be extended for the semi-synthesis of non-
natural erythropoietin, where the terminal galactose could be enzymatically modified by the 
addition of sialic acid. 
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7 Experimental section 
7.1 General Experimental Details 
7.1.1 Instrumentation 
'H NMR spectra were recorded at 250, 300 and 500 MHz, ' 3C NMR spectra were recorded 
at 63 and 75 MHz and 19F NMR spectra were recorded at 235 MHz on a Bruker 250Y 
instrument. Chemical shifts (cs) were reported in ppm and coupling constants (J) in Hz, 
signals were sharp unless stated as broad (br), 5: singlet, d: doublet, t: triplet, m: multiplet 
and q: quartet. Residual protic solvents: CDCI 3 (&: 726, s), CD 10D (oF,: 3.31, p), DO 
(4.79, s), were used as the internal calibrant in spectra unless otherwise stated. 
Electrospray mass spectrometry was carried out on a Micromass Quattro LC electrospray 
with an applied voltage of 25-60V. 
Automated peptide synthesis was conducted using a peptide synthesizer: 	Applied 
Biosystems 433A Peptide Synthesizer, employing the FastmoclM  protocol. 
7.1.2 Chromatography 
Analytical TLC was carried out on Merck aluminium backed plates coated with silica gel 
60F254. Flash chromatography was earned out over Fisher silica gel 60 A particle size 35-70 
micron. Components were visualized using UV light (254 nm) followed by p-anisaldehyde 
dip. 
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Purification of peptides on a semi-preparative scale was carried in a reverse phase gradient 
(water/acetonitrile (5-95%), 0.1 % TFA, over 45 minutes). The HPLC was equipped with a 
binary pump (P680 HPLC pump Dionex), a semi-preparative column (Phenomenex Luna, 
lOu, C18, bOA, 250 x 10), UV detector (UVD 170U/340U Dionex), and a fraction 
collector. 
7.1.3 Solvents and reagents 
All reagents and solvents were standard laboratory grade and used as supplied unless 
otherwise stated. Where a solvent was described as dry it was purchased as anhydrous 
grade. All organic extracts were dried over anhydrous magnesium sulphate prior to 
evaporation under reduced pressure. 
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7.2 Experimental Procedures 
1, 2, 3, 4, 6-Penta-0-acetyl-a-D-galactopyranose, 1491 
Ho 	OH AcO 	OAc 
H004 







HC104 (100 1iL) was added dropwise to a stirring solution of acetic anhydride (225 niL) at 0 
°C. Galactose 48 (25.0 g, 0.13 mol) was added in small portions to the reaction mixture 
during I h. After 3 h, TLC (7:3 ethyl acetate/hexane) indicated that the reaction was 
complete. The reaction mixture was concentrated to one third of its original volume. The 
mixture was diluted with chloroform (600 mL) and washed with saturated aqueous NaHCO 3 
(4 x 150 mL), water (150 mL) and brine (150 mL). The organic phase was dried with 
MgSO4 , filtered and evaporated under reduced pressure to afford 49 (54.0 g 100 %) as a 
pale brown solid. R= 0.42 (7:3 ethyl acetate/hexane). 'H-NMR (250 MHz, CDC1 3 ) (5 (PPM): 
6.34 (lH, d, J.2= 1.7 Hz, Hl); 5.46 (IH, d, .14. 5= 1.1 Hz, H4); 5.27-5.23 (2H, m, H2, H3); 
4.31 (1H, dd, J= 6.5 Hz, J45= 1.1 Hz, H5); 4.06-4.04 (2H, m, H6a, H6b); 2.18, 2.12, 2.00, 
1.98 and 1.97 (15H, 5 x s, CH 3CO). 13C-NMR (63 MHz, CDC1 3) 6 (PPM): 170.3, 170.0, 
168.9, 166.3 (CO); 89.6, 67.3, 67.2, 66.4 (CU); 61.2 (Cl-I 2 ); 20.5 (CH 3 ). FAB-MS calculated 
forC 16H220 11 [MH} 391.1162, found 391.12404. 
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The crude peracetylated galactose 49 (54.2 g, 0.14 mol) was dissolved in chloroform (75 
mL) and the solution was stirred at 0 °C. A solution of HBr 30 % w/v in acetic acid (170 
mL) was added and stirring was continued at 0 °C. After 2 h, TLC (1:1 ethyl acetate/hexane) 
indicated that the reaction was complete. The reaction mixture was diluted with chloroform 
(250 nit) and washed with water (3 x 150 mL) and saturated aqueous NaHCO 3 (4 x 150 
mL). The organic phase was dried with MgSO 4, filtered and evaporated under reduced 
pressure to afford 50 (57.13 g; 100 %) as a yellow syrup. R= 0.43 (1:1 ethyl 
acetate/hexane). 'H-NMR (250 MHz, CDCI 3) ó (ppm): 6,67 (IH, d, 112=  3.9 Hz, HI); 5.50 
(1H, dd,J34= 3.3 Hz, J4 1.1 Hz, H4); 5.39 (1 H, dd,J23= 10.6 Hz, J3-4=  3.3 Hz, H3); 5.03 
(IH, dd, J23= 10.6 Hz, J.2 3.9 Hz, H2); 4.47 (1H, ddd, J5b=  6.8 Hz, J56a=  6.3 Hz, J 5 = 1.1 
Hz, Fl5) 4.18 (1 H, dd, J6a-6' 11.42, JS-ôa=  6.3 Hz, H6 a); 4.08 (1H, dd, J= 11.42, 15-6b= 
6.8 Hz, H6b);  2.13, 2.09, 2.05 and 1.99 (12H, 4 x s, CH 3 CO). ' 3C-NMR (63 MHz, CDCI 3 ) ô 
(ppm): 170.3, 170.0, 169.9, 169.7 (CO); 88.0, 71.0, 67.7, 66.9 (CH); 60.8 (CH'); 20.6 (CH 3). 
FAB-MS calculated for C 14H 19BrO9 [MH] 410.0212 (based on 7913r) and 412.0212 (based 
on "'Br), found 409.01342 and 411.01150. 
3, 4, 6-Tri-O-acetyl-D-galactal, 1511 
	





A suspension of zinc dust (64.0 g, 0.97 mol) in water (2 10 nit) was stirred mechanically at 0 
°C. Acetic acid (210 ml-) was added to the stirring mixture. A solution of the crude 
galactosyl bromide 50 (48.6 g, 0.12 mol) in anhydrous ether (120 ml-) was added dropwise 
to the stirring reaction at 0 °C. After the addition was complete, the reaction was allowed to 
warm to room temperature overnight. After 13 h, the reaction mixture was filtered with 
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suction. The filtrate was evaporated under reduced pressure. The residue was dissolved in 
ethyl acetate (400 mL) and the organic phase was washed with water (3 x 100 ML) and 
saturated aqueous NaHCO 3 (3 x 100 mL). The organic phase was dried with MgSO 4 , 
filtered and evaporated under reduced pressure to afford 51 (30.1 g; 94 %) as a brown oil. 
R1= 0.25 (1:1 ethyl acetate/petroleum ether 40-60). 'H-NMR (250 MHz, CDC1 3 ) 6(Ppm): 
6.44 (IH, dd, J12= 6.3 Hz, J, 3= 1.8 Hz, HI); 5.62-5.60 (1H, in, J34= 4.6 Hz, J3= 1.8 Hz, J2 
= 1.3 Hz, H3); 5.39 (1H, dd,J3 = 4.6 Hz, J4 -5=  1.6 Hz, 1-14); 4.80-4.78(1H, m, J, 2= 6.3 Hz, 
J23= 1.3 Hz, H2); 4.30-4.04 (3H, m, H5, F16 a , E-i6b); 2.19, 2.15 and 2.09 (9H, 3 x s, CH3 C0). 
13C-NMR (63 MHz, CDC1 3 ) 6(ppm): 170.5, 170.2, 170.1 (CO); 145.4, 98.8, 72.7, 64.2, 64.1 
(CH); 61.9 (CH,) 20.7 (CH 3). FAB-MS calculated for C 12 H 1607 [MH] 273.0896, found 
273.09743. 
3, 4, 6-Tri-O-acetyl-2-azido-2-deoxy-D-galactapyranosyl nitrate,' 04.160  1521 
AcO 	OAc 	 AcO 	OAc 
AcO 	
CAN, NaN 3 
CH3CN 	
AcO 
N 1 	ONO, 
51 	 52 
The crude glycal 51(36.0 g, 0.13 mol), CAN (219.3 g, 0.40 mol) and NaN 3 (13.0 g, 0.20 
mol) were dissolved in anhydrous acetonitrile (870 ml-) and reacted at -15 °C under nitrogen, 
in the presence of molecular sieves. After 3 h, TLC (6:4 petroleum ether 40-60/ethyl 
acetate) indicated that the reaction was complete. The crude reaction mixture was diluted 
with cold ether (200 mL) and cold water (200 mL), then filtered through Celite and the 
aqueous phase was washed with diethyl ether (3 x 100 mL). The organic phase was dried 
with MgSO4, filtered and evaporated under reduced pressure. The crude product was 
purified by flash chromatography over silica (8:2 hexane/ethyl acetate) to afford a mixture of 
anomers (ratio of anomeric a:8 mixture (7:1)) 52(21.5 g; 44%) as a white resin. R= 0.38 
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(6:4 petroleum ether 40-60/ethyl acetate). 'H-NMR (250 MHz, CDC1 3 ) 6 (ppm) a-anomer: 
6.32 (1H, d, 112: 4.2 Hz, I-li); 5.50-5.46 (1 H, m, H4); 4.35-4.33 (1H, m, H5); 4.23 (IH, dd, 
J23: 11.3 Hz, J34 : 3.2 Hz, 1-13); 4.18-4.03 (31-1, m, H2, H6a, H6b); 2.15,2.05,2.02(91-1,3 x s, 
CH3CO). ,8-anomer: 5.64 (1 H, d, 112: 8.8 Hz, Hi); 5.41 (1 H, m, H4); 5.05 (1 H, d, J, 3 : 10.6 
Hz, 134: 3.26, H3); 3.85 (1 H, dd, J23 : 10.6 Hz, J12 : 8.8, H2); 2.18, 2.10, 2.03 (9H, 3 x s, 
CH 3 CO). 13C-NMR (63 MHz, CDC1 3 ) 6 (PPM)  a-anomer: 170.2, 169.7, 169.4 (CO); 96.8, 
69.6, 68.5, 66.6 (CH); 60.9 (CH,); 55.9 (CH) 20.5 (CH 3 ). ,G-anomer: 170.2, 169.7, 169.4 
(CO); 97.9, 71.7, 66.8, 65.7 (CH); 60.9 (CH,); 57.3 (CH); 20.5 (CH 3 ). FAB-MS calculated 
for C 12H 16N40 10 [MH]' 377.0866, found 377.09447. 
3, 4, 6-Tri-O-acetyl-2-azido-2-deoxy-D-galactopyranose,' 37.138 1531 
AcO 	OAc 	 AcO 	
OAc 
i. DIPEA, PhSH, CH 3 CNd, 
AcO 	
ii. TBDMS-CI, imidazoic. DMF 	AcO OTBDMS 
N 3 	ONO, 	
54 52 	
N3 
A solution of the azidonitrate 52 (6.2 g, 16.50 mmol) and thiophenol (5.2 mL, 49.40 mmol) 
in dry acetonitrile (100 mL) was treated with DIPEA (2.9 mL, 16.50 mmol) under nitrogen 
at room temperature. After 5 minutes, TLC (1:1 hexane/ethyl acetate) indicated that the 
reaction was complete. The reaction mixture was concentrated and purified by flash 
chromatography over silica (1:1 hexane/ethyl acetate) to afford the hemiacetal as a yellow 
oil. The azido deoxy galactopyranose intermediate was dissolved in DMF (50.00 ml-) and 
cooled to 0 °C. TBDMS-CI (4.98 g, 33.0 mmol) and imidazole (4.50 g, 66.0 mmo!) were 
added to the reaction mixture, which was allowed to warm at room temperature. After 4 h, 
TLC (7:3 petroleum ether 40-60/ethyl acetate) indicated that the reaction was complete. The 
reaction mixture was diluted with water (40 mL) and the product was extracted with DCM (3 
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x 35 mL). The organic phase was washed with water (30 mL), dried with MgSO 4, filtered 
and evaporated under reduced pressure. The crude product was purified by flash 
chromatography over silica (7:3 petroleum ether 40-60/ethyl acetate) to afford 54 (6.48 g; 88 
as a transparent oil. Rj= 0.42 (7:3 petroleum ether 40-60/ethyl acetate). H-NMR (250 
MHz, CDC1 3 ) ô (ppm): 5.29 (1 H; dd; J3 = 3.4 Hz, J4 1.1 Hz; H4); 4.73 (1 H; dd; J2 = 10.9 
Hz, J3 = 3.4 Hz H3); 4.56 (1H; d; J12= 7.6 Hz; Hi); 4.16-4.02 (2H; m; H6 a, H60; 3.82 (1 H; 
dd; J56a=J5-6b=  7.2 Hz, J45= 1.1 Hz; H5); 3.58 (iH; dd; J23= 10.9 Hz, J12 7.6 Hz; H2); 
2.13, 2.02, 2.01 (9H; 3 x s; 3 x CH 3CO); 0.92 (9H; s; (CH 3 ) 3C-Si); 0.15 (6H; s; CH3 -Si). 
13C-NMR (63 MHz, CDCI 3) 5 (ppm): 170.4, 169.8 (CO); 97.4, 70.7, 70.6, 66.4, 63.0 (CH); 
60.3 (CH 2); 25.5 (CH3); 20.6 (CH 3, C(CH 3) 3); 18.0 (qC, SiC(CH 3 ) 3 ); -4.5 (CH 3, SiCH 3 ). 
FAB-MS calculated for C8H3 1 N30Si [MH]' 446.1880, found 446.19587. 
Tert-butyldimethylsllyl-2-azido-2-deoxy-fl-D-galactopyranoside, 12 ' 
[551 
AcO 	_-0Ac 	 HO 	OH 
0 	 0 





The acetyl protected glycoside 54 (4.8 g, 10.80 mmol) was dissolved in dry methanol (80 
mL) to which 0.5 M NaOMe solution in methanol (560 l.LL, 0.28 mmol) was added. The 
reaction was allowed to stir for 20 h at room temperature, after which time, TLC (7:3 
petroleum ether 40-60/ethyl acetate) indicated that the reaction was complete. The reaction 
mixture was neutralized using ion exchange resin, Amberlyst- 15, filtered and evaporated 
under reduced pressure. The crude product was purified by flash chromatography over silica 
(the column was packed with DCM; the mobile phase was ethyl acetate) to afford 55 (3.3 g; 
96 %) as a white solid. R= 0.35 (7:3 petroleum ether 40-60/ethyl acetate). 'H-NMR (250 
Mhz, CDCI 3 ) ô (ppm): 4.51 (1 H; d; .J 7.2 Hz; Hi); 4.11 (1H; dd;123= 14.5 Hz, J12= 7.2 
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Hz; H2); 3.98 (1H; d; J3 = 2.8 Hz; H4); 3.91-3.83 (1 H; m; H5); 3.47 (1H; dd; J23=  14.5 Hz, 
134 2.8 Hz; H3); 3.44-3.39 (2H; m; H6 a, H6h); 0.92 (9H; s; (CH 3) 3 C-Si); 0.15 (6H; s; CH 3-
Si). 13 C-NMR (63 MHz, CDCI 3) 5 (ppm): 97.4, 74.0, 71.8, 68.5, 66.3 (CH,); 62.5 (CH,); 
25.5 (CH 3, C(CH 3 ) 3 ); 17.8 (qC, SiC(CH 3 ) 3); -4.4 (CH 3 , SiCH3). FAB-MS calculated for 
C 12H25N305Si [MH] 320.1563, found 320.16418. 
Tert-butyldimethylsilyl-2-azido-2-deoxy-4, 6-0-benzylidene-fl-D-










p-Toluene suiphonic acid (0.17 g, 0.91 mmol) was added to a stirred solution of the silyl 
derivative 55 (11.62 g, 36.43 mmol) and benzaldehyde dimethylacetal (15 mL, 102.0 mmol) 
in DMF (300 mL). The reaction mixture was allowed to stir at 50 °C for 4 h. After this time, 
TLC (1:1 petroleum ether 40-60/ethyl acetate) indicated that the reaction was complete. The 
reaction was allowed to cool and triethylamine (880 1iL) was added. The solvent was 
evaporated under reduced pressure. The crude product was purified by flash 
chromatography over silica (1:1 petroleum ether 40-60/ethyl acetate) to afford 56 (13.2 g; 89 
%) as a transparent oil. R= 0.50 (1:1 petroleum ether 40-60/ethyl acetate). 1 H-NMR (250 
MHz, CDCI 3 ) ô (ppm): 7.43-7.20 (5H; m; ArH); 5.37 (lH; s; Ph-CH); 4.37 (1H; d; Ji-:=  7.4 
Hz; Hi); 4.10 (1H; dd;J(b= 12,4 Hz, J5 -6,,= 1.5 Hz; H6a); 3.99-3.95 (1H; rn; H4); 3.89 (1 H; 
dd; .J6a-6h  12.4 Hz, J5-6b=  2.0 Hz; H6 b); 3.33-3.23 (3H; m; H2, H3,H5); 0.74 (91-1; s; (CH 3 ) 3C-
Si); 0.01 (6H; 5; CH3 -Si). 3 C-NMR (63 MHz, CDCI 3 ) 6 (ppm): 137.3 (qC, Ar); 129.2, 
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128.2, 126.3 (Ar-H); 101.3, 97.1, 74.4, 71.0 (CH); 69.0 (C11 2); 66.4, 66.3 (CH); 25.6 (çH3, 
C(CH3 ) 3 ); 17.9 (qC, SiC(CH 3 )3); -4.2 (CH 3 , SiCH 3 ). FAB-MS calculated for C 19H29N 305 Si 
[MH] 408.1876, found 408.19548. 
2, 3, 4, 6-Tetra-0-acetyl-a-D-0-galactopyranosyl trichloroacetimidate,' 20243 [a- 
231 (via 58) 
AcO 	OAc 
0 
AcO 	 - 
AcO 
OAc 
i. Benzylamine, THF 
ii. CCI 3 CN/DBU, DCM, 0°C 
AcO 	OAc 
AcO 




The peracetylatcd galactose 49 (7.8 g, 20.0 rnmol) was dissolved in anhydrous THF (120 
mL) and benzylamine (2.6 mL. 24.0 mmol) was added under nitrogen. The reaction mixture 
was then stirred at 50 °C for 24 h under nitrogen. After that time TLC (4:1 ethyl 
acetate/petroleum ether 40-60) indicated the presence of both hemi-acetal and a little 
unreacted starting material. Then the reaction mixture was concentrated under reduced 
pressure. The crude product was purified by flash chromatography over silica (4:1 ethyl 
acetate/petroleum ether 40-60) to afford the anomeric deacetylated molecule 58 (6.2 g; 95 
%) as a yellow oil. Rf= 0.46 and 0.30 (4:1 ethyl acetate/petroleum ether 40-60). ESI-MS: 
m/z= 371.3 [MNa]; C14H20010 requires m/ 348.3. A solution of 58 was dissolved in DCM 
(125 mL) and cooled to 0 °C, and trichloroacetonitrile (7 mL, 60 mmol) and DBU (3 mL, 
20.0 mmol) were added. After 5 h stirring at 0 °C under N 2 , the reaction was concentrated to 
afford a solid. The crude product was purified by flash chromatography over silica (I: 
ethyl acetate/petroleum ether 40-60) to afford a-23 (8.5 g; 86 %) as a dark brown oil. R f= 
0.34 (2:1 ethyl acetate/petroleum ether 40-60). 'H-NMR (250 MHz, CDCI 3) ö (ppm): 8.65 
(I H, s, NH); 6.59 (1H, d, .J12= 3.2 Hz, Hi); 5.55 (1 H, dd, J3 .4= 2.9 Hz, J4 . 5= 1.0 liz, H4); 
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5.42 (1H, dd, .J23= 10.8 Hz, J3 = 2.9 Hz, H3); 5.35 (1 H, dd, J23= 10.8 Hz, J12 3.2 Hz, H2); 
4.43 (1H, dt, J 6= 7.2 Hz, J4 	1.0 Hz, H5); 4.16 (1H, dd, J6-6b=  11.2 Hz, J5-6a—  7.2 Hz, 
H6a); 4.07 (1H, dd, J6a-6b=  11.2 Hz, 	6.8 Hz, H6b); 2.29, 2.15, 2.14, 2.13 (12H, s, 
CH3CO), 13C-NMR (63 MHz, CDC13 ) ö (PPM):  170.7, 170.5, 170.4, 161.3 (qC)); 93.9, 69.4, 
67.9, 67.7, 67.3 (CH); 61.6 (CH 2); 21.0 (CH3 ). ESI-MS: ,n/z= 515.7 [MNa]; C 16 H 20NO 10C1 3 
requires m/z (35.5C 1) 492.0. 
2, 3, 4, 6-Tetra-0-acetyl-D-galactopyranosyl-(fl-1, 3)-terf-butyldimethylsilyl-2-










The acceptor 56 (3.0 g, 7.30 mmol) and the trichioroacetimidate derivative 23 (7.25 g, 14,7 
mmol) were dissolved in dry DCM (90 mL) containing molecular sieves 4A, and were 
stirred at room temperature for 1 h under nitrogen. The mixture was then cooled to -18 °C 
and a solution of TMSOTf(162 iL, 0.90 mmol) in DCM (12 mL) was added. After 1 h, the 
reaction mixture was allowed to warm to room temperature. After 1 h, TLC (1:1 petroleum 
ether 40-60/ethyl acetate) indicated that the reaction was complete. The reaction mixture 
was diluted with DCM (100 rnL) and neutralized with solid NaHCO 3 , then filtered, and the 
solvent was removed under reduced pressure. The crude product was purified by flash 
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chromatography over silica (1:1 petroleum ether 40-60/ethyl acetate) to afford 62 (4.29 g; 80 
as an orange oil. R t= 0.27 (1:1 petroleum ether 40-60/ethyl acetate). H-NMR (250 
MHz, CDCI 3 ) (5 (ppm): 7.53-7.35 (5H; m; ArH); 5.53 (1 H; s; Ph-CH); 5.38 (1 H; dd; .J34= 3.5 
Hz, 145= 1.1 Hz; H4); 5.24 (1H; dd; J2.3  10.4 Hz, .11.2= 8.0 Hz; H2); 5.01 (1H; dd; J23= 10.4 
Hz, J3 .4 3.5 Hz; H3); 4.79 (1H; d; Jj.2  8.0 Hz; Hi); 4.53 (1H; d; J 12 7.6 Hz; Hi'); 4.16-
4.12 (6H; m; H5, H6a, H6b, H4', H6' a, H6'b); 3.88(111; dt;J56.= 6.5 Hz, J4--5- 1.0 Hz; H5'); 
3.71 (1H; dd; J2. y= 10.7 Hz, J12.= 7.6 Hz; 1-12'); 3.42 (1 H; dd; J23= 10.7 Hz, J3.4= 3.4 Hz; 
H3'); 1.99, 1.90, 1.87 and 1.81 (12H, s, CH 3CO); 0.93 (9H; s; (CH 3 ) 3 C-Si); 0.15 (6H; s; CH 3 -
Si). ' 3C-NMR (63 MHz, CDCI 3 ) (5 (PPM): 170.2 (GO);  137.3 (qC, Ar); 128.8, 128,0, 126.1 
(Ar-H); 102.2, 100.6, 97.4, 78.2, 74.9, 70.8, 70.6, 66.8, 66.5 (CH); 61.2 (CI-I-); 60.3 (CH); 
25.5 (CH 3, C(CH3)3); 20.6 (CH 3 ); 17.9 (qC, S1C(CH 3 ) 3 ); 14.1 (CH 3 ). ESI-MS: m/z= 760.8 
[MNa]; C 33 H47N 30 14Si requires m/z 737,2. 
2, 3, 4, 6-Tetra-0-.acetyl-D-galactopyranosyl-(fl-1, 3)-2-azido-4,6-0-benzy1idene-
2-azido-2-deoxy-D-galactopyranose, 245 1631 
 
Ph 
TBAF in THF 
p. 
AcOH 
To a mixture of the protected disaccharide 62(1.59 g, 2.16 mmol) and acetic acid (1.2 mL, 
21.60 mmol) in anhydrous THF (65 inL) was added TBAF (1M in THF) (8.6 mL, 8.63 
mmol). The mixture was stirred at room temperature. After 15 h, TLC (ethyl acetate) 
indicated that the reaction was complete. The solvent was removed under reduced pressure. 
The crude was diluted with ethyl acetate (100 mL) and washed with water (100 mL) and 
brine (100 mL); the organic phase was dried with MgSO 4, filtered and the solvent was 
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removed under vacuum. The crude product was purified by flash chromatography over 
silica (the column was packed with 6:4 ethyl acetate/petroleum ether 40-60; the mobile phase 
was ethyl acetate) to afford a white solid 63 (1.03 g; 76 %). R1= 0.15 and 0.07 (6:4 ethyl 
acetate/petroleum ether 40-60). H-NMR (250 MHz, CDCI 3), anonieric a:fl mixture. ESI-
MS: m/z — 641.1 [MNH 4]; rn/z= 646,6 [MNa] ; C27 1-1 33N30 14 requires m/z= 623.2. 
2, 3, 4, 6-Tetra-0-acetyl-D-galactopyranosyl-(8-1, 3)-1, 4, 6-tri-O-acetyl-2-azido-





63 	OAc 	 N1 	OH 
AcO 	OAc 	A'O 	OAc 
' 	
r 
66 	OAc 	 N3 	OAc 
The disaccharide 63 (1.54 g, 2.47 mmol), was dissolved in 80 % acetic acid aqueous solution 
(250 rnL) and the solution was heated at 80 °C for 2 hours. Then the reaction was 
concentrated, and the resulting product was dissolved in a solution of pyridine/acetic 
anhydride (2:1) (250 mL). After stirring for 16 h the reaction was concentrated to afford a 
brown oil (2.3 g). The crude product was purified by flash chromatography over silica (the 
column was packed with 3:1 petroleum ether 40-60/ethyl acetate; the mobile phase was 
gradually changed to 1:3 petroleum ether 40-60/ethyl acetate) to afford the purified - 
product fl-66 (R 1= 0.50) and cc-product a-66 (R= 0.42), (ratio of anomeric a:fl mixture (7:3), 
(total 1.6 g; 100 %), (3:1 ethyl acetate/petroleum ether 40-60). 1 H-NMR (250 MHz, CDCI 1 ) 
ö (ppm): ,8-anomer: 5.40 (lH, d, .Jp=  8.3 Hz, Hl'); 5.34 (IH, d, Jy. 3.3 Hz, H4'); 5.30 
(lH, d, J3.= 2.2 Hz, H4); 5.11 (IH, dd, J23= 10.5 Hz, J1 . 2= 7.7 Hz, H2); 4.96 (IH, dd, J2.3= 
10.5 Hz, J3 = 2.2 Hz, 1-13); 4.65 (1 H, d, 112  7.7 Hz, Hl); 4.20-3.83 (6H, m, H5, H5', H68 , 
H6b, H6a ', H6b); 3.66 (1H, dd, J23  10.5 Hz, J1 . 2 8.3 Hz, J2 0.9 Hz, H2'); 3.58 (11-1, dd, 
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.12-3= 10.3 Hz,  J3 '-4,= 3.4 Hz, H3'); 2.14, 2.02, 1.99, 1.97, 1.95, 1.93, 1.92 (211-1, s, CH 3CO). 
13CNMR (63 MHz. CDC13) (5(ppm): ,6-anomer: 169.8, 169.6, 169.5, 169.3, 168.8, 168.6, 
168.0 (CO); 100.7, 92.0, 76.9, 71.7, 70.1, 69.9, 68.0, 67.1, 66.0, 61.2 (CH); 60.3 (CH 2); 20.2, 
19.9, 19.8 (CH 3). 'H-NMR (250 MHz, CDCI 3 ) 6(ppm): a-anomer: 6.29 (1 H, d, .11-2 = 3.7 
Hz, Hi'); 5.49 (1 H, d, &-4- 2.5 Hz, H4'); 5.35 (1 H, dd,J3=r  3.4 Hz, J4-5= 1.1 Hz, H4); 5.17 
(1H, dd, J23= 10.5 Hz, .11.2=7.7 Hz, H2); 4.99 (1H, dd, J23=  10.5 Hz, J3= 3.4 Hz, H3); 4.72 
(1H, d, J 2= 7.8 Hz, Hi); 4.23-3.84 (6H; m; H5, H5', H68, H6b, H6'a, H6'b)Z 3.98 (1H, dd, J2-
= 10.6 Hz, .J= 2.5 Hz, 1-13'); 3.87 (1H, dd, .12.3= 10.6 Hz, Jl2=  3.7 Hz, H2'); 2.16, 2.14, 
2.13, 2.05, 2.02, 1.99, 1.97, (211-1, s, CH3CO). 13C-NMR (63 MHz, CDCI 3 ) 6 (PPM):  a-
anomer: 170.4, 170.3, 170.1, 170.0, 169.4, 169.3, 168.5 (CO); 10 1.2, 90.5, 74.7, 70.6, 69.2, 
68.6, 66.5 (CH); 62.0, 60.8 (CH 2); 58.8 (CH); 20.8, 20.5 (CH 3). ESI-MS: ,n/z=679.2 
[MNH4]; m/z= 684.2 [MNa]; C 26H35N30 17 requires m/z= 661.2. 
2, 3, 4, 6-Tetra-0-acetyl-D-galactopyranosyl-(fl- 1, 3)-4, 6-di-O-acetyl-2-azido-1 - 
bromo-1, 2-dideoxy-a-D-galactopyranose, 246 1691 
A_ : 
o AcO 	0 0 ~4 OAc 	N 	Oc 	 OAc 66 	 69 	 N3 B r  
A solution of the acetylated disaccharide 66 (1.73 g, 2.62 mmol) in anhydrous DCM (35 mL) 
was stirred for 12 h in the presence of TiBr 4 (2.39 g, 6.50 mmol). Then the mixture was 
diluted with DCM (150 rnL), and washed with ice water (2 x 200 ML), then was dried with 
MgSO4 , filtered and the solvent was removed under vacuum to afford a brown syrup product 
69 (1.62 g; 91 %). R 1 0.51 (1:2 petroleum ether 40-60/ethyl acetate). 'H-NMR (250 MHz, 
CDCI 3 ) 6 (ppm): 6.46 (1H, d, JI2z 3.8 Hz, HI '); 5.52 (1 H, dd, .Jv  3.1 Hz, J4' 0.91 Hz, 
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H4'); 5.35 (1H, dd,J3 = 3.3 HZ, J4-5= 1.0 Hz, H4); 5.18 (IFI, dd,.J2 . 3= 10.5 Hz, J1 .2= 7.7 Hz, 
H2); 4.97 (1 H, dd, J23 10.5 Hz, J34= 3.4 Hz, H3); 4.72 (1H, d, .J1 .2= 7.8 Hz, HI); 4.38-4.05 
(6H; m; H5, H5', H6 a, H6b, H6' a, H6'b); 4.00 (1 H, dd,i2 .3•= 10.2 Hz, J3'-4,==  3.1 Hz, H3'); 3.89 
(1H, dd, .J23= 10.2 Hz, J1 '.= 3.8 Hz, H2'); 2.14, 2.12, 2.04, 2.03, 1.96 (18H, s, CH 3CO). 
13C-NMR (63 MHz, CDCI3 ) d (PPM): 170.4, 170.4, 170.2, 170.0, 169.5, 169.3 (CO); 101.2, 
90.0, 75.7, 72.4, 71.0, 70.7, 68.8, 68.3, 66.8, 61,7 (CH); 61.1, 60.8 (CH 2); 20.6, 20.5 (CH 3). 
ESI-MS: m/z 700.4 [MNH4]; m/z= 705.4 [MNa]; C24H32BrN30 15 requires m/z= 682.4. 
)VU_(FI uorene 9_ny1 methoxycarbony1)O_12, 3, 4, 6-tetra-0-acetyl-D-
galactopyranosyl-(J3-1, 3)-4, 6-di-O-acetyl-2-azido-2-deoxy-a-D-
galactopyranosylj-L-threonine benzylester, 1771 
Ac 	OAc 	AcO OAc 
	
69 
A.O 	 N3 Br 
FIO..CEL 3 
_-L. Bn 
46 FrnocHN 	T 
0 
AgCI04 . 2,4.6-collidine 
MS, DCM 
A solution of the protected amino acid 46 (1.53 g, 3.55 mmol) in anhydrous DCM (18 mL) 
containing 4A molecular sieves, 2,4,6-collidine (1.2 mL, 8.88 mmol) and AgCI0 4 (1.84 g, 
8.88 mmol), was stired under argon at room temperature. The disaccharide 69 (2.42 g, 3.55 
mmol) was dissolved in anhydrous DCM (18 mL) under argon, and added dropwise to the 
stirring mixture. The reaction was allowed to stir overnight, after which time TLC (6:4 
hexane/ethylacetate) indicated that the reaction was complete. The mixture was filtered 
through Celite and the solvent was removed under vacuum. The crude product was purified 
by flash chromatography over silica (the column was packed with 2:1 hexane/ethyl acetate; 
the mobile phase increased polarity through the chromatography) to afford the purified 
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product 77 (1.66 g; 45 %), Rf= 0.6 (3:1 ethyl acetate/hexane); and 2,3,4,6-tetra-O-acetyl-D-
galactopyranosyl-(fl- 1 ,3)-4,6-di-O-acetyl-2-azido-2-deoxy-D-galactopyranose 78 (0,48 g; 22 
%), R= 0.15 (3:1 ethyl acetate/hexane). 'H-NMR (250 MHz, CDC1 3) ö (ppm) 77: 7.75 (2H, 
d, JA-B=  7.5 Hz, Ar-Hp,fl(C ); 7.58 (2H, d, JC-D  7.5 Hz, Ar-Hp,,,0 ); 7.41-7.27 (9H, m, Ar-H,,,0 
and Ar-1-lh[); 5.65 (1H, d, .1= 9.5 Hz, NH); 5.45 (11-I, d, 2.1 Hz, 1-14); 5.35 (1H, dd, 
.J34= 3.4 Hz, J= 1.0 Hz, H4); 5.21 (21-I, s, -0O2-Cth-Ph);  5.16 (1H, dd, 13.3= 10.4 Hz, J12= 
7.9 Hz, H2); 5.00 (1H, dd, J23= 10.4 Hz, J34= 3.4 Hz, 1-13); 4.83 (1H, d, Ji,=  3.8 Hz, HI'); 
4.68 (1H, d, 1L-2=  7.9 Hz, Hi); 4.51-3.88 (12 H, m, H3', H5, H5', H6a, H6h, H6a', H6b, 3Hpmoc , 
2HTh1); 3.51 (1H, dd, .J3'3= 10.7 Hz, .J12=  3.8 Hz, H2'); 2.14, 2.12, 2.04, 2.03, 1.97 (18 H, s, 
CH3CO); 1.30 (3H, d, 1= 6.2 Hz, CH 3). ' 3C-NMR (63 MHz, CDCI 3) ó (ppm) 77: 170.3, 
170.0, 169.5 (CO); 157.1 (CONH); 156.7 (COO); 143.8, 143.6, 141.2 (Ar); 128.7, 128.5, 
127.7, 125.0, 121.3, 120.0, 119.9 (Ar-H); 10 1.4, 99.2, 74.8, 70.7, 69.3, 68.7, 67.8 (CH); 67.3 
(CH,); 66.7 (CH); 62.8, 60.9 (CH 2); 59.6 (CH); 58.7, 47.0 (CH); 23.9 (CH 2 ); 20.6, 20.5, 18.4 
(CH3). ESI-MS 77: m/z 1050.0 [MNH4], m/z 1055.0 [MNa]; C50H56N4020 requires m/z= 
1033.0. 
2, 3, 4, 6-Tetra-0-acetyl-D-galactopyranosyl-(fl-1, 3)-1, 4, 6-tri-O-acetyl-2-azido-
2deoxy D_ga 1actopyranose,24ô 1661 
M 	 MOO 
AL,OPyr (1:2) 
A10- 	Lo—' 	90% 	 Ac( 	 OLO-~L 0 
78 	OM 	 N3  OH 66 OAc 	 N3 OM 
The disaccharide 78 (0.68 g, 1.10 mmol) was dissolved in pyridine (10 niL) and the mixture 
was cooled down to 0 °C. Acetic anhydride (5 mL) was added dropwise. After the addition 
was complete the addition, the mixture was allowed to warm to room temperature and stirred 
continuously overnight. After stirring for 16 h the reaction was concentrated under vacuum. 
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The crude was purified by flash chromatography over silica (packed with 3:1 petroleum 
ether 40-60/ethyl acetate; the mobile phase was gradually changed to 1:3 petroleum ether 40-
60/ethyl acetate) to afford the epimeric mixture (ratio of anomeric a:fl mixture (7:3) 66 (0.63 
g; 90%). 'H-NMR (250 MHz, CDC1 3)ó(ppm): fl-anomer: 5.40(IH, d, J12 = 8.3 Hz, HI'); 
5.34 (1H, d, J3'-4.=  3.3 Hz, H4'); 5.30 (1 H, d, J3-4=  2.2 Hz, 114); 5.11 (1H, dd,J23= 10.5 Hz, 
J1 . 2= 7.7 Hz, H2); 4.96 (1H, dd, J23= 10.5 Hz, J3= 2.2 Hz, H3); 4.65 (1 H, d, J 2= 7.7 Hz, 
HI); 4.20-3.83 (6H, m, i-IS, H5', H6a, H6b, F16a ', H60; 3.66 (111, dd, .J2 .3 .= 10.5 Hz, J7 8.3 
Hz, J2 .4'= 0.9 Hz, 112'); 3.58 (IH, dd, J23 = 10.3 Hz, J3 .4 = 3.4 Hz, H3'); 2.14, 2.02, 1.99, 
1.97, 1.95, 1.93, 1.92 (21H, s, CH3CO). 13  C-NMR (63 MHz, CDCI 3 ) (ppm): ,8-anomer: 
169.8, 169.6, 169.5, 169.3, 168.8, 168.6, 168.0 (CO); 100.7, 92.0, 76.9, 71.7, 70.1, 69.9, 
68.0, 67.1, 66.0, 61.2 (CH) 60.3 (Cl-I 2); 20.2, 19.9, 19.8 (CH 3 ). H-NMR (250 MHz, 
CDCI 1 ) 5 (ppm): a-anomer: 6.29 (1 H, d, J= 3.7 Hz, HI'); 5.49 (1 H, d, J34 = 2.5 Hz, 1-14'); 
5.35 (1 H, dd,134= 3.4 Hz, J4-5=  1.1 Hz, H4); 5.17 (1 H, dd,J, 3= 10.5 Hz, J 1 . 2= 7.7 Hz, H2); 
4.99 (1H, dd, j23=  10.5 Hz, .13 .4= 3.4 Hz, H3); 4.72 (IH, d, .11.2 = 7.8 Hz, Hi); 4.23-3.84 (6H; 
m; H5, H5', H6 ;j , H6h, H6' a , H6b); 3.98 (1 H, dd, J 3 = 10.6 Hz, J3 = 2.5 Hz, H3'); 3.87 (111, 
dd, J2'3'=  10.6 Hz, Jj .2. 3.7 Hz, H2'); 2.16, 2.14, 2.13, 2.05, 2.02, 1.99, 1.97, (211-1, s, 
CH 3 CO). 13C-NMR (63 MHz, CDCI 3 ) 5 (ppm): a-anomer: 170.4, 170.3, 170.1, 170.0, 
169.4, 169.3, 168.5 (CO); 10 1.2, 90.5, 74.7, 70.6, 69.2, 68.6, 66.5 (!CH); 62.0, 60.8 (CH'); 
58.8 (CH); 20.8, 20.5 (CH 3 ). ESI-MS: ,n/z=679.2 [MNH 4]; m/z= 684.2 [MNa]; 
C 26H35N30 17 requires ,n/z= 661.2. 
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IV-(F1uorene-9-nylmethoxycarbonyJ)-O-I2, 3, 4, 6-tetra-O-acetyl-D-
galactopyranosyl-(fl-1,3)-4,6-di-O-acetyl-2-acetamido-2-deoxy-a-D-
gaIactopyranosylI-L-threonine benzylester, 1811 
Zn. CuSO4 
THF/AeO!AcOH (3:2:) 
The glycoamino acid 77(0.22 g, 0.23 mmol) was dissolved in THF/Ac 20/AcOH (3:2:1) (2.6 
mL). Zinc dust (0.2 g) was added followed by asaturated aqueous solution of CuSO 4 (38 
l.LL). After 3 h, the reaction mixture was filtered through Celite and the Celite pad was 
washed with THE The filtrate was reduced under vacuum to afford the crude product as a 
yellow oil. The crude product was purified by flash chromatography over silica (3:1 ethyl 
acetate/petroleum ether 40-60) to afford the purified product 81(0.2 g; 95 %) as an ambar 
oil, R= 0.26 (3:1 ethyl acetate/petroleum ether 40-60). 'H-NMR (250 MHz, CDCI 3) ö 
(ppm): 7.71 (2H, d, JAB=  7.1 Hz, Ar-Hp,0 ); 7.54 (2H, d, Jr=  7.1 Hz, Ar-Hp,?,,); 7.29-7,25 
(914, m, Ar-H r),, and Ar-H) 1 l); 5.95 (1H, d, J= 9.2 Hz, AcNH); 5.80 (IH, d, J= 9.3 Hz, 
NH); 5.32-5.11 (4H, m, H4, H4', -0O2-Cth-Ph);  5.07 (1 H, dd, .123  10.4 Hz, J12 7.9 Hz, 
H2); 4.91 (1 H, dd, J23 10.4 Hz, .J34 3.2 Hz, H3); 4.79 (1H, d, J12.= 3.6 Hz, Hl'); 4.55 
(1 H, d, J1 .2= 7.8 Hz, HI); 4.47 (2H, d, J= 6.7 Hz, CHCthO);  4.39 (1 U, dd, .J33'= 11.0 Hz, Ji. 
3.6 Hz, H2); 4.30 (1H, t, J= 6.7 Hz, CI-ICH 2O); 4.24-3.83 (8 H, m, US, H5', H6 a, H6b, 
H6a ', H6b, 2Hiiir); 3.79 (1 H, dd, J2 ..3 .= 11.0 Hz, .J34•= 2.7 Hz, 113'); 2.35, 2.32, 2.27, 2.24, 
2.23, 2.19 (21 H, s, CH3 CO); 1.45 (3H, d, J= 6.2 Hz, CH,). 13 C-NMR (63 MHz, CDCI 3 ) ô 
(ppm): 170.5, 170.3, 170.2, 170.0, 169.9, 169.8, 169.4 (CO); 156.3 (CONH); 143.5, 143.4, 
141.2 (Ar); 134.2 (COO); 128.8, 128.7, 128.4, 127.7, 127.0, 124.7, 120.0 (Ar-H); 100.4, 
99.8, 77.1, 76.7, 72.9, 70.5, 68.5, 68.4, 67.7 (CH); 67.6 (CH 2 ); 66.5 (CH); 62.8, 60.9 (CH 2 ); 
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58.4, 48.4, 47.0 (CH); 23.2 (CH 2); 20.5, 18.2 (çH 3 ). ESI-MS: ,n/z= 1066.4 [MNH4], m/z-
107 1.4 [MNa]; C 52H60N2021  requires mlz= 1048.4 
1V'(F1 uorene-9-nylmethoxycarbonyl)-O-[2, 3, 4, 6-tetra-0-acetyl-D-
galactopyranosyl-(J1-1,3)-4, 6-diacetyl-2-acetamido-2-deoxy-a-D-
galactopyran osylj-L-threonine, 113 1821 
I12, 10% Pd/C 
McOH 
The glycoamino acid 81 (1.8 g, 1.72 mmol) and 10 % PdIC (0.1 g) were taken up in 
anhydrous methanol (50 mL). The reaction mixture was then catalytically hydrogenated 
under a hydrogen atmosphere for 3 11 at room temperature. The catalyst was then removed 
by filtration through Celite and the Celite pad was washed with methanol. The filtrate was 
evaporated under vacuum to afford 82 (1.57 g; 95 %) as a white solid. H-NMR (250 MHz, 
CDCI 3 , TFA 1 %) ó (ppm): 7.75 (2H, d, JA-13 7.4 Hz, Ar-HF); 7.48 (2H, dd, "CD  7.14 
Hz, JD-B=  4.4 Hz, Ar-H[,, frC); 7.41 (2H, dd, JCD 7.5 Hz, Ar-Hp,,,); 7.32 (2H, dd, JAB=  7.4 
Hz, Ar-HF,,.); 7.15 (1H, d, J= 10.2, AcNH); 6.80 (lH, d, J= 9,7 Hz, NH); 5.46 (11-1, d, .J1 . 2 .= 
2.6 Hz, Hl'); 5.40 (1H, d, J34= 3.0 Hz, H4); 5.12 (1 H, d, J3'.4 3.0 Hz, 114'); 5.09 (t H, dd, 
J2 . 1= 10.5 Hz, J1 .2= 7.9 Hz, H2); 4.95 (1 H, dd, J23= 10.5 Hz, J34 3.0 Hz, H3); 4.68 (2H, m, 
CHCO); 4.56 (IH, d, 112=  7.6 Hz, HI); 4.36-4.01 (8H, m, 2 x CH-Thr, H3', H6, H6 a ', 
H6b, H6b' and CHCH 2O); 3.90 (1 H, dd, H2'); 3.86 (1 H, dd, H5'), 3.82 (1 H, dd, H5); 2.17, 
2.16, 2.10, 2.08, 2.05 and 2.00 (21H, s, CH3CO); 1.09 (3H, d, J= 6.3 Hz, Cl-I 1 ). ' 3C-NMR 
(63 MHz, CDCI 1 , I % TFA) 6 (ppm): 171.3, 170.3, 170.0, 169.5, 169.0 (CO); 157.1 (CO 2H); 
143.3, 143.2, 140.6 (Ar); 126.9. 126.3, 124.2, 124.1, 119.1 (Ar-H); 100.4, 98.9, 75.3, 73. 1, 
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70.1, 69.6, 69.1, 68.1, 66.9, 66.5 (CH); 65.7, 62.4, 60.3 (CH 2); 57.8, 48.0, 46.5 (CH); 21.3, 
18.9, 18.8, 18.6, 17.2 (CH 3). ESI-MS: m/z= 976.9 [MN1714]F, m/z — 981.9 [MNa]; 
C45F154N2021 requires m/ 958.9. 
Synthesis of compound 83 
	
HO 	OH 	HO 	
OH' 83 
CONH 	 COH 
OH 
0 	




Solid phase glycopeptide synthesis. 
Solid-phase peptide synthesis was carried out manually using a plastic syringe fitted with a 
Teflon filter and connected to a vacuum waste chamber via a Teflon valve. Synthesis of the 
glycopeptide (CSSQLET*S)  was carried out on pre-loaded Finoc-Ser(tBu)-NovaSyn TGT 
resin (loading = 0.22 mmol/g). The scale of the synthesis of the glycopeptide was 0.10 
mmol. The Fmoc group was removed by treatment with 20 % piperidine in DMF (5 and 15 
mm) between each coupling and dcprotcction step. Coupling reactions with Fmoc amino 
acids were achieved using 1.0 mmol (10 equiv.) of each of HBTU/HOBt and DIPEA in 
DMF, for 3 h. The coupling reaction with Fmoc-(Core-1)-Thr, 82, was achieved using 0.15 
mmol (1.5 equiv.) of the glyco-building block and DCC/HOBt for 24 h in DMF. The 
reaction progress was monitored using LCMS and the Kaiser ninhydrin test.  247  Between each 
coupling and deprotection step, the resin was washed with DCM and DMF (5 min each). 
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The resin was washed with DCM and DMF five times (5 min each wash). The glycopeptide 
was cleaved from the resin by incubation with the cleavage cocktail (95 % TFA, 2.5 % water 
and 2.5 % EDT) for 3 h. The resin was subsequently washed twice with the cleavage 
cocktail (10 min each wash). The glycopeptide was precipitated with cold diethyl ether and 
centrifuged for 10 mm. The precipitate was dried and redissolved in a solution 1:1 
water/acetonitrile and lyophilised to afford a fluffy white solid. 
Deprotect ion of the acetyl groups. 89 
The fluffy white solid was dissolved in a I mL phosphate buffer (0.1M, pH8 solution); with 
5 % hydrazine hydrate and 10 % MESNA. The solution was stirred gently for 16 h at room 
temperature. The crude product was purified by reverse phase semi preparative HPLC 
(water-acetonitrile 5 %-95 % in 40 minutes, 0.1 % TFA). The fractions were freeze-dried to 
afford 83 (28 mg; 29 %) as a fluffy white solid. 
Analytical data for compound 83: C51 H 85N 11 029S. MW: 1347.52. Found: [M] - 1348.00 
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2-Phthalimido-2-deoxy-1, 3, 4, 6-tetra-0-acetyl-fl-D.-glucopyranose, 92 [851 
OH 	
i) NaOMe/MeOH 	 OAc 
ii) Phthalic anhydride/EI 3 N 
iii) Ac,O/pyridine 	 AcO 
01-I 
84 	NH2'HC! 	 85 	NJ-IPhth 
To a stirred solution of sodium methoxide (3.0 g, 46.30 mmol) in anhydrous methanol (75 
mL) was added glucosamine hydrochloride 84 (10.0 g, 46.30 mmol). The reaction mixture 
was stirred for 30 ruin at room temperature and then filtered with suction. Phthalic 
anhydride (3.5 g, 23.0 nimol) was then added to the filtrate and stirring was continued for a 
further 20 mm. A further portion of phthalic anhydride (3.5 g, 23.00 mrnol) was then added 
followed by triethylamine (7.6 mL, 55.60 mmol). The reaction mixture was stirred at room 
temperature for 10 min and then cooled for 1 h in an ice bath and then filtered with suction. 
The precipitate was washed with cold methanol (2 x 20 mL) and dried under high vacuum. 
The dry white solid was then suspended in acetic anhydride (45 mL) and cooled down to 0 
°C, and then pyridine (22.7 mL) was added carefully with stirring. The reaction was the 
stirred at room temperature for 16 h. After this time, the reaction mixture was poured into 
ice/water (200 mL) and extracted with chloroform (3 x 200 mL). The combined organic 
extracts were washed with 5 % aqueous HCI (I x 120 mL), saturated aqueous Nal-1CO 3 (120 
mL), water (120 mL) and brine (100 mL). The organic phase was dried with MgSO 4 , 
filtered and concentrated under reduced pressure to afford an orange oil. The crude product 
was purified by flash chromatography over silica (1:1 hexane/ethyl acetate) to afford the 
pure product 85 (6.6 g; 30 %) as a white foam. R f= 0.56 (4:1 ethyl acetate/petroleum ether 
40-60). 'H-NMR (250 MHz, CDC1 3 ): 5(ppm): 7.74-7.62 (4H, m, ArH); 6.35 (1 H, d, J 1 . 2= 
8.9 Hz, HI); 5.73 (1 H, dd,J2 . 1=J3 .4= 9.8 Hz, H3); 5.05 (1 H, dd,J3 .4=J45= 9,8 Hz, H4); 4.34 
(1H, dd, J6,-6b=  11.6 Hz, J5.6a  3.3 Hz, H6a); 4.30 (1 H, dd, J12= 8.9 Hz, J2 = 9.8 Hz, 112); 
3.98 (1 H, dd, 'a6b  11.6 Hz, .J5.6b=  4.2 Hz, i-16b);  3.91 (1H, ddd, J45= 9.8 Hz, Ja=  3.3 Hz, 
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J5-6b 4.2 Hz, H5); 1.92, 1.88, 1.81 and 1.70 (12H, 4 x s, CH 3CO). 13 C-NMR (63 MHz, 
CDCI 3) 15 (PPM): 169.8, 169.3, 168.8, 167.9, 166.7 (CO), 134.0 (Ar-H); 130.6 (Ar); 123.2 
(Ar-H); 89.1, 72.0, 69.8, 67.7 (CH); 60.9 (H 2); 52.9 (CH); 20.0 (CH 3). FAB-MS calculated 
for C22 H23 N0 11 : 476.9, found 494.9 {MNH4}. 
3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-J3-D-glucopyranosyl azide,' 83 1861 
OAc 	 OAc 
AcO1 	
TMS-N3 , SnCI4 	
U. AcO 
DCM 
85 	NPhth 	 86 	NPhth 
To a suspension of 1, 3, 4, 6-tetra-0-acetyl-2-deoxy-2-phthalirnido- 18-D-glucopyranose 85 
(2.36 g, 4.82 mmol) in DCM (25 mL) were added trimethylsilyl azide (770 tL, 5.78 mmol) 
and tin tetrachloride (280 1iL, 2.41 mmol) and the mixture was stirred for 24 h. After that 
time TLC (3:1 ethyl acetate/petroleum ether 40-60) indicated that the reaction was complete. 
The reaction was diluted with DCM (50 mL) and washed with saturated aqueous NaHCO 3 
(40 mL) and water (40 mL). The organic phase was dried over MgSO 4. filtered and 
concentrated under reduced pressure. The crude product was dissolved in the minimum 
volume of DCM, and precipitation was initiated by the addition of methanol to afford 86 
(1.61 g; 73 %) as a white crystalline solid. R- 0.36 (3:1 ethyl acetate/petroleum ether 40-
60). H-NMR (250 MHz, CDCI 3 ): 8ppm): 7.88-7.84 (2H, q, J4. 5= .16.7= 5.5 Hz, .14.6= J5. 7= 
3.1 Hz, ArH-4,-7); 7.76-7.73 (2H, q, J5-6=5.4  Hz, J46 J57 3.1 Hz, ArH-5,-6); 5.79(1H, dd, 
J2 . 3= 10.6 Hz, J3-4=  9.2 Hz, H3); 5.64 (1 H, d, J12 9.5 Hz, HI); 5.18 (1 H, dd,.J3 . 4=J34= 9.5 
Hz, H4); 4.38-4.16 (3H, m, H-2, H6 a , I-1 6b); 3.97 (1 H, m, H5); 2.12, 2.03 and 1.85 (9H, 3 x s, 
CH 1 CO). 13 C-NMR (63 MHz, CDCI 3 ) 8ppni): 170.6, 170.0 and 169.4 (CO); 134.5 (Ar-H); 
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131.2 (Ar); 123.7 (Ar-H); 85.5, 73.9, 70.3, 68.4 (CH); 61.7 (CH 2); 53.9 (CH); 20.7, 20.5, 
20.3 (CH3). FAB-MS calculated for C 20H20N409 [MNH4] 478.1230, found 478.1348. 





i) NaOMe. McOH 




The glycosyl azide 86 (1.61 g, 3.50 mmol) was dissolved in methanol (24 ML). A 0.5 M 
solution of NaOMc in methanol was added until a pH of 10 was obtained. After the reaction 
was stirred for 16 h, it was neutralized by addition of acetic acid. The mixture was then 
concentrated and azeotroped with toluene before being placed under high vacuum for lh. 
The resulting white solid was dissolved in DCM (12 mL) to which was added DIPEA (1.2 
mL, 7.0 mmol) and DMAP (43 mg, 0.35 mmol). TBDPSCI (I mL, 3.85 mmol) was then 
added, and the reaction was stirred for 16 h. After that time TLC (4:1 ethyl 
acetate/petroleum ether 40-60) indicated that the reaction was complete. The reaction 
mixture was washed with water (2 x 20 ml-) and brine (2 x 20 mL). The organic phase was 
dried with MgSO 4 , filtered and concentrated under reduced pressure. The crude product was 
Purified by flash chromatography over silica (5 % methanol in DCM) to afford 87 (1.87 g; 
93 %) as a transparent oil. Rf= 0.56 (4:1 ethyl acetate/petroleum ether 40-60). 'H-NMR 
(250 MHz, CDC1 3 ): ö(ppm): 7.76-7.61 (91-1, m, ArH); 7.43 (5H, m, ArH); 5.35 (1 H, d, J12= 
9.5 Hz, 1-Il); 4.40 (1H, dd,J34= 10.5 Hz, J2-3=  7.8 Hz, H3); 4.05 (1 H, dd,J1 . 2= 9.5 Hz, J, - 3= 
7.8 Hz, H2); 3.97 (1 H, m, H5); 3.70 (1H, m, H4); 3.65 (2H, m, H6 a, H65); 1,09 (911, s, 
C(CH 3 ) 3 ). 13 C-NMR (63 MHz, CDCI 1 ) 45 (ppm): 168.2 (CO);  135.5 (Ar-H); 134.2 (Ar); 
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132.8 (Ar-H); 131.3 (Ar); 129.8, 127.7, 123.5 (Ar-H); 85.3, 77.2, 72.5, 71.2 (CH); 63.8 
(CH,); 55.8 (CH); 26.7 (CH 3, C(H3 )3); 19.1 (qC, C(CH 3 ) 3). FAB-MS calculated for 
C 30H32N406Si [MH] 573.2091, found 573.2169. 
0-(2, 3, 4, 6-Tctra-0-acetyl-D-galactopyranosyl)-(fi-1, 4)-6-O-tert-
butyldiphenylsilyl-2-deoxy-2-phthalimido- 16-D-glucopyranosyl azide,' 8 ' 1881 
Act) 	OAc 
AcO 
OTL3DPS "0 AcO 	OAc 	






NPhth MS 4 A, -20 °C.rI 	 OAc 	
NPhth 88 
The trichioroacetimidate derivative 23 (4.69 g, 9.50 mmol) and the silylated sugar 87 (2.72 
g, 4.75 mmol) were dissolved in dry DCM (25 mL), containing 4A molecular sieves, and the 
solution was cooled down to -20 °C. A solution of 0.1 M TMS-OTf in dry DCM (4.8 mL, 
0.48 mmol) was added. After 2 h, the reaction was warmed to room temperature. After I h, 
TLC (8:2 toluene/ethyl acetate) indicated that the reaction was finished. The reaction 
mixture was diluted with DCM (50 mL) and neutralized with solid NaHCO 3, then was 
filtered and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography over silica (4:1 toluene/ethyl acetate) to afford 88 (3.93 g; 
92 %) as a white foam. Rr= 0.26 (4:1 toluene/ethyl acetate). H-NMR (250 MHz, CDCI 3 ): S 
(ppm): 7.66-7.35 (1011, m, 2 x C 6H5 ); 7.16-7.06 (4H, m, Pht-H); 5.36 (lH, d, J2=  9.5 Hz, 
HI'); 5.27 (IH,d,J3 .4 J45 3.3 Hz, 1-14); 5.15 (1H, dd,J23 10.4 Hz, J[ -2=  8.1 Hz, H2); 4.90 
([H, dd, J23 10.4 Hz, J3 3.3 Hz, H3); 4.65 (IH, d, 12  8.1 Hz, Hl); 4.42 (1H, dd, .J,.= 
10.4 Hz, J3'' 8.5 Hz, H3'); 4.06 (1 H, dd, J2'3'  10.4 Hz, J1 ' 2. 9.5, H2'); 4.00-3.45 (7H, m, 
H5, H6a, H6b, H4', H5', H6 a', H60, 2.26, 2.04, 1.90, 1.65 (12 H, 4 X S, COCH 3); 1.04 (9H, 5, 
C(CH3 ) 3 ). ' 3C-NMR (63 MHz, CDC1 3 ) 8(ppm): 170.4, 170.0, 169.9, 169.2, 168.1, 167.5 
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(CO); 135.4 (Ar-H); 134.0 (Ar); 132.8 (Ar-I-I); 131.3 (Ar); 129.7, 127.7, 123.4 (Ar-H); 
100.9, 85.2, 80.0, 77.2, 71.9, 71.1, 70.6, 68.6, 66.8 (CH); 63.5, 61.2 (CH 2); 55.8 (CH); 26.6 
(CH3, C(CH3 ) 1 ); 20.3 (COCH 3); 19.1 (qC, C(CH 3) 3). FAB-MS calculated for CH 50N40 15 Si 
[MH] 903.3042, found 903.311. 
2, 3, 4, 6-Tetra-0-acetyl-D-galactopyranosyl-(fl-1, 4)-3, 6-di-O-acetyl-2-









OTBDPS 	 )TBAF AcOH, TEIF 
AcO 
88 	OAc 	 89 	OAc 	
NFIAc 
To a solution of the disaccharide 88 (946 mg, 1.05 mmol) and acetic acid (600 JAL, 10.50 
mrnol) at 0 °C in THF (31.5 ml-) was added a I M solution of TBAF in THF (4.2 mL, 4.20 
mmol). The reaction mixture was stirred for 15 h at room temperature. The mixture was 
subsequently concentrated to a yellow oil. This oil was dissolved in n-BuOH (20 mL), and 
ethylendiamine (5 mL) was added. The reaction was heated to 90 °C and stirred for 16 h. 
The mixture was then concentrated under high vacuum and dissolved in a solution of 2:1 
pyridine/Ac 20 (100 mL) and the reaction was stirred for 8 hours. The reaction was again 
concentrated to afford a yellow oil which was purified by silica gel chromatography (the 
column was packed with I % methanol in DCM; the mobile phase was 3 % methanol in 
DCM) to afford the purified product 89 (1.2 g; 76 %) as a white foam. R f= 0.23 (3 % 
methanol in DCM). 'H-NMR (360 MHz, CDC1 3 ) 5 (opm): 5.96 (lI-I, d, .JNII"=  9.5 Hz, 
NHAc); 5.32 (1 H, dd, 134= 3.3 Hz, H4): 5.10-5.04 (21-1, rn, H2, HI '); 4.96 (1 H, dd, J23=  10.2 
Hz, J= 3.2 Hz, H3); 4.53-4.48 (2H, rn, HI, H3'); 4.12-3.71 (7H, m, H5, H6 a, H6b, H2', H4', 
H63 , H60; 3.68 (1H, m, H5); 2.26, 2.13, 2.10, 2.08, 2.04, 1.20, 1.95 (21 H, 7 x s, COCH 3). 
13C-NMR (63 MHz, CDCI 3 ) 8(ppm): 171.0, 170.4, 170.3, 170.1, 170.0, 169.3 (CO); 101.1, 
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88.3, 75.6, 74.5, 72.6, 70.6, 70,5, 68.9, 66.4 (CH); 61.7, 60.6 (H 2); 52.9 (CH); 23.0, 20.7, 
20.5, 20.4 (H3). FAB-MS calculated for C 26H36N40 16 [MH] 661.2126, found 661.1630. 
2, 3, 4, 6-Tetra-0-acetyl-D-galactopyranosyl-(8-1, 4)-2-acetamido-2-deoxy-3, 6-
di-O-acetyl- 1-N-[1-(2-b romo)acetyll -5-D-glucopyranose, 1901 
OA, 	 OAc 
ii) broino acericanhydride, DMF 
N 3 	 AcO 
OAc 
89 	 N1IAc 	 90 	 NUAc 
The peracetylated disaccharide 89 (1.98 g, 3.0 mmol) and 10 % Pd/C (205 mg), were 
dissolved in anhydrous methanol (90 mL), and stirred at room temperature under an 
atmosphere of hydrogen for 2 h. The catalyst was then removed by filtration through Celite, 
and the filter pad was washed with methanol. The solvent was removed under vacuum. The 
crude product was redissolved in anhydrous DMF (20 mL), and bromoacetic anhydride 
(1.01 g, 3.90 mmol) was added. The reaction was stirred at room temperature overnight. 
The reaction was diluted with chloroform (200 mL), and washed with 5 % HCI (200 mL), 
saturated aqueous NaHCO 3 (200 mL), and water (200 mL). The organic phase was dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography over silica (2.5 % methanol in DCM) to afford a brown 
solid foam 90 (2.19 g; 95 %). R= 0.25 (2 % methanol in DCM). 'H-NMR (250 MHz, 
CDC1 3) ö (ppm): 7.65 (1H, d, J= 8.1 Hz, C1'-NHCO); 7.04 (1H, d, JNH=  8.3 Hz, NHAc); 
5.27 (11-1, dd, J= 3.0 Hz, J= 0.6 Hz, H4); 5.05 (1 H, m, H3'); 4.97 (1 H, dd, J12= J23= 
10.1 Hz, H2), 4.90 (lH, dd, .J 3= 10.1 Hz, J3 3.2 Hz, H3); 4.42 (114, d, J12= 10.1 Hz, 1-Il); 
4.35 (lH, d, .J1.2.=  11.61 Hz, HI'); 4.06-3.66 (8H, m, H2', H4', H5, H5', 1i6, H6b, fl6a ', 
H60; 3.75 (2H, s, COCII 2 Br); 2.11, 2.09, 2.08, 2.05, 2.04, 1.98, 1.94 (21H, 7 x s, CH 3CO). 
13C-NMR (63 MHz, CDCI 3 ) 8(ppm): 172.2, 171.0, 170.3, 170.1, 169.2, 167.4 (CO); 101.0, 
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80.0, 76.8, 74.4, 72.7, 70.9, 70.6, 68.9, 66.9 (H); 62.0, 60.9 (H 2); 52.7 (CH); 28.2 (CH 2 ); 
22.9, 20.9, 20.6, 20.5 (CH 3 ). IR (CHC1 3) cm': 3018.4, 1751.2 and 1670.2. FAB-MS 
calculated for C, 8 H39BrN20 17 [MNa] 777.13297 (based on 7913r), found: 777.13018. 
2-Acetamido-2-deoxy-3, 4, 6-tri-O-acetyl-a-D-glucopyranosyl chloride, 92 [94] 










N-Acetyl glucosarnine 93 (20.0 g, 90.46 mmol) was added to stirring acetyl chloride (30 
mL). The suspension was stirred magnetically for 20 h. Afterwards the reaction was diluted 
with CHC1 3 (50 mL) and the resulting solution was washed with ice-water (50 mL) and ice-
saturated aqueous NaHCO 3 (50 mL). The organic phase was dried over MgSO 4, filtered and 
concentrated under reduced pressure. The crude product was purified by silica gel 
chromatography (the column was packed with 1: I petroleum ether 40-60/ethyl acetate; 
mobile phase 1:2) to afford a transparent solid 94 (11.36g; 34 %). R= 0.40 (Ethyl acetate). 
'H-NMR (300 MHz, CDCI 3 ) ö (ppm): 6.15 (1 H, d,J1  2=  3.7 Hz, HI): 6.03 (1 H, d,JNu2= 8.7 
Hz, NH); 5.30(11-I, dd,J23=J34= 9.9 Hz, H3); 5.17 (1H,J-4=J4= 9.9 Hz, H4); 4.51 (111, 
ddd, .12 3 = 9.9 Hz, 1NH2=  8.7 Hz, J 2 3.7 Hz, H2); 4.28-4.20 (2H, m, H5, H6 a), 4.11-4.07 
(I H, m, Hôh); 2.06, 2.01 and 1.95 (9H, s, CH 3CO). 3C-NMR (75 MHz, CDCI 1) ô (PPM): 
171.4, 170.6, 170.2, 169.1 (CO); 93.7, 70.9, 70.1, 67.0 (CH); 61.1 (Cl-I 2); 53.4 (CH); 23.0, 
20.7, 20.5 (CH 3 ). FAB-MS calculated for C 14 1120N05C1 [MH] 366, found 366. 
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2-Acetamido-2-deoxy-3, 4, 6-tri-O-acetyl--D-gIucopyranosy1 azide, 92  1951 
-OAc 	 OAc 










To a solution of the glucosyl chloride 94 (11.36 g, 31.12 mmol), TBAHS (10.57 g, 31.12 
mmol) and NaN3 (6.07 g, 93.36 mmol) in DCM (110 mL), was added saturated aqueous 
NaHCO3 (110 mL). The resulting biphasic solution was stirred vigorously at room 
temperature for I h. Ethyl acetate (200 mL) was then added and the organic layer was 
separated and washed with saturated aqueous NaHCO 3 (100 rnL), and water (2 x 100 mL). 
The organic phase was dried over MgSO 4, filtered and concentrated under reduced pressure, 
to afford a white solid 95 (9.54 g;  82 %). R= 0.30 (Ethyl acetate). 1 H-NMR (300 MHz, 
CDCI 3) 8(ppm): 6.02 (1 H, d, .JNH-2= 8.9 Hz, NH); 5.26 (1 H, 9.8 Hz, .123=  9.6 Hz, H3); 
5.08 (1 H, J34= J45= 9.8 Hz, H4); 4.78 (1 H, d, J12= 9.3 Hz, HI); 4.25 (111, dd, J6,-6b=  12.4 
Hz, J56a= 4.8 Hz, H6a); 4.14 (1 H, dd, J6a-6b=  12.4 Hz, -46b=  2.3 Hz, H6b); 3.91 (1H, ddd, J2 
i" 9.6 Hz, Ji2= 9.3 Hz, JNI2=  8.9 Hz, H2); 3.80 (1 H, ddd, J45= 9.8 Hz, J5 = 4.8 Hz, J5-6b=  
2.3 Hz, H5); 2.10, 2.02, 2.01 and 1.96 (12H, s, CH 3 CO). 13 C-NMR (75 MHz, CDCI 3) 5 
(ppm): 170.9, 170.7, 170.6, 169.3 (CO); 88.4, 73.9, 72.2, 68.2 (CH); 61.9 (CH,); 54.1 (CH) 
23.2, 20.7, 20.6, 20.6 (Cl-I 3). FAB-MS calculated for C 141-1 20N408 [MHJ 372.3, found 373.0. 
2-Acetamido-2-deoxy-3-0-acetyl-4, 6-0-p-methoxybenzylidene-fi-D-
glucopyranosyl azide,92 [961 
OAc 
AcO -4-0 AcO 
95 	NHAc 
I) NaOMe. Mc()H 
ii) p-anisaMehyde dirnethytacetal. TsOl-1 
iii) Ac,O. pyridine 
PMP 
	
AcO 	 N 3 
96 	NI-lAc 
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The glycosyl azide 95 (3.0 g, 8.07 mmol), was dissolved in dry MeOH (15 mL), sodium 
methoxide (200 ttL of a 0.5 M solution in methanol) was added and the reaction mixture was 
stirred for 2 h at room temperature. The reaction mixture was neutralized by adding acetic 
acid (10 giL), and concentrated under reduced pressure to afford the crude deacetylated 
product as a pale yellow foam. The crude azide was dissolved in anhydrous DMF (10 mL) 
and p-anisaldehyde dimethylacetal (3.37 g, 18.54 mmol) and p-Tosic acid (0.28 g, 1.61 
mmol) were added. After stirring for 1.5 h at 50 °C, the reaction mixture was concentrated 
under vacuum. The residue was poured into a cold mixture of saturated aqueous NaHCO 3 
(30 mL) and DCM (30 mL) and cooled for 10 min at 4 °C. The precipitate was crystallized 
from ethyl acetate (30 mL). The product was filtered, dried under vacuum and isolated as a 
white solid. The resulting product was dissolved in pyridine (20 mL) and acetic anhydride 
(10 mL). The mixture was stirred for 24 h at room temperature and then concentrated under 
vacuum. Dichloromethane (150 mL) was then added and the organic phase was washed 
with water (20 mL), and saturated aqueous NaHCO 3 (20 mL). The organic layer was dried 
over MgSO4, and the solvent was removed under vacuum to afford the crude product as a 
white solid which was crystallised form ethyl acetate to afford the pure product 96 (1.19 g; 
70 %) as a white solid. R,= 0.30 (Ethyl acetate). 'H-N MR (300 MHz, CDCI 3 ) óppm): 7.34 
(211, d, J= 8.7 Hz, ArH); 6.88 (2H, d, .J= 8.8 Hz, ArH); 5.88 (1H, d, JI2NHAC =  9.5 Hz, 
NHAc); 5.48 (1H, s, CHPh); 5.24 (IH, dd,J 2 9.9 Hz, H3); 4.48 (lH, d, 3 J, 2= 9.2 Hz, HI); 
4.32 (1 H, dd, J6.-6b=  10.5 Hz, J5-6a=  4.6 Hz, H6a); 4.11 (1H, ddd, J23= 9.9 Hz, JH2NFIAC=  9.5 
Hz, 12= 9.2 Hz, H2); 3.79 (3H, s, CH 30); 3.77-3.61 (3H, m, H4, HS, H6b);  2.09 and 2.00 
(6H, s, CH 3 CO). 3C-NMR (75 MHz, CDCI 3) 8(ppm): 171.4, 170.9 (CO); 159.8, 128.8 
(Ar); 127,1, 113.2 (Ar=H); 101.2, 88.8, 78.1, 71.4, 68.1 (CH); 67.9 (CH'); 54.9 (CH 3); 53.3 
(CH); 22.2, 20.3 (CH 3). FAB-MS calculated for C 18H,2N407 [MNa] 429.0, found 429.0. 
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2-Acetamido-2-deoxy-3-O-acetyl-6-O-p-methoxybenzyl-/1-D-glucopyranosyl 




Na(CN)BH3 	Flo 	 0 
TFA AcO 
96 NHAc 	 NHAc 
TFA (6.8 mL, 88.7 mmoi) in dry DMF (55 mL) was cooled down to 0 °C, and was added 
dropwise to a stirring solution of the sugar azide 96 (3.6 g, 8.87 mmol), sodium 
cyanoborohydride (2.79 g, 144.35 mmoi) and 4A molecular sieves in dry DMF (70 mL) at 0 
°C in an ice bath. After the addition was complete, the ice bath was removed and the 
reaction mixture was stirred at room temperature for 16 h. Next, the reaction was filtered 
with suction. The filtrate was poured into ice-cold saturated aqueous NaHCO 3 and the 
product was extracted with dichloromethane (5 x 60 mL). The combined organic extracts 
were washed with a saturated aqueous solution of NH 4CI (100 mL) and water (100 mL). 
The organic phase was dried over MgSO 4, filtered and concentrated under reduced pressure. 
The crude product was purified by silica gel chromatography (the column was packed with 
1: I petroleum ether 40-60/ethyl acetate; mobile phase: ethyl acetate) to afford 97 (1.0 g; 66 
%) as a white solid. R f= 0.20 (Ethyl acetate). 'H-NMR (300 MHz, CDCI 3 ) S(ppm): 7.28 
(2H, d, J= 8.7, ArH); 6.91 (2H, d, J= 8.7, ArH); 6.02 (1 H, d, 412-NHAc =  9.2 Hz, NHAc); 5.08 
([H, dd, J23= 10.5 Hz, J34= 9.2 Hz, H3); 4.59 (IH, d, J12= 9.3 Hz, Hi); 4.54 (2H, q, 
OCH2Ph); 4.09 (1H, ddd, J2 . 3 10.5 Hz, J1 93 Hz, JH7NHAC=  9.2 Hz; H2); 3.78 (3H, s, 
CH 30); 3.77-3.46 (4H, m, H4, F15, H6 a, I-I60; 3.26 (1H, bp, OH); 2.09 and 1.96 (6H, s, 
CH3CO). ' 3C-NMR (75 MHz, CDC1 3 ) 8(ppm): 171.8, 171.4 (CO); 159.3, 129.7 (Ar); 129.4, 
113.8 (Ar-H); 88.8, 77.4, 75.4 (CH); 73.4, 68.9 (CH 2); 68.6 (CH); 55.1 (Cl-I 3 ); 53.1 (CH); 
22.7, 20.7 (C H 3 ). FAB-MS calculated for C 8 1-1 24N407 [MH] 431.4, found 431.4. 
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2-Acetamido-2-deoxy-3-O-acetyl-4-O-tert-butoxycarboxymethyl-6-O-p-












To a solution of the sugar derivative 97 (2.28 g, 5.60 mmol) in DMF (15 mL) at 0 °C, NEt 3 
(1.6 mL, 11.20 mmol) was added and the solution was stirred for 30 mm. Then, tert-
butyibromo acetate (3 mL, 20.30 mmol) and silver oxide (2.3 g, 10.20 mmol) were added. 
The reaction was stirred overnight at room temperature under nitrogen gas with exclusion of 
light. The crude reaction was diluted with DCM (50 rnL) and filtered through Celite. The 
organic phase was washed with saturated aqueous NaHCO 3 (4 x 50 mL) and water. The 
organic phase was dried MgSO 4, filtered and concentrated under reduced pressure. The 
crude product was purified by silica gel chromatography (the column was packed with 1:1 
petroleum ether 40-60/ethyl acetate; mobile phase 1:2) to afford 98 (1.67 g, 57 %) as a 
brown oil. R1= 0.5 (ethyl acetate). 'H-NMR (300 MHz, CDC1 3 ) 5 (ppm): 7.21 (2H, d, J= 
8.7, ArH); 6.85 (2H, d, J= 8.7, Arl-l); 6.35 (1H, d, JH2N1IAC=  9.6 Hz, NHAc); 5.14 (lH, dd, .12. 
= 10.9 Hz, .134= 8.4 Hz, 1-13); 4.57 (11-I, dd, .134= J45= 8.4 Hz, H4); 4.43 (1 H, d, Jj2= 11.5 
Hz, HI); 4.03-4.01 (lH, m, H2); 3.98 (2H, s, COCthBr):  3.77 (3H, s, CH 30); 3.75-3.58 (3H, 
m, H5, H6a, H60; 2.07 and 1.95 (6H, s, CH 3CO); 1.41 (9H, s, (CH 3 ) 3C). 13 C-NMR (75 
MHz, CDCI3 ) 8(ppin): 171.4, 170.5, 168.6 (!CO); 159.3, 130.1 (Ar); 129.6, 129.4, 113.8 (Ar-
H); 88.7, 81.8, 76.7, 75.1 (CH); 73.2, 70.3, 67.9 (CH4; 55.3 (CH 3 ); 53.4 (CH); 28.1 (CH 3 ); 
22.7, 20.7 (CH 3). FAB-MS calculated for C 24 H34N409 [MNa] 545.5, found 545.5. 
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2-Acetamido-2-deoxy-3, 6-di-O-acetyl-4-0-tert-butoxycarboxymethyl--fl-D-
glucopyranosyl azide, [99] 
OPMB 	
i) CAN, CH3CN/H2O(9:1) 	 OAc 
ii) Pyr/Ac20 (2:1) 	
- 'BuO,C'O- -CO 
98 	 NHAc 	 99 	 NHAc 
The azido sugar 98 (145 mg, 0.28 mmol) was dissolved in 9:1 MeCN/H2O (1.5 mL) and 
CAN (307 mg, 0.56 mmol) was added. After I h, TLC (ethyl acetate) indicated that the 
reaction was complete. The crude reaction was diluted with DCM (25 mL) and washed with 
saturated aqueous NaHCO 3 (10 rnL). The organic phase was dried over MgSO 4, filtered and 
concentrated under reduced pressure. The residue was dissolved in a solution of 2:1 
pyridine/Ac 20 (6 mL), and the reaction was stirred for 16 h. The reaction was concentrated 
to afford a yellow oil. The crude product was purified by silica gel chromatography (the 
column was packed with 1: 1 petroleum ether 40-60/ethyl acetate; mobile phase 1:2) to afford 
the purified product 99 (95 mg; 85 %) as a colourless oil. R 1= 0.5 (ethyl acetate) 'H-NMR 
(300 MHz, CDCI 3 ) 5 (ppm): 6.32 (1H, d, J= 9.6 Hz, NHAc); 5.17 (1H, dd, J3 = 10.4 Hz, J2 
= 9.2 Hz, H3); 4.65 (1H, d, Jl-2  9.2 Hz, HI); 4.43 (1 H, dd, 12.2 Hz, JS-6a=  2.1 Hz, 
H6); 4.29 (1 H, dd, '6a,b  12.2 Hz, '56b  4.7 Hz, H6b); 4.12-3.96 (3H, in, H4, CH 2); 3.78 
(I H, m, H5); 3.53 (1 H, dd, J.2= J2 . 3= 9.2 Hz, H2); 2.10, 2.08, 1.96 (9H, s, CH iCO); 1.42 
(9H, s, (CH 3 ) 3C). 13 C-NMR (75 MHz, CDCI 3 ) () (PPM): 171.3, 170.6, 170.4, 168.4 (CO); 
88.5 (CH); 82.1 (qC, C(CH 3 )3 ); 77.5, 74.4 (CH); 74.4 (CH 2); 70.2 (CH); 62.7 (CH 2); 53.3 
(CH); 28.0 (CH 3, C(CH3 ) 3); 23.1, 21.1, 20.8 (CH 3 ). FAB-MS calculated for C 18 H28N409 
[MNa] 467.4, found 467.4. 
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2-Acetamido-2-deoxy-3, 6-di-O-acetyl-4-0-carboxymethyl-/i-D-glucopyranosyl 
azide, 11001 
OAc 	 OAc 
95% TFA. 5% 1-1,0 
A 
,BuO2 C' O  
cO ACID 	 N 3 
99 	 NI-lAc 	 100 	 NHAc 
A solution of the monosaccharide derivative 99 (422 mg, 0.95 mmol) in TFA/H 20 (95:5, 10 
ml-) was stirred at room temperature for 2 h. Afterwards, the solution was concentrated nder 
vacuum to give the desired compound 100 (382 mg; 98 %) as a brown oily wax. 'H-NMR 
(300 MHz, CDCI 3) (5(ppm): 6.67 (IH, d, 1=9.4 Hz, NHAc); 5.21 (JH, dd, J23 J3 = 9.5 Hz, 
H3); 4.68 (lH, d, J1 .2= 9.4 Hz, HI); 4.49 (dd,Jóa.6b 11.6 Hz, H6 a); 4.31 (dd,Jofl6b= 11.6 Hz, 
J5-6b= 4.4 Hz, H6b); 4.24(2H, ci, 1=3.7 Hz, CH,); 4.02-3.99 (1 H, m, H2); 3.77 (1 H, m, 1-15); 
3.61 (1 H, dd, .J= J 5 = 9.5 Hz, H4); 2.12, 2.09 and 2.03 (9H, s, CH 3 CO). 13C-NMR (75 
MHz, CDCI 3) ô(ppm): 171.2, 170.4, 170.1, 168.0 (CO); 87.7 (H); 75.2 (CH-,); 75.1, 74.2, 
70.1 (CH); 63.4 (CH 2); 54.3 (CH); 22.2, 20.7 (Cl-I 3). JR (CHC1 3 ) cm -1 : 3300.0, 3020.3, 
2119.6, 1733.9, 1683.7 and 1217.0. FAB-MS calculated forC 14H20N4O9 [MH]: 389.13085, 
found: 389.1 3041. 
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7. Experimental section 
General experimental details for manual PSDC 103 synthesis. 
Solid-phase peptide synthesis was carried out manually using a plastic syringe fitter with a 
Teflon frit and connected to a vacuum waste chamber via a Teflon valve. Synthesis of the 
PSDC 103 was carried out on MBHA Rink amide resin (loading = 0.58 mmol/g). 
General Solid-phase peptide synthesis: Ac-L-Cys-L-Lys-L-Cys-NH 2 . 
The synthesis of the compound 103 was conducted on 0.05 mmol scale. The Fmoc group 
was removed by treatment with 20 % piperidine in DMF (I x 5 and I x 15 mm) between 
each coupling step. Coupling reactions with Fmoc amino acids were conducted using 0.25 
mmol (5 equiv.) of each of HBTU/I-lOBt and DIPEA for 3 h. The reaction progress was 
monitored using the Kaiser ninhydrin test. Between each coupling and deprotection step, the 
resin was washed with DCM and DMF (5 min each). 
The resin was treated with a mixture (Ac 20/pyridine, 2:1) for 16 h. Finally the resin was 
washed exhaustively with DMF and DCM. 
General SBu deprotection. 
DTT (100 mg) was dissolved in dry DMF (900 iL) and 2.5 % v/v DIPEA (25 [LL) was 
added. After stirring for 5 minutes the solution was transferred to a peptide synthesis vessel 
containing resin-bound S tBu protected peptide. After 16 h the resin was filtered and washed 
exhaustively with DMF, DMF/H 20 (1:1), DMF and finally DCM. The SBu procedure was 
repeated twice. 
General bromoacetamide couplings. 
Bromoacetamide 90 (2 equiv. per thiol: 0.05 mmol x 2 thiols x 2 equiv.= 151 mg, 0.20 
mmol) was dissolved in DMF (400 ML) and NEt 3 (42 ML, 0.3 mmol) and transferred to a 
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peptide synthesis vessel containing resin-bound SBu deprotected peptide. The reaction was 
allowed to proceed for 24 h. After this time, the resin was filtered and washed exhaustively 
with DMF, DMF/l-1 20 (1:1), DMF and finally DCM. 
General A/bc deprotection.' 79 
The resin was washed for 5 min with a solution of DMF/CHCI 3/AcOH/N-methyl morpholine 
(NMM) (18.5:18.5:2:1). Pd(PPh 3 )4 (115 mg, 0.1 minol) was dissolved in a solution of 
DMF/CHC1 3/AcOH/NMM (18.5:18.5:2:1) (0.05 M Pd(PPh3 )4). The mixture was stirred 
under nitrogen for 2 h with exclusion of light. The process was repeated again. Finally, the 
resin was then washed sequentially with the following solutions: 0.5 % DIPEA in DMF (v/v) 
(4 x 2 mL); DMF (6 x 2 mL); 0.5 % (wlv) sodium diethyldithiocarbamate trihydrate in 
DMF (4 x 2 mL); followed by a final wash with DMF (6 x 2 mL). 
Coupling of 2-acetaniido-2-deoxv-3, 6-di-O-acetyl-4-carboxymethyi-/3-D-glucopyranosyl 
azide 100 and peracetylation of the molecule. 
The resin was washed with DMF (2 mL). Coupling reactions with 2-acctamido-2-deoxy-
3,6-diacctyl-4-carboxymethyl-fl-D-glueopyranosyl azide 100 were conducted using 0.25 
mmol (5 equiv.) of the sugar, HBTU/HOBt and DIPEA for 3 h. 
Afterwards, the resin was treated with a mixture of pyridine and acetic anhydride (2:1) for 16 
h. Finally the resin was washed exhaustively with DMF and DCM. 
Cleavage of compound 103. 
The resin was washed with DCM and DMF five times (5 min each wash). The compound 
103 was cleaved from the resin by incubation with the cleavage cocktail (95 % TFA, 2.5 % 
water and 2.5 % EDT) for 3 h. The resin was treated again with the same cleavage cocktail 
for another 3 h. The compound 103 was precipitated with cold diethyl ether and centrifuged 
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for 10 mm. The precipitate was dried and redissolved in a 1: 1 water/acetonitrile solution and 
lyophilised. 
Compound 103 purfIcation. 
The crude product was purified by reverse phase semi preparative HPLC (water-acetonitrile 
5 %-95 % in 40 minutes, 0.1 % TFA), tR= 30.3 mm. The corresponding fractions containing 
103 were pooled and freeze dried to afford a fluffy white solid (32 mg, 30 % overall yield of 
10 steps). 
Analytical data for compound 103: C 54H 12 N 13046 S 2 . MW: 2113.05. Found: [M] - 2113.05, 
[M] 2 1057.52 





















General experimental details for manual PSDC 104 synthesis.. 
Solid-phase peptide synthesis was carried out manually using a plastic syringe fitter with a 
Teflon filter and connected to a vacuum waste chamber via a Teflon valve. Synthesis of the 
PSDC 104 was carried out on MBHA Rink amide resin (loading = 0.58 mmol/g). 
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General Solid-phase peptide synthesis: Ac-L-Cys-L-Lys-L-Cys-NH 2 
The synthesis of compound 104 was conducted on 0.10 mmol scale. The Fmoc group was 
removed by treatment with 20 % piperidine in DMF (5 and 15 min) between each coupling 
and deprotection step. Coupling reactions with Fmoc amino acids were conducted using 
0.50 mmol (5 equiv.) of each of HBTU/HOBt and DIPEA for 3 h. The reaction progress 
was monitored using the Kaiser ninhydrin test. Between each coupling and deprotection 
step, the resin was washed with DCM and DMF (5 min each). 
The resin was treated with a mixture (Ac 20/pyridine, 2:1) for 16 h. Finally the resin was 
washed exhaustively with DMF and DCM 
General S'Bu deprotection. 
DTT (200 mg) was dissolved in dry DMF (1.8 mL) and 2.5 % v/v DIPEA (50 PL) was 
added. After stirring for 5 minutes the solution was transferred to a peptide synthesis vessel 
containing resin-bound S'Bu protected peptide. After 16 h the resin was filtered and washed 
exhaustively with DMF, DMF/I-1 20 (1:1), DMF and finally DCM. The S'Bu deprotection 
procedure was repeated twice. 
General bromoacetamide couplings 
Bromoacetamide 90 (2 equiv. per thiol: 0.10 mmol x 2 thiols x 2 equiv.= 302 mg, 0.40 
mmol) was dissolved in DMIF (1 mL) and NEt 3 (84 iL, 0.6 mmol) and transferred to a 
peptide synthesis vessel containing resin-bound S'Bu deprotected peptide. The reaction was 
allowed to proceed for 24 h. After this time, the resin was filtered and washed exhaustively 
with DMF and the DCM. 
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General Alloc deprotection.' 79 
The resin was washed for 5 min with a solution of DMF/CHCI 3/AcOH/iV-methyl morpholine 
(NMM) (18.5:18.5:2:1). Pd(PPh 3)4 (230 mg, 0.2 inmol) was dissolved in a solution of 
DMF/CHCI 3/AcOH/NMM (18.5:18.5:2:1) (0.05 M Pd(PPh 3 )4). The mixture was under 
stirred nitrogen for 2 h with exclusion of light. The process was repeated again. Finally, the 
resin was washed sequentially with the following solutions: 0.5 % DIPEA in DMF (v/v) (4 x 
2 mL); DN'IF (6 x 2 mL); 0.5 % (w/v) sodium diethyldithiocarbamate trihydrate in DMF (4 
x 2 mL); followed by a final wash with DMF (6 x 2 mL). 
Coupling of 2-acetamido-2-deoxy-3, 6-di-O-acetyl-4-carboxymetvl-J3-D-giucopyranosyl 
azide 100 and peracetvlation of the molecule 
The resin was washed with DMF (2 mL). Coupling reactions with 2-acetamido-2-deoxy-
3,6-diacetyl-4-carboxymethyl-fl-D-glucopyranosyl azide, 100 (97 mg, 0.25 rnmol, 2.5 
equiv.), 2.5 equiv. PyBOP/HOBt and 5 equiv. DIPEA for 16 h. The process was repeated. 
Afterwards the resin was exhaustively washed with DCM and DMF. 
Cleavage of compound 104. 
The resin was washed with DCM and DMF five times (5 min each wash). The compound 
104 was cleaved from the resin by incubation with the cleavage cocktail (95 % TFA, 2.5 % 
water and 2.5 % EDT) for 3 h. The resin was treated again with the same cleavage cocktail 
for another 3 h. The compound 104 was precipitated with cold diethyl ether and centrifuged 
for 10 mm. The precipitate was dried by flushing with nitrogen for 30 mm. 
Acetvl deprotection of the carbohydrates. 
The precipitate was resuspended with a water/methanol solution (10:1) of 5 % hydrazine (6 
mL). The reaction was stirred at room temperature for 24 ii. 
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Compound 104 pury'Ication. 
The crude product was purified by reverse phase semi preparative HPLC (water-acetonitrile 
5 %-95 % in 40 minutes, 0.1 % TFA), t= 14.2 mm. The corresponding fractions containing 
104 were pooled and freeze dried to afford a fluffy white solid (72 mg; 47 % overall yield of 
10 steps). 
Analytical data for compound 104: C 56H93N 13032 S2 . MW: 1524.79. Found: [M]: 1525.79; 
[M] 2 : 763.48; [M±NH2NH2 ] 2 :779,40; [M+2NH 2 NH2] 2 : 795.63. 
2-Bromo-N-p rop-2-ynyl-acetamide, 209 11121 
115 	NH 	 0 




Br 	II ).L..Br 	 112 H 
-..,..--- _'  
Propargylamine 115 (200 ML, 2.90 mmol) was dissolved in water (30 mL) and this was 
followed immediately by the addition of bromoacetic anhydride 116(3.7g, 14.50 mrnol) and 
NaHCO3 (5.0 g). The reaction was stirred at room temperature for 16 h. The reaction was 
quenched with 5 % v/v aqueous HC1 solution (50 mL), and the product was extracted with 
ethylacetate (3 x 50 mL). The organic phase was washed with NaOH I N (5 x 100 mL) and 
water (2 x 100 mL). The organic phase was dried with MgSO 4, filtered and concentrated 
under reduced pressure to afford 112 (0.4 g; 76 %) as a crystalline solid. Rf== 0.33 
(petroleum ether 40-60/ethyl acetate 1:1). 'H-NMR (250 MHz, CDCI 3 ) 8(ppm): 6.78 (IH, s, 
NH); 4.07 (2H, q, J= 5.4 Hz, J= 2.6 Hz, CH,); 3.88 (21-1, s, COCft aBr); 2.27 (1 H, t, J= 2.6 
Hz, CH).  13C-NMR (63 MHz, CDCI 3) 8(ppn): 165.3 (CO); 78.5 (qC, alkyne); 72.2 (CH), 
29.9, 28.6 (CH,). IR (CH0 3) cm': 3307.7, 3018.4, and 1670.2. FAB-MS calculated for 
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2-Bromo-N-prop-2-ynyl-acctamidc 112 (100 rug, 0.57 mmol) was dissolved in DMF (4 
mL). Benzylmercaptan 117 (700 1iL, 5.77 mmol) and triethylamine (885 1iL, 6.35 rnmol) 
were added. The reaction was stirred for 16 h. The crude of the reaction was diluted with 
chloroform (10 ML), and washed with NaOH (1M, 10 rnL), 5 % HC1 (10 mL), saturated 
aqueous NaHCO 3 (10 mL) and water (10 rnL). The organic phase was dried with MgSO 4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography over silica (petroleum ether 40-60/ethyl acetate, 1:1) to afford 119 (105 mg; 
84 %) as a brown solid. R 1= 0.38 (petroleum ether 40-60/ethyl acetate 1:1). H-NMR (300 
MHz, CDCI 3 ) 8(pp,n): 7.34-7.22 (5H, m, Ph); 6.91 (1 H, bp, NH); 3.95 (2H, q, J= 5.4 Hz, J= 
2.5 Hz, CH2); 3.72 (2H, s, COCfl2S); 3.12 (2H, s, PhCIj2S); 2.24 (1H, t, J= 2.5 Hz, CH). 
13C-NMR (75 MHz, CDC1 1 ) 8(ppn): 168.4 (CO);  137.0 (Ar); 129.0, 128.8, 127.5 (Ar-fl) 
79.3 (qC, alkyne); 71.8 (CH), 37.1, 35.0, 29.4 (CH2). JR (CHC1 3) crn': 3300.0, 3018.4, and 
1670.2. FAB-MS calculated for C 12 H 13N0S [MH] 220,07906 (based on 79Br), found 
220.079 10. 
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1-N-(3, 4, 6-Tri-O-acetyl-2-deoxy-2-N-acetyl-fl-D-gtucopyranosyl)-4-(N'-






N NFIAc 	 Na ascorbatc 
91:1 CFICIyEtOI1I11,0 	
ACOAcO 





The azido sugar 95 (100 mg, 0.27 mmol) and N-propargyl-bromoacetamide 112 (47 mg, 0.27 
mmol) were dissolved in a biphasic solution of CHCI 3/EtOI-I/H 20 (9:1:1) (1.1 mL). Sodium 
ascorbate (54 mg, 0.27 mmol) and CuS0 4 51-1 20 (2 mg, 0.007 mmol) were added. The 
reaction was shaken at 600 rpm, 50°C overnight. Afterwards, it was diluted with CHCI 1  0 0 
ml-) and washed with saturated aqueous NaHCO 3 (3 x 20 mL), and the organic phase was 
dried with MgSO4, filtered and concentrated under reduced pressure to afford 114 (98 trig; 
66 %) as a brown solid. R= 0.40 (ethyl acetate). H-NMR (300 MHz, CDC1 3 and 5 % v/v 
CD30D) 8(ppm): 7.72 (1 H, bp, CH-triazole); 5.76 (1 H, d, J12=  9.7 Hz, Hi); 5.21 (1 H, dd, 
J23= .134=9.8 Hz, H3); 4.99 (1H, dd, .J3.4= .14.5=9.8 Hz, H4); 4.28 (1H, bp, H2); 4.19 (2H, s, 
CNH); 4.08 (2H, dd, J6,-6b=  12.7 Hz, J5-6a=  4.8 Hz, l-16a); 3.92 (11-1, dd, '6a-6b  12.7 Hz, .15. 
ob= 1.8 Hz, H60; 3.87-3.83 (1 H, in, H5); 3.63 (2H, s, COCthBr); 1.86, 1.85, 1.82 (9H, 3 x s, 
CH 3CO); 1.52 (3H, s, CthCONH).  13C-NMR (75 MHz, CDCI 3 and 5 % of CD 30D) c 
(ppm): 171.7, 170.9, 170.4, 169.6 (CO); 82.0. 74.5, 72.0, 68.0 (çH);  61.7 (CH 2 ); 53.1 (CH); 
35.0 (CH2, Ar-CH,-NH); 28.0 (CH,, CO-CH 2-Br); 21.8, 20.2, 20.1, 20.1 (Cl-I 3 ). FAB-MS 
calculated for C 19H26BrN 509 [MH]: 548.09867 (based on 79Br), found: 548.10034. 
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1 -N-(3, 	4, 	6-Tri-O-acetyl-2-deoxy-2-N-acetyl-,6-D-glucopyranosyl)-4-(N'- 




CuSO451-1,0 	 AcO I AcO 






The azido sugar 95 (100 mg, 0.27 mmol) and propargyl derivative 119 (59 mg, 0.27 mmol) 
were dissolved in a biphasic solution of CHCI 3/EtOH/H 20 (9:1:1) (1.1 mL). Sodium 
ascorbate (54 mg, 0.27 mrnol) and CuS0 4 5H20 (2 mg, 0.01 mmol) were added. The 
reaction was shaken at 600 rpm, 50 °C overnight. Afterwards, it was diluted with CHCI 3 (10 
mL) and washed with saturated aqueous NaHCO 3 (3 x 20 mL), and the organic phase was 
dried with MgSO4 , filtered and concentrated under reduced pressure to afford 118 (146 mg; 
91 %) as a brown solid. R 1= 0.33 (ethyl acetate). 'H-NMR (300 MHz, CDCI 3 and 5 % v/v 
CD 3 0D) 5(pprn): 7.75 (IH, s, CH-triazole); 7.24-7.18 (5H, m, Ph); 5.86 (1H, d, J1 .2= 9.9 Hz, 
HI); 5.33 (1H, dd, J23 J3 .4=9.9 Hz, H3); 5.12 (lH, dd, J3 .4= J45=9.9 Hz, H4); 4.38 (1 H, dd, 
J1 . 2= J23=9.9 Hz, H2); 4.35 (2H, s, CNH); 4.19 (IH, dd, '6a-6b=  12.6 Hz, JS-6a  4.8 Hz, 
H60; 4.03 (1 H, dd,J6a 6b 12.6 Hz,J55b 1.9 Hz, H6b); 3.94(IH, ddd,J45=9.9 Hz, J5 6 4.8 
Hz,Jsb= 1.9 Hz, H5); 3.66 (2H, s, COCthS);  3.03 (2H, s, SCjjPh); 1.97, 1.95, 1.93 (9H, 3 
x s, CH3CO); 1.62 (3H, s, CH 1 CONH). 13C-NMR (75 MHz, CDC1 3 and 5 % v/v CD 3 0D) 5 
(ppm): 171.4, 170.9, 170.6, 169.7, 169.6 (CO); 137.1 (Ar); 128.9, 128.5, 127.2 (Ar-H); 121.2 
(Ar); 85.9, 74.7, 72.2, 68.0 (CH); 61.7 (CH,); 53.3 (CH); 36.8, 34.8, 34.7 (CH,); 23.6, 22.2, 
20.5, 20.4 (CH). FAB-MS calculated for C 26H 33N 509S [MH]: 592.20717, found: 
592.20858. 
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I -N-(3, 4, 6-Tri-O-acetyl-2-deoxy-2-N-acetyl-/J-D-glucopyranosyl)-4-(N'-
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The sugar derivative 114 (50 mg, 0.09 mmol) was dissolved in DMF (615 1iL). 
Benzomercaptan 117 (106 1.tL, 0.90 mmol) and triethylamine (138 [LL, 0.73 mmol) were 
added. The reaction was stirred for 16 h. The reaction was diluted with chloroform (10 
mL), and washed with NaOH (IM, 10 ML), 5 % HCI (10 mL), saturated aqueous NaHCO 3 
(10 mL) and water (10 mL). The organic phase was dried with MgSO 4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography over silica (petroleum ether 40-60/ethyl acetate, 9:1 to 1:9) to afford 118 
(40 mg; 75 %) as a brown solid. R'= 0.33 (ethyl acetate). 'H-NMR (300 MHz, CDCI 3 and 5 
% v/v CD 30D) 8(ppm): 7.75 (1H, s, CH-triazole); 7.24-7.18 (5H, m, Ph); 5.86 (1 H, d, .J1.2= 
9.9 Hz, Hi); 5.33 (1 H, dd, J2 J34=9.9 Hz, H3); 5.12 (1 H, dd, J= J4 . 5=9.9 Hz, H4); 4.38 
(1H, dd, A -2= J23=9.9 Hz, H2); 4.35 (2H, s, CNH); 4.19 (1 H, dd, .J(, a 6b= 12.6 Hz, '156a  4.8 
Hz, H6a); 4.03 (1 H, dd,J6a 6b 12.6 Hz,J5,b= 1.9 Hz, H60; 3.94 (1 H, ddd,J45=9.9 Hz, J5-6,= 
4.8 Hz, J5-6b=  1.9 Hz, H5); 3.66 (2H, s, COCthS); 3.03 (2H, s, SCthPh); 1.97, 1.95, 1.93 
(9H, 3 x s, CH 3CO); 1.62 (3H, s, CJI3CONH). ' 3C-NMR (75 MHz, CDC1 3 and 5 % of 
CD3 0D) 5(ppm): 171.4, 170.9, 170.6, 169.7, 169.6 (CO); 137.1 (Ar); 128.9, 128,5, 127.2 
(Ar-H); 121.2 (Ar); 85.9, 74.7, 72.2, 68.0 (CH); 61.7 (cl-I2);  53.3 (CH); 36.8, 34.8, 34.7 
(CH,); 23.6, 22.2, 20.5, 20.4 (CM 3). FAB-MS calculated for C 26H33N 509S [MH]: 
592.207 17, found: 592.20858. 
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1 -N-(2-Deoxy-2-N-acetyl-/J-D-glucopyranosyl)-4-(N'-methytidenyl-2 '-
thiobenzyiacetamido) -1, 2, 3-triazole, [120] 
OH 
NH,NH. H2O. FOH 
118 NHAc 	 120 	
NHAc 	
Bn 
The modified sugar 118 (137 mg, 0.23 mmol) was dissolved in a 2 % solution of hydrazine 
monohydrate in ethanol (5 mL). After 3 days TLC (10 % methanol in DCM) indicated that 
the reaction was complete. The solvent was removed under high vacuum, and the crude 
product was purified by flash chromatography over silica (10 % methanol in DCM) to afford 
the pure product 120 (71 mg: 66 %) as a light brown wax. R 0.01 (10 % methanol in DCM). 
'H-NMR (300 MHz, D 20/CD 30D) S (ppm): 8.04 (IH, s, CH-triazole); 7.30-7.24 (5H, m, 
Ph); 5.76 (lH, d, J12= 9.8 Hz, Hi); 4.40 (2H, s, triazo1e-C-NH); 4.20 (11-1, dd, J12= 17 3= 
9.8 Hz, H2); 3.90-3.54 (5H, m, H3, H4, H5, H6,, H60; 3.78 (2H, s, CO-CH'-S); 3.12 (2H, 5, 
S-CH,-Ph); 1.76 (3H, s, COCth). 13C-NMR (75 MHz, D 20/CD 30D) 8(ppm): 173.5, 172.2 
(CO); 146.0, 139.0 (Ar); 130.2, 129.5, 128.2, 123.0 (Ar-H); 88.2, 81.2, 75.6, 71.4 (CH); 62.3 
(CH2); 56.8 (CH); 37.5, 35.8, 35.5 (CH 2 ); 22.6 (CH 3 ). FAB-MS calculated for C 20 H27N 506S 
[MH]: 466.17548, found: 466.17335. 
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1-N-(2-Deoxy-2-N-acetyl-fI-D-glucopyranosyl)--4-(N'-methylidenyl-2 '-
















To a vigorously stirring suspension of the unprotected sugar 121 (10 mg, 0.04 mmol) in tert-
butanol (87 j.tL), was added propargyibromoacetamide 112 (30 mg, 0.17 mmol). The 
reaction was initiated by the addition of a solution of CuS0 4 5H20 (2 mg, 0.02 mmol), 
sodium ascorbate (3 mg, 0.02 mmol) and lrisbenzyltriazolylmethylaminc (TBTA) (4 mg, 
0.08 mrnol) in water (87 1iL). The reaction was shaken at 37 °C, 1200 rpm, for 5 h. 
Afterwards, the reaction was diluted with water (325 tL), centrifuged at 1400 rpm for 5 
minutes, and filtered through celite and cotton wool in a Pasteur pipette. The crude product 
was purified by reverse phase semi preparative HPLC (water-acetonitrile 5 %-30 % in 40 
minutes, 0.1 % TFA) The corresponding fractions were freeze dried to afford 122 (12 mg; 
71 %) as a foamy white solid. 'H-NMR (300 MHz, D 200 (ppm): 8.10 (1 H, s, CH-triazole); 
5.80 (IH, d, J12= 9.7 Hz, HI); 4.49 (2H, s, CflN); 4.22 (IH, dd, 112= 12.3=9.8 Hz, H2); 
3.94-3.50 (7H, m, H3, H4, H5, H6 0, H6h, COCBr); 1.71 (3H, s, CH 3 CONH). ' 3C-NMR 
(75 MHz, D20) (5 (PPM): 174.5, 170.2 (CO); 86.8, 79.3, 73.9, 69.7 (CH); 60.8 (CHI); 55.7 
(CH); 35.3 (Crn, Ar-CH 2-NH); 28.3 (CH 2, CO-CH 2-13r); 22.0 (CH 3). FAB-MS calculated 
for C13H,0BrN50: 421.33 (based on 79Br), found 422.33 and 424.33[MH]'. 
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The compound 103 (5 mg, 0.0023 rnrnol) and propargyl bromoacetamide 112 (1 mg, 0.0023 
mmol) were dissolved in a biphasic solution of CHCI 3/EtOH/H 20 (9:1:1) (220 IlL). Sodium 
ascorbate (I mg, 0.0023 mmol) and CuS0 4 5H20 (0.1 mg, 0.0002 mmol) were added. The 
reaction was shaken at 600 rpm, 37 °C overnight. Afterwards, the reaction was diluted with 
ethyl acetate and washed with saturated aqueous NaHCO 3 (3 x 10 mL), and the organic 
phase was dried with MgSO 4, filtered and concentrated under reduced pressure to afford the 
pure product 130 (2.5 mg; 50 %) as a fair brown wax. 
Analytical data: C 89 H 127 BrN 14047 S2 . MW: 2289.06. Found: 
[MI-2  1146,15. 




7. Experimental section 
The compound 104 (10 mg, 6.60x10 3 mmol) and propargylbromoacetamide 112 (5 mg, 
2.60x 10-2  mmol) were dissolved in an aqueous solution of sodium ascorbate (2.60x I 0 
mmol, 52.00 mM, 50 l.LL) and a ter/-butanol solution of tris-benzyltriazolylmethylamine 
(TBTA) (1.30x10 3 mmol, 13.10 mM, 100 giL). Afterwards, an aqueous solution of 
CuS04 5H 20 (1.30x 10-3  mmol, 26.20 mM, 50 ILL) was added. The reaction was shaken for 
16 hours at 37 °C, 1200 rpm. Then, it was diluted with water (800[IL), centrifuged at 1400 
rpm for 5 minutes, and filtered through celite plug in a Pasteur pipette. The crude product 
was purified by reverse phase semi preparative HPLC (water-acetonitrile 5 %-50 % in 40 
minutes, 0.1 % TFA), tR = 16.6 mm. The corresponding fractions containing 131 were 
pooled and freeze dried to afford a fluffy white solid (7 mg; 64 %). 
Analytical data: C 61 H99BrN 14033S 2 . MW: 1698.51. Found: [M] 1701.4; [M±Na] 2 862.59; 
[M+NH4] 2 860.09; [M] 12 851.09. 
Synthesis of compound 11371 
HS 
o 
132 	0 OH 
0. 1 M sodium phosphate buff 
ph 1 7.4. 37 °C, ON. 
131 
1. 
The desired EPO peptide fragment (residues 21-32), 132 (2 mg, 1.15x 10 -3 mmol) and the 
131 (10 mg, 5.53x 10 - 3  mmol) were dissolved in a 0.1 M sodium phosphate buffer solution, 
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pH 7.4 (400 tL). The mixture was incubated at 600 rpm, 37 °C, overnight. The crude 
product was purified by reverse phase semi preparative HPLC (water-acetonitrile 5 %-95 % 
in 40 minutes, 0.1 % TFA), tR=  16.2 mm. The corresponding fractions containing 133 were 
pooled and freeze-dried to afford a fluffy white solid (2 mg; 29 %). 
Analytical data: C 170 H279N43005 S5 . MW: 4541.80. Found: [M+K] 3 : 1528.0, [M+2K] ' 4 : 
1156.0, [M+2K] 5 : 925.0, [M+3K] 16 : 777.5 







&H H 	 H 
I 	 SASH 
133 
H4 J 
flg(OAc). 10% AcOI-1 
DTF 
0HN 134 
133 (2 mg, 3.00xlO mrnol) was dissolved in 10 % AcOH (340 1iL) at a cone. of 5 mg/mL, 
and mercury (II) acetate (3 mg, 9.00x10 3 mmol), was added followed 90 min later by 
dithiothreitol (3 mg, 2.00x10 2 mmol), to a final concentration of 50 mM. The mixture was 
allowed to stand at room temperature for 5 hours. The white precipitate that formed was 
removed by centrifugation at 13000 rpm for 5 mm. The remaining solution was purified 
directly by reverse phase semi preparative HPLC (water-acetonitrilc 5 %-95 % in 40 
185 
7. Experimental section 
minutes, 0.1 % TFA), tR = 16.3 mm. The corresponding fractions containing 134 were 
pooled and freeze dried to afford a fluffy white solid (2 mg; 100 %). 
Analytical data: C 164 H269N41 083 S 8 . MW: 4399.65. Found: [M] 3 : 1468.2, [M] 4: 1101.7, 
[M+2K] 45 : 925.0, [M+3K)] 6 : 777.5, [M(scaffold-N 3 )] 42 : 741.9. 
Synthesis of compound 136: (EPO derived peptide fragment (residues 22-32)) 
OFF S 	 OH 
N -A
11






N 	ir H,N 
H 	 H H 




0 	OFF 	 136 
Solid phase peptide synthesis. 
Solid-phase peptide synthesis was carried out automatically in a peptide synthesizer (Applied 
Biosystems peptide synthesizer model 433A). Synthesis of the peptide sequence: 
(CQC(SStBu)ITTGC(Acm)C(SStBu)AS) was carried out on PEGA Rink amide resin 
(loading = 0.26 mmol/g). The scale of the synthesis of the glycopeptide was 0.05 mmol. 
The Emoc group was removed by treatment with 20 % piperidine in NMP (5 and 15 mm) 
between each coupling and deprotection step. Coupling reactions with Fmoc amino acids 
were done using 1.0 mmol (10 equiv.) of each of HBTU/HOBt and DIPEA in DMF, for 30 
mm (Fastmoc 1M protocol). Between each couplings and deprotection, the resin was washed 
with DCM and DMF (5 min each). 
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General StBu deprotection. 
DTT (100 mg) was dissolved in dry DMF (0.9 mL) and 2.5 % v/v DIPEA was added. After 
stirring for 5 minutes the solution was transferred to a peptide synthesis vessel containing 
resin-bound S'Bu protected peptide. After 48 h the resin was filtered and washed 
exhaustively with DMF, mixtures of DMF/H 20 (1:1), DMF and finally DCM. This 
procedure was then repeated once again. 
General bromoacetamide couplings 
N-(Propargyl)-bromacetamide 112 (2 equiv. per thiol: 0.05 mmol x 2 thiols x 2 equiv.= 35 
mg, 0.20 mmol) was dissolved in DMF (1 mL) and NEt3 (42 1iL, 0.6 mmol) and transferred 
to a pcptide synthesis vessel containing resin-bound StBu  deprotected peptide. The reaction 
was allowed to proceed for 24 h. After this time, the resin was filtered and washed 
exhaustively with DMF and the DCM. 
Cleavage of compound 136. 
The resin was washed with DCM and DMF five times (5 min each wash). The compound 
136 was cleaved from the resin by incubation with the cleavage cocktail (95 % TFA, 2.5 % 
water and 2.5 % EDT) for 3 h. The compound 136 was precipitated with cold diethyl ether 
and centrifuged for 10 mm. 
Compound 136 purification. 
The crude product was purified by reverse phase semi preparative HPLC (water-acetonitrile 
5 %-95 % in 40 minutes, 0.1 % TFA), tR=  25.5 mm. The corresponding fractions containing 
136 were pooled and freeze dried to afford 136 as a fluffy white solid (13 mg; 19% yield). 
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Analytical data for compound 136: C 52 H82N 14020S5 . MW: 1350.47. Found: [M]: 1352A2; 
[M] 42 676.74. 
Synthesis of compound [1381 
Il.N N 
136 0 OH 
OH 
o 
OH 	 OH 
121 
N (; 
1• IOTA. Cu804 511,0, 
0.1 M PBS bi1cr. pH 8 
oil 	 On 




sIl S 	 OH 	 OIl 
I-I 





To a solution of the modified peptide 136 (1.5 mg, 1.04x10 3 mmol) in a 0.1 M PBS buffer 
solution (pH 8.0, 800 1jL), a PBS solution of the azido sugar 121 (1.0 mg, 4.15x10 3 mmol, 
41.00 mM, 100 iL) was added. Afterwards, sodium ascorbate (5.3 mg, 2.70x10 2 mmol) 
and tris-benzyltriazolylmethylamine (TBTA) (14.3 mg, 2.70xl0 2 mmol) were added to the 
solution. The final suspension was sonicated for 5 minutes in a cold bath. Finally, a PBS 
solution of CuS04 5H 20 (0.3 mg, 1.04x10 3 mmol, 10.40 mM, 100 1.tL) was added. The 
reaction was finally shaken for 24 hours at 20 °C and 1200 rpm. Then, the crude of the 
reaction was centrifuged at 14000 rpm for 5 minutes, and filtered through a celite plug in a 
Pasteur pipette. The crude product was purified by reverse phase semi preparative HPLC 
(water-acetonitrile 5 %-95 % in 40 minutes, 0.1 % TFA), tR= 15.6 mm. The corresponding 
fractions containing 138 were pooled and freeze dried to afford 138 as a fluffy white solid 
(1.3 mg; 65%). 
Analytical data: C 6811 110N22030S4 . MW: 1842.66. Found: [M] 4 1844.20, [MJ 2 923.10. 
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S 	 OH 
H 	 H 
H 	' H 	).H 	
"SAr,n 
139 	OOH 
The modified cysteine alkyne peptide 136 (3.6 mg, 2.67x10 3 mmol) and 104 (14.3 mg, 
9.38x10 3 mmol) were dissolved in a 0.1 M PBS buffer solution (pH 8.0, 1.9 mL). Sodium 
ascorbate (13.0 mg, 6.66x10 2 mmol) and Iris-benzyltriazolylmethylamine (TBTA) (35.0 mg, 
6.66x10 2 mmol) were added to the solution. The final suspension was sonicated for 5 
minutes in a cold bath. Finally, a PBS solution of CuSO 4'5H20 (0.7 mg, 2.67x10 3 mmol, 
26.70 mM, 100.0 tL) was added. The reaction was finally shaken for 24 hours at 20 °C and 
1200 rpm. Then, the crude of the reaction was centrifuged at 14000 rpm for 5 minutes, and 
filtered through a celite plug in a Pasteur pipette. The crude product was purified by reverse 
phase semi preparative HPLC (water-acetonitrile 5 %-95 % in 40 minutes, 0.1 % TFA), tR= 
16.3 mm. The fractions containing 139 were pooled and freeze dried to afford 139 as a 
fluffy white solid (tR= 16.1 mm) (8.1 mg; 69 %); and a white fluffy white solid 104 (tR=14.2 
mm) (5.1 mg; 59% of recovered starting material). 
Analytical data: CI64H26%N0054S5. MW: 4400.6. Found: [M] 13: 1468.6, [M+K)f4 : 1111.5, 
[M] 4 : 1101.7, [M] 5 : 881.7, [M(scaffold-N 3 )] 2 : 741,9. 
7. Experimental section 




p-Nitrophenyl mannopyranoside 150 (200 mg, 0.66 mmol) was dissolved in acetic anhydride 
(1.3 mL) at 0 °C. Pyridine (650 ML) was added dropwise. The mixture was stirred 
overnight. After 16 h, TLC (1:1 ethyl acetate/chloroform) indicated that the reaction was 
complete. The solvent was removed under reduced pressure. The crude product was diluted 
with dichloromethane (50 mL) and washed with 1 M HCI (50 mL), saturated aqueous 
NaHCO 3 (50 mL) and water (50 mL); then was dried with MgSO 4, filtered and the solvent 
was removed under vacuum to afford 151 (308 mg; 100 %) as a yellow solid. R f= 0.46 (1:1 
ethyl acetate/chloroform). 'FI-NMR (250 MHz, CDC1 3 ) 6 (ppm): 8.21 (2H, d, J0 ,,,= 7,1 Hz, 
H-meta); 7.19 (2H, d,J0m= 7.1 Hz, H-ortho); 5.61 (1H, d, .J 12= 1.8 Hz, Hi); 5.55 (IH, dd,J3 
4=10.0 Hz, J2-3=  3.5 Hz, H3); 5.45 (lH, dd,J23 3.5 Hz, J12= 1.8 Hz, H2); 5.37 (iH, dd,J3 
4=145= 10.0 Hz, H4); 4.26 (11-I, dd, J6a-b'  12.0 Hz, JS.,a=  5.6 Hz, H6 1 ); 4.05 (1 H, dd, 6a-6b 
12.0 HZ, -4-6b= 2.5 Hz, H6b): 3.98 (1H, m, H5); 2.20, 2.04, 2.03, 2.01 (121-1,4 x s, CH 3CO). 
' 3C-NMR (63 MHz, CDC1 3 ) S (PPM):  170.3, 169.9, 169.6 (CO); 160.1. 143.1 (Ar); 125.8, 
116.4 (Ar-H): 95.7, 69.8, 68.9, 68.5, 65.6 (CH); 61.9 (CH,); 20.7 (CH 3). ESI-MS: m/z= 
487.12 [MNH4], m/z- 492.12 [MNa], C20H23N0 12 requires m/z= 469.12. 
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p-Aminophenyl-2, 3, 4, 6-tetra-0-acetyl-a-D-mannopyranoside, 11521 
ICO2NH4, MeOH, Pd/H 
NI-I 
p-Aminophenyl-2,3,4,6-tetra-0-acetyl- a-D-mannopyranoside 151 (308 mg, 0.66 mmol) was 
dissolved in 25 mL of MeOH containing ammonium formate (832 mg, 13.22 mmol) and 10 
% Pd/C (62 mg). The mixture was stirred at room temperature under nitrogen. After I h, 
TLC (1:1 ethyl acetate/chloroform) indicated that the reaction was complete. The crude 
product was filtered through celite and the solvent was removed under reduced pressure. 
The crude was diluted with dichloromethane (25 rnL) and washed with water (25 mL); then 
dried with MgSO4, filtered and the solvent was removed under vacuum to afford 152 (289 
mg; 100 %) as a solid. R= 0.22 (1:1 ethyl acetate/chloroform). H-NMR (250 MHz, 
CDCI3) S (ppm): 6.88 (2H, d, J0.= 8.9 Hz, H-ortho); 6.60 (21-1, d, Jom=  8.9 Hz, H-meta); 
5.52 (IH, dd,J3 . 4= 10.0 Hz, J2-3=  3.5 Hz, 1-13) -, 5.40 (IH, dd,J23= 3.5 Hz, J12= 1.8 Hz, H2); 
5.32 (lI-I, t, J3 . 4= f 5= 10.0 Hz, H4); 5.30 (IH, d, J12= 1.8 Hz, Hl); 4.26 (lH, dd, j6a6h=  11.8 
Hz, 5.0 Hz, F16a); 4.12-4.08 (21-1, m, H-5, H6b);  3.26 (2H, s, NH,); 2.16, 2.03, 2.01 
(12H, s, COCth). 13 C-NMR (63 MHz, CDC1 3 ) S (PPM):  170.6, 170.0, 169.9, 169.7 (CO); 
148.6, 142.0 (Ar); 118.0, 116.0 (Ar-H); 96.7, 69.5, 68.9, 68.9, 66.0 (CH); 62.1 (CH 2); 20.8, 
20.7 (CH). ESI-MS: m/z= 462.15 [MNa], C 20 H 23N0 12 requires m/z= 439.15. 
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2-lodoacetyl chloride, 169  (1531 
HO 	 Cl I 
	SOC 12 	jfI 
0 	 0 
153 
Thionyl chloride (79 IAL, 1.08 mmol) was added dropwise with stirring to iodoacetic acid 
(167 mg, 0.90 mmol) and the resulting suspension was stirred at room temperature with 
exclusion of moisture and light. After 24 h the excess thionyl chloride was removed under 
reduced pressure to afford the acid chloride 153 (141 mg; 70 %) as an orange oil, which was 
used without further purification. 
N(2-Iodoacetyl)-p-aminophenyl-2, 3, 4, 6-tetra-0-acetyl mannopyranoside, 
11541 










A solution of 152 (289 mg, 0.66 mmol) in dry DCM (4 mL) was treated with pyridine (54 
1iL, 0.66 mmol) and cooled to -30 °C with exclusion of light and under nitrogen. Then, this 
solution was treated dropwise with 2-iodoacetyl chloride 153 (141 mg, 0.66 mmol) dissolved 
in anhydrous DCM (4 mL). After 0.5 h, the reaction was allowed to warm to room 
temperature. After a further hour, TLC (1:1 ethyl acetate/chloroform) indicated that the 
reaction was complete. The reaction was quenched with chloroform (50 rnL) and the 
resulting solution was washed with 1 M HCI (40 mL), saturated aqueous NaHCO 3 (40 mL) 
and water (40 mL). The organic phase was dried over MgSO 4, filtered and concentrated 
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under reduced pressure. The crude product was purified by flash chromatography over silica 
(1:1 ethyl acetate/chloroforni) to afford 154 (276 mg; 69 %) as an orange solid. Rf= 0.36 
(1:1 ethyl acetate/chloroform). 'H-NMR (250 MHz, CDC1 3) 6 (ppm): 8.35 (1H, s, NH); 7.43 
(2H, d, Jom=  9.0 Hz, H-meta); 6.73 (2H, d, Jm=  9.0 Hz, H-ortho); 5.50 (1H, dd, J3 = 10.2 
Hz, 123  3.4 Hz, H3); 5.44 (1 H, d,J, 2= 1.9 Hz, 1-11); 5.39 (1 H, dd, .12.3= 3.4 Hz, J 2= 1-9 Hz, 
H2); 5.32 (1H, dd, .13.4= 10.0 Hz, H4); 4.24 (lH, dd, Jôa-ôb=  12.3 Hz, J56a= 5.5 Hz, H6a); 4.07 
(2H, m, H-5, H6b); 3.80 (2H, s, COCH 2 I); 2.16, 2.02, 2.01, 2.00 (12H, 4 x s, COCH 3). ' 3 C-
NMR (63 MHz, CDCI 3 ) 6 (ppm): 170.4, 169.9, 169.5, 165.5 (CO): 152.3, 132.7 (Ar); 121.5, 
116.8 (Ar-H); 95.8, 69.1, 68.9, 68.7, 65.7 (CH); 61.9 (CH 2); 20,7, 20.5 (CH3); -0.32 
(COC1). ESI-MS: m/z 625.06 [MNH4]', mlz= 630.06 [MNa] 4 , C22H2 1NO 11 requires 
m/z= 607.06. 










154 .4 	 155 	 'N 
1-I H 
The iodoacetamide 154 (276 mg, 0.46 inmol) as a solution in anhydrous methanol (36 mL) 
was treated with a solution of sodium methoxide (0.5 M in methanol (276 jiL, 0.14 mmol)) 
under nitrogen with the exclusion of light and the resulting solution was stirred at room 
temperature for 3 h. After 3 h the reaction was quenched with a solution of acetic acid 0.1 M 
(140 1.iL) and concentrated under reduced pressure. The solid was redissolved in water and 
washed with ethyl acetate (2 x 10 mL) and finally the aqueous layers were freeze dried to 
afford 155 (184 mg: 91 %) as a pale brown solid, 'H-NMR (250 MHz, D 20) 8 (ppm): 7.33 
(2H, d, .Jom  9.0 Hz, H-meta); 7.10 (2H, d, 'om  9.0 Hz, H-ortho); 5.54 (1 H, d, .11.2= 1.7 Hz, 
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H3); 4.13 (1H, dd, J2 . 3= 3.3 Hz, J 1 . 2= 1.7 Hz, H2); 4.01 (11-I, dd, J3 . 4= 8.4 Hz, J23=  3.3 Hz, 
H3); 3.85 (2H, s, COCJjI); 3.77-3.67 (4H, m, H4, 115, H6 a, H6b). ' 3 C-NMR (63 MHz, D 20) 
S (ppm): 171.9 (CO); 154.5, 133,0 (Ar); 124.8, 119.1 (Ar-H); 99.9, 74.9, 71.9, 71.4, 68.1 
(CH); 62.2 (CH 2); 0.00 (COCjI). FAB-MS calculated for C 4H 18 1N07 [MNa] 462.00257, 
found: 462.0035 1. 
Ligations between Green Fluoresecent Protein (GFP)-intein chitin binding 
domain to agarose beads and unnatural glycopeptides B and D' 28 
GFP-Sci Intein Binding Domain (CBD) Fusion Protein was overexpressed in Escherichia 
co/i strain BL2I-(DE3) transformed with pTYBI-GFP. The cell free extract was loaded on 
chitin beads, New England Biolabs (NEB), and equilibrated with column buffer (10 mL, 20 
mM Tris-HC1 pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM PMSF). The cell-free extract 
loaded was provided as a gift by Dr. D. J. P. Richardson. 
The beads were washed with 200 mM sodium phosphate solution, pH 8, 100.0 mM sodium 
chloride, 2 % w/v MESNA, 5 mM TCEP solution (5 rnL). The column was allowed to run 
by gravity and then plugged. Finally, the desired unnatural glycopeptide (165: 4.2 mg, 
9.5410 mmol; 169: 1.6 mg, 3.64- 104  mmol) was dissolved in the previous sodium 
phosphate buffer solution (100.0 AL), and the contents were mixed gently for 48 h. After 2 
days of reaction, the crude was eluted with 200 mM sodium phosphate solution, pH8, 100 
mM sodium chloride, 5 mM TCEP solution (2 mL). The eluted samples were concentrated 
in a Vivaspin 2 mL concentrator, 30,000 molecular weight cut-off (MWCO). Afterwards, 
the green precipitate was dialysed with 4 mL of Dulbecco's PBS solution, pH 7424l Finally, 
the product was resuspended with 200 ML of Dulbecco's PBS solution, pH 7.4. 
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Dulbecso's PBS solution, pH 74•241 
NaCl 8g 
KCI 0.2g 
Na 2 HPO4 1.15 g 
KH2 PO4 0.2 g 
CaCl 2 0.1 g 
MgCl2 6H20 0.1 g 
H-,O 1000 m 
All the salts were mixed together and made up to 1000 mL of water. 
Interaction tests between unnatural glycoprotein and agarose beads coated with 
Ricinnus Cominunis RCA120242 
50 .tL of the re-suspended glycoprotein in 200 .tL of Dulbecco's PBS solution, pH 7.4, was 
dispatched in a 1.5 mL eppendorf tube. Parallel to this experiment was dispatched the same 
amount in the same buffer system GFP. A digital photograph was taken under UV light 
(A365 nm). A small amount of agarose beads coated with Ricinnus Communis RCA 120 was 
added to each eppendorf, and it was shaken gently for 30 mm. Afterwards, a second digital 
photograph was taken under UV light (:365 nm). Finally, the agarose beads coated with 
Ricinnus Communis RCA 120 were washed twice with 50 sL of Dulbecco's PBS solution, pH 
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The straightforward synthesis of a novel class of neogly- 	 ON 
copeptide and its fusion with a larger peptide thiesenter using 	 o 
sequential chernoseleetive ligations is described.  
The synthesis of glycosylated proteins is it formidable challenge 
and it is tier to say that synthetic glycoproteins have had modest 
impact, thus far. on the study of glycobiology when compared 
to genetic methods. This is largely due to tire well documented 
dilficulties associated uith synthesis of oligos.wxharides and 
glycopept ides such as the requirement for extensive protection and 
deprenteetron strategs and the stereosekljve lbnmit ton of glyco-
sidic tinkagc We. and others have pursued alternative ttiIhnxh-
olugies Sir the assembly of modified peptides and proteins' 
Using the click ligation`  ('or bioconjugation was of particular 
interest due to its nrtiabitity and compatibility with the aqueous 
milieu.' We had previously shown that glycosyl kidoticetamides 
canreact with the sulihdryl groups of cysteine on solid-phase
to afford glycopeptide mimetics and that this methodology was 
compatible with useful protein assembly methods such as native 
chemical ligation iNCLO We were keen to investigate whether 
the coupling oh glycosyl azides with peptides displaying acetylene 
dipolampltiks may also he useful for this purpose since the 
glycosyl azides are more stable and can be prepared in fewer steps 
than the corresponding glycosl iodoacetamides (Scheme I). 
Initially we prepared the peraolty hded gtycopy ranosylaz.kks of 
.ricetytglucosunrine (I) .V-acetyllactosantine 12) and chitohiose 
31 which are all constituents of the V-linked class. of glyco. 
proteins. We investigated conditions for their union with the 
heterobifunctional adaptor 2-bromoacetyl propa tlaniide (4)' 
and the reaction of these saccharides with 4 proceeded smoothly 
under conditions reported in the revetti literature." the 1.4- 
addition product being favoured 1w tire presence ola ('ulilcatalyst 
'Table If. The crude products did not require purification by 
coluenti chromatography. 
Pleased with the facility with which such glycoconjugatescould 
be prepared we next aimed to expose the bromoamxtamides to 
conditions typically encountered in peptide chemistry and native 
chemical ligation. We were particularly interested in the potential 
to modify the thiol groups of cysteine residues. Additionally. to 
demonstrate the serstttility of the approach, we explored the pos-
sibility of reacting thief groups directly with the hromoucctainle 
products 5-7 on solid phase and the reaction of cysteine thiols 
witl14suclt that click chemistry could subsequently be investigated 
in solution or on solid- plt.ts with peptides displaying acetylenes 
t,n,erwtt (al,'s.s' i.,,rrrlrq,. J),parrna ,.ri 4  (%v,üsrru ('Irr,sr.iphrr in - 
odd Lals,r,nrrrk's. 20 ,on/r,n Store!. Lrorrlo,r. UK tI'('Ilj rr.4J E-,,n,ii. 
dnmatnmilia,maari.ar.ijk. Tel, +44 Ii 21) 7679 4654 
Electronic suptslerrnentrmrs' inl'ornsrIion (1 751) ..vailrrhk: esperiniorstol 
procedures and analytical duta tsr all instIncts lcornipoundr. 4 141. See 
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Scheme I (onstruciron of os'et ncogtycopeptrdcx. 
Tibk I Svrithes of neogtvcopeptide precairsor hromoourtantidcs 
S:rrwharklu 	 Catalyst 	 Product Yield f.f 
I.R =Ac 	 ('u(i)l(5s'q.)' 	5 	1 ItO 
I. It = Ar (srhli)Sl), (O. t eq.)" 	5 97 
1 It = (OAeI - I)'Got' 	Cu(n)SO, (1).1 eq.) 	6 	 91 
3. It = ((tAct, )-Glcl'sAc- 	Cu(n)SO, (it. 1 eq.) 	7 117 
Methanol as solvent. 'Acusecopper spcciesgener:Lreth in the presence at' 
.1 equivalent somtirim.rrsrorharein 'I. I I ('11(1 .FtOtt4l.O rssols'Cnt. 
tsnlatd ykIri. 
tSchenirr 21. As anticipated. 4 and 5 reacted cleany with benzyl 
mercaptan forming model tltioetlters 8 and 9 in S.V. and 75'. , 
yield respectirsely. S also reacted cleanly ,  with perucetylated 2. 
acetanmidu-2.deoxy.oglucopyrunosyl aide, affording 9 in 91:.. 
Tier rjrrvrl '. : 	Rovil Sor','.'l ':irerr s_rOt. 	 Org. Biorsroi Chem. 2006.4. 2847-2850 1 2847 
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Scbeiine 2 Model reactions with beniyltncrcuptnn den,ongnite that the 
order in which the reactions take place appears unimportant. Reqgnaxa,uI 
,'s./fftouv i 	SIl.tt.i'.DMF. t6.tt.t'.aI75" For Hand 9respevtiveIv 
ii) w,dirrnt assaorbat 	1.1 eq.). ('u)ii)SO, 511 .00.1 eq.). CI [CL. Et011, 
11.09 I 1),17 C. Ioh. 01".. iii)2''s.v/v hvdr 	ne nsonohydrsrie lOot), 
72 Ii. 66".' 
yield. To establish whether the products might be stable to the 
usual acidic peptide cleavage condittons 9 was subjected to 95's. 
aqueous TEA lbr 3 h. NMR analysis of the crude material after 
evaporation showed no decomposition had taken place. Finally 
the acetyl esters were cleanly renroned upon exposure to T., v/v  
hydrozine hydrate in EtOH for 72 It and the fully depn3tevted 
compound 10 was obtained.' Encouraged by the preliminary 
results we assembled a peptide fragtnent hilt, similar in sequence 
to humnati erytitropoictin (residues 21 32). plus an N-terminal 
cvsteine residue, and furnished with two disulfide bend protected 
cysteinc residues at pre-detemiirmcd positions (sehemue 3). The 
peptide was assembled using standard protocols for Fmoc solid-
phase peptide svnlhesisamid inanautomated fashion. Thecysteimse 
residues were deprotected on solid-pitase by exposure to t(Y'. w/v 
dithiothreitol (DTT) containing 2.5'. v/v DIPEA to expose the 
thiol functional groups.' N-Acetvtglncosatnimse and the disaceha-
ridechitobiose were then incorporated by exposure critic resin to 
bromoacetanrides 5 or 7. employing three equivalents 5 or 7 per 
thiol in each reaction. After l(s It reaction at room temperature. 
cleavage of it 'uiiall resin sample indicated that the reaction was 
complete as the starring material was not observed. After cleavage 
from the solid support by treatment of the resin with 95' TEN. 
2.5' ethanedithiol and 2 5'. 11.0 for four hours the crude 
products were purified by semi-preparative IIPLC. lyophilized. 
and treated with 2Y,, v/v aqueous hydrazine hydrate containing 
5". w/v DTT to obtain the fully deprotrxted products Il and 13 
in quantitative yield ldetermined by hELd. Ilmomoacetamide 6 
and amxrytenic bronroacetamnide 4 could also be incorporated into 
synthetic peptides in an identical fashion. 
/"5, , 	
0 
Sobw 3 Rsvq,s'ntsa.rdm'mmd/mscem's: it lW w/v DTT. 2.5'.. DIPEA, t)MF Ih h. itS or 7)3 eq. per tttmol). 2.5". v/v M.N. DMF. lb I,. iii) 95', TFA. 
2...,ethunedithinL 2.5" 11.0.4 h. iv)2" v/s aqueous hrvitmoiume rnormolwdrat I h. 
2848 I Org. Ssomol Chem., 2006, 4, 2847 2850 	 flw, 'assi r 	 ii'.' Royal Osiots of '.Hrs', 
Annexe 1: Published work 
,i,N 	 EPO (rsaldue 1-19) i—cones 
'4 
0 (mues I 	
1 
Scheie 4 The iwoglycopeptides ow con paiibto with natis -e chemical ligation wactions' Ravge,is awl (rmditk'nn: i) 6 M guanidine lICt. 19s n/v 
MESNA. 300 m Na phosphate buffer (pH 0A)(. 10mM TCEP. ii) 2..aqus'ns If : NNIl : . 
Fragment 13 was 1hen coupled to a peptide thioester in it 
native chemical ligation reaction.' The construction oltlte peptkie 
thioester, corrospoitdiitg to human erythropoietin residues I 19. 
and its release from the solid support were monitored using the 
dual-linker approach recently described by Lnveriagt and co-
workers.' In the ligation reaction equimolar quantities of each 
peptide were combined in 0.25 ml 0f6 M guaniditle hydrochloride 
containing 3(8) mill sodium phosphate buffer: pH 1.0. I.'.. 
win inercaptoethunesulfonic acid I MESNA I and tO mM Iris-
earbonyetlrstphosphine (T('FP) For 56 It with shaking at room 
temperature lSchenie 41.' After this time the reaction mixture  
was purified by directly loading it onto a semi-preparative IIPL(' 
olumii. The ligated product I l4lwas the on sp,siesobserved by 
Ft PLC.' 
In summary we have developed a novel class oF neoglycopeplide 
that is compatible with modification of cystcine mutant proteins. 
witltsyntheticpeptides andnatisecheinical ligation. Furtltermv're 
the fusion of gcosylazidcs with peptides displaying acetylenes 
may be of particular interest since N(L hits been shown to hut 
when large oligro.iccharide appendages are located proxitmul to 
the ligation site) Therefore. if acetylene, can he installed so 
as to encode for glvcosylation then bulky saccharide motifs 
may be installed after ligation using click chemistry in solution. 
We have utrewy observed that the reaction between peptides 
displaying acetylenes derived from 4 and glycosylazides proceeds 
on solid-support.' Although the linkage between thecarboby'drate 
and peptide moiety is unnatural, difficulties associated with the 
synthesis of native glycopeptides and glycoprotetns dictates that  
new modes olpresentation ofc;urbohydrates (or other appendages) 
should be explored concomitantly) Such neoglycoconjugutes may 
improve the pharmacokinetic profile of therapeutic glvcopro-
teins. The Fact that the netsgl)copeptides described are simple 
to prepam homogeneous, and are also compatible with native 
chemical ligation. may render them attractive building blocks for 
neoglycoprotein assembly. 
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